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INTRODUCTION 
 
Nicotine addiction is one of the most alarming public health problem of this century. In fact, results 
shown by several agencies, such as the World Health Organization (WHO) and the Center for 
Disease Control (CDC) underline a disconcerting situation, which do not involve only developed 
countries. It has been estimated that over a billion of people smoke tobacco (WHO, 2006), and 
despite the large amount of pharmacological and non-pharmacological strategies to quit smoking, at 
the state of art, tabagism is still considered one of the first causes of preventable death worldwide 
(WHO, 2006).  
Drug addiction is a complex and  relapsing disorder characterized by several symptoms, such as the 
compulsive seeking of a drug and drug abuse despite its side effects (Koob and Volkow, 2010). 
Among this spectrum, nicotine addiction obviously represents a crucial problem in terms of 
prevalence (higher than other drugs) (Markou, 2008) and negative long-term physical problems. 
Even though only a certain percentage of people who use drugs of abuse becomes addicted (for 
nicotine is around 50%), some genetic and environmental factors have been described as triggers of 
addiction. For what concerns nicotine dependence, various polymorphisms in some genes encoding 
for specific receptors or receptor subunit of the central nervous system (e.g. dopaminergic receptors, 
nicotinic acetylcholine receptors) (Ray et al., 2009), associated with stressful life events and other 
non-biochemical modifications, have been suggested so far. In addition, most of these events 
pinpoint how progresses in the neuroscience and neuropharmacology –related field can be crucial to 
better understand this problem. 
Recently, studies have been focused on the modulatory effect of certain endogenous system in the 
response to drugs of abuse in the brain reward circuitry. Among these systems, a wide amount of 
studies are taking into account the possibility that the endogenous cannabinoid (eCb) system might 
be a suitable candidate to regulate nicotine-induced reinforcing properties. The eCb system is a 
family of lipid molecules, enzymes and receptors, also described in the brain reward circuitry 
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(Melis and Pistis, 2007), where cannabinoid type 1 receptors (CB1-Rs) are also a target for the 
exogenous cannabinoid Δ9-tetrahydrocannabinol.  
In the last five years several studies suggested that the CB1-Rs antagonist SR141716-A 
(rimonabant) prevents nicotine-induced effect within the brain reward circuitry (using different 
paradigms and techniques) (Cohen et al., 2002; Cheer et al., 2007). Additionally, it has been 
recently proposed the role of other components of the eCb system as putative modulators of 
nicotine effect. 
The present thesis is focused on this second possibility and it summarizes the results obtained 
carrying out experiments using in vivo extracellular electrophysiological single unit recordings in 
anaesthetized rats to study the effect of pharmacological inhibition of fatty acid amide hydrolase 
(FAAH). FAAH is the main enzyme which inactivates the eCb anandamide (AEA) and other n-
acylethanolamides (NAEs), such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), 
structurally similar to eCbs but devoid of CB1-Rs affinity (Fu et al., 2003). 
FAAH activity reduces the levels of AEA, OEA and PEA and pharmacological tools to deactivate 
this metabolic process have been proposed so far. For example, the carbamic acid derivate 
URB597, an irreversible inhibitor of FAAH, allows a long-lasting increase of AEA and NAEs 
levels in the brain and peripheral tissue (Kathuria et al., 2003; Fegley et al., 2005). 
For this reason, in the present study it was addressed whether FAAH inactivation by URB597 might 
act as a negative modulator of nicotine-induced effect in two of the most important groups of 
neurons of the brain reward circuitry: the ventral tegmental area dopaminergic neurons and the 
GABAergic medium spiny neurons of the nucleus accumbens shell. Furthermore, it was also tried 
to identify the mechanism by which URB597 modulates these effects and, finally, whether 
URB597’s action is only related to nicotine effects or it can be extended to other drugs of abuse. 
In the first chapter, the abuse liability of nicotine, evaluated through some of the most important 
parameters such as its biochemistry, epidemiology, pharmacology and neural effects in the brain 
reward circuitry will be discussed. In the second chapter, the eCb system and the novel family of 
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eCb-like molecules, devoid of CB-Rs affinity, will be introduced to better clarify the rationale of 
this study. In the third chapter, a brief excursus on methods and materials employed to carry out this 
project will be presented. In the forth chapter, it will be reported a summary of results obtained 
through the in vivo electrophysiological technique. Finally, in the fifth chapter, a detailed discussion 
of these results will be shown to connect present data to the literature and to provide some 
important final remarks about the meaning of our study. 
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Chapter I 
NICOTINE ABUSE AND ADDICTION: A MULTIDIMENSIONAL 
APPROACH 
 
 
Introduction 
Nicotine is the main psychoactive component of tobacco plant and it contributes to tobacco 
smoking habit (Stolerman and Jarvis, 1995). This compound is an alkaloid mainly found in the 
Solanacee plant Nicotiana Tabacum, where it constitutes the 0.6-3.0% of dry tobacco weight 
(Siegmund et al., 1999). Nicotine is commonly extracted from four different types of Nicotiana 
Tabacum known as Bright, Burley, Maryland and Turkish (Hoffmann and Hoffmann, 1998), 
although other species of Nicotiana, such as N.Rustica, are widely used to extract nicotine and 
manufacture cigarettes and cigars (Hoffmann and Hoffmann, 1998). 
Acute administration of nicotine to humans produces mild euphoria and mild cognitive 
enhancement (Markou, 2008) and its continuative use leads to tolerance and withdrawal (depressed 
mood, irritability and mild cognitive deficits) when the access to the drug is prevented (Shiffman et 
al., 2004). Most of these effect are due to the high nicotine-binding affinity for a specific class of 
receptors named ―nicotinic acetylcholine receptors‖ (nAChRs), whose properties and localization 
within the central and peripheral nervous system will be better explained below.     
Even though cigarette consumption is the most common route to administer nicotine, the 
phenomenon known as tabagism involves a wide array of different aspects (from the epidemiology 
of tobacco use to the neural basis that facilitates nicotine-induced effects in the central nervous 
system) which will be elucidated in this chapter. 
9 
 
1. Physical and social epidemiology of nicotine consumption 
 
Different agencies have provided a large amount of evidence regarding the widespread tobacco use 
and nicotine addiction. For example, data revealed by the World Health Organization (WHO) and 
the Center for Disease Control (CDC) have shown that 1.3 billion of people in the world smoke 
cigarette (WHO, 2006). In the United States, the 5
th
 world producer of tobacco manufactures, with 
approximately 45 millions of smokers (CDC, 2008) (male prevalence: 26.3%; female prevalence: 
21.5%) (WHO, 2008), tobacco-related health care cost is evaluated around 76 billions of dollars, 
almost 20 folds over than China (3.5 billions of dollars) (WHO, 2002), where tobacco use involves 
more than 300,000,000 of people (WHO, 2002) (male prevalence: 59.5%; female prevalence: 3.7%) 
(WHO, 2008).  
These data obviously report a disconcerting problem, which is almost all confined to tobacco 
smoking behavior. In fact, according to the National Institute on Drugs of Abuse (NIDA) the 98% 
of tobacco users take nicotine through cigarette smoke (Fratta et al., 2005), minimizing to a scarce 
2% the rest of consumption. 
Furthermore, inhaling tobacco through cigarette smoke remains the most dangerous route of 
administration because of its sudden release of toxic compounds, which have been used for 
manufacturing them. In fact, beyond the well-known abuse liability of nicotine, it is now well-
established that tobacco smokers have an increasing probability to develop several physical 
problems. Among them, severe types of cancer (mouth, bladder, lungs etc…), cardiovascular 
disease and respiratory problems (U.S. DHHS, 2004) have been reported in chronic smokers. 
Additionally, it has been estimated that tobacco-related illness lead to die with an higher rate than 
HIV-related disease, other drugs of abuse and motor vehicle accidents (U.S. DHHS, 2004).  
The American Psychiatric Association (APA) considers nicotine dependence as the occurrence of 
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both tolerance and withdrawal symptoms related to nicotine use under different forms and the 
compulsive consumption despite its side effects (APA, 2000). The abuse liability of nicotine is also 
responsible for nicotine relapse. In fact, despite the development of different strategies (e.g. nicotine 
replacement therapy), only 3-5% of people trying to quit smoking benefit from them (Stead et al., 
2008).     
In addition, beyond the strict correlation between tobacco consumption and physical injuries, a lot 
of interest has been focused on the link between nicotine addiction and psychiatric problems. In 
fact, according to the APA, smoking behavior and nicotine dependence have an higher prevalence in 
psychiatric patients than normal people (APA, 2000). For example, recent evidence points toward a 
self-medication use of nicotine in patients with schizophrenia-related cognitive impairment 
(Williams and Gandhi, 2008), although a correlation between nicotine use in schizophrenic patient 
came out earlier (O'Farrell et al., 1983). In addition, also a link between nAChRs (see below) and 
depression (Bertrand, 2005) has been recently suggested, involving the role of nicotinic receptors in 
the pathophysiology of mood disorders. These observations are robustly improved by animal 
studies showing an α4β2 nicotinic receptor involvement in some measures impaired in psychotic 
patients (Radek et al., 2010). Moreover, further data have shown an α7 nicotinic receptor subunit 
contribution in the modulation of P20-40, a paradigm set to evaluate animal models of psychosis 
(Martin and Freedman, 2007).  
Furthermore, a series of studies have also postulated the existence of a genetic vulnerability to 
nicotine dependence. In fact, studies in twins have reported a sustained degree of heritability of 
cigarette smoking (>50%) (Lessov-Schlaggar et al., 2008) coupled to an heritability of specific 
withdrawal symptoms (Xian et al., 2005). These studies also include in the predisposition to 
nicotine use: 
(1) the presence of smoking-related phenotypes accountable to the polymorphism of the cytochrome 
P450 CYP2A6 (Malaiyandi et al., 2005); 
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(2) the role of variants in some genes encoding for nAChRs specific subunits, such as the CHNRA4 
(encoding for  the α4) (Li et al., 2005; Hutchison et al., 2007) and the CHNRA3 and 5 (encoding for 
the α3 and the α5) (Saccone et al., 2007; Berrettini et al., 2008); 
(3) the polimorphysm in some dopaminergic (DA) genes (Lerman et al., 1999; Vandenbergh et al., 
2007; Huang et al., 2008) which might improve the rewarding properties of nicotine itself;      
Taken together, these considerations remarkably point out the alarming problem of nicotine abuse 
and addiction, which is quickly growing up in developed, less developed, and developing countries.  
 
2. Brief history of nicotine: from the Pre-Columbian medical use to the XXI century 
 
Early information about manufactured cigars from Nicotiana plants derives from the artworks 
painted on 10
th
 century Maya’s vessel (Kingsborough, 1825). Nonetheless, there is evidence of 
tobacco use also in 16,000 B.C., and during the course of 3,000/5,000 B.C. in Ecuador and Peru 
native’s cultures (Dowieko, 2008). 
The biggest source of data comes out from the Cristoforo Colombo landing in America. While 
exploring the Isle of Guahain (currently San Salvador) the sailors of Colombo’s crew noticed a 
strange behavior defined as ―drinking smoke‖ practiced by the so-called ―Indians‖, and which was 
reported on the Gonzalo Fernandez de Oviedo’s milestone ―Historia General y Natural de las 
Indias‖ (1526) (Penn, 2007). Presumably, the name tobacco belongs to this age and it was translated 
as a mistake from the cane pipe that indigenes utilized to smoke (called tobago by them) (Meyer, 
1999). 
These ancient populations, from Maya to American natives, used to smoke tobacco for religious 
purposes and some reports describe that Indians offered their pipes filled with tobacco to Colombo’s 
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crew thinking they were divinity. Moreover, a great array of references comes from the exploration 
of other sailors in the ―New World‖, who frequently noticed the therapeutic use of tobacco plants by 
indigenes (e.g. Pedro Alvarez Cabral, Amerigo Vespucci etc...) (Dickson, 1954; Brookes, 1937, 
1952). 
After Colombo's age tobacco plants were also imported in Europe where they became very popular 
in Spain and other countries. According to some studies, the first person who cultivated Nicotiana 
Tabacum in Europe was the French Ambassador to Portugal Jean Nicot, who sent seed of tabacum 
to France and introduced its use at the Royal Court of Paris during the XVI century (Penn, 2007). 
Henceforth, the belief of smoking tobacco medical properties became so popular to induce Caterina 
De Medici and King Charles IX to treat their migraine headache taking nicotine (Jeffers and 
Gordon, 1996). In fact, during the same century other empirical opinions, such as those belonging 
to the Spanish school of the physician Nicolas Monardes, hypothesized a therapeutic role of 
Nicotiana plants for curing a great array of physical problems (Monardes,1596) up to be considered 
as a panacea (Dickson, 1954). Nevertheless, despite this optimistic approach to tobacco use, some 
studies reported an early evidence of a negative effect caused by smoking behavior. For example, 
the Italian scientist Francesco Redi (1671) demonstrated an harmful action of tobacco oil injection 
in animals (Goodman, 1994), which was confirmed by latest studies occurred when nicotine was 
isolated. Noteworthy, other source of criticism came from Phylaretes (Phylaretes, 1602), Vaughan 
(Vaughan, 1612), and James Hart (Hart, 1633) most of them concerning the over inclusive 
consideration of tobacco as a panacea and its harmful effect when abused.    
The headword nicotine was obviously given in honor of Jean Nicot by Jean Liebault, a botanist, 
who was the first to cultivate this plant in France. He called this plant ―Herba Nicotiana‖ 
rearranging the nickname of  Nicot "ambassador’s nicotiane" (Charlton, 2004). In the XIX century 
nicotine was, then, isolated by Wilhelm Posselt and Ludwig Reimann (1828), and it was recognized 
as the main pharmacological ingredient of tobacco plants (Henningfield and Zeller, 2006) with an 
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extremely high poisonous property (Goodman, 1994). Nevertheless, as early as 1723,  nicotine, like 
crude extract of tobacco, had been already used and recognized as a powerful insecticide agent 
(Metcalf, 1948), and sometimes as a quick and effective killer-drug (Wennig, 2009).    
These steps constituted something essential to reach the nicotine empirical (Melsens, 1844) and 
chemical structure (Pinnier, 1891-95) and how to synthesize it (Pictet and Crepieux, 1903), which 
opened the field of study related to nicotine-induced effects in the human body and the manufacture 
industry of cigarette and cigars. 
 
3. From leaves to lungs: biochemistry and pharmacology of nicotine  
 
Before introducing how nicotine acts on the central nervous system as an abuse substance, it is 
worth to quickly describe the biochemistry and the pivotal passages that allow the biosynthesis of 
this compound, together with its main pharmacological features. 
 
3.1 Biochemistry and biosynthesis  
As previously mentioned, nicotine (C10H14N2) is an alkaloid found in a solanacea plant, whose 
biosynthesis takes place in the roots and accumulates in the leaves. It reaches the ~95% of total 
alkaloids of tobacco plants (Baldwin, 1989; Hashimoto and Yamada, 1994), followed by other 
compounds such as nornicotine, anatabine and anabasine (Benowitz and Jacob, 1998). Nicotine is 
a compound whose chemical and physical data are summarized in tab 1.1, and it appears like a pale 
yellow to dark brown liquid with a slight, fishy odor when warm, strongly alkaline in reaction and 
with a tendency to from salt with acid (Metcalf, 1948). The chemical structure of nicotine is 
composed by 2 different rings: pyrrolidine and pyridine (Katoh et al., 2005), and this explains its 
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IUPAC name 3-[(2S)-1-methylpyrrolidin-2-]pyridine (tab 1.1). The chemical root for the pyrrolidine 
ring is the ornithine and/or arginine-formed symmetrical diamine putrescine. Putrescine is 
methylated by the S-adenoshylnmethionine-dependent enzyme putescine N-methyltransferase 
(Biastoff et al., 2009), a protein isolated from roots of different plants (Nicotiana Tabacum, Atropa 
Belladona, Datura Stamonium) (see for example Walton et al., 1990; 1994), yielding N-
methylputrescine (Hashimoto and Yamada, 1994) which is then deaminated by the diamine oxidase. 
A cyclization product of this oxidation process is the N-methylpirrolinum cation (Katoh et al., 
2005). This chemical process is common to almost all known alkaloids (Ziegler and Facchini, 
2008). 
 
                   
Nicotine/3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
Density 1.01 g/cm3
Molecular weight 162.26 g/mol
Boiling point 477°F
Melting point -277°F
Formula C10H14N2
A
B C
 
TAB1.1.Nicotine chemical features. (a) Panel showing some important chemical 
parameters of nicotine. (b) Chemical structure of nicotine. (c). Three dimensional 
chemical structure of nicotine 
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The pyridine ring derives from aspartate, which, through the aspartate oxidase, is oxidated in α-
amino-succinate (αIS). From αIS, a synthetization process by the quinoliate synthase forms 
quinoliate and, through quinoliate phospho-ribosyltransferase, it is converted in nicotinic acid 
mononucleotide (NaNM). Finally, using a nicotinamide adenine dinucleotide (NAD) biosynthesis 
pathway, NaNM is converted in nicotinate (Dawson et al., 1958; Dawson et al., 1956. Yang et al., 
1965) which is an esther of nicotinic acid (niacine or vitamin B3 of β-pyridine carbonic acid). 
The condensation between pyrrolinum cation and nicotinic acid creates the 3,6-dihidronicotine 
which is next dehydrogenated in nicotine by still poorly characterized enzymes (Ziegler and 
Facchini, 2008). A schematic representation of this anabolic process is presented in fig 1.1. Several 
studies have demonstrated that nicotine synthesis might have a defensive role against herbivore 
insects’ attack, which can damage and/or kill tobacco plants. In fact, under leaf damage caused by 
herbivore insect, a specific jasmonic acid-mediated signal is activated leading to a massive increase 
of the gene encoding for nicotine synthesis in the roots (Shoi et al., 2000; Sinclair et al., 2000). This 
mechanism leads to protect tobacco plants through the toxic effect of nicotine on the central 
nervous system of insects. 
The translocation from the root to the leaf takes place in the xylem, where nicotine is transported 
after its synthesis (Shoi et al., 2000; Shoi et al. 2002; Katoh et al.2005). Once in the leaf, nicotine is 
trapped into the vacuole after being delivered at the mesophyl cells (Hashimoto and Yamada, 2003), 
forming ion-pairs with organic acids (Katoh, 2005), and here it is accumulated. 
Nicotine can be found in 2 different isoforms: the levorotary (S)-nicotine, which is the negative (-) 
stereoisomer and shows affinity for the nAchRs, and the (R)-nicotine, with scarce or null effect on 
the above mentioned receptors. Tobacco products contain a larger amount of levorotary nicotine 
whit just a moderate amount of (R) stereoisomers. In fact, (R)-nicotine reaches the 0.1-0.6% of the 
total amount of nicotine (Armstrong, 1998), and it is almost all confined to racemization products 
under combustion (Matta et al., 2007).   
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These steps are essential to produce tobacco manufactures. In fact, when accumulated in the leafs 
nicotine is extracted following different methods and different cures, in order to obtain desiccated 
leafs of tobacco with a variable rate of nicotine inside.        
 
                             
                           
A
B C
 
Fig1.1 Nicotine biosynthesis. Schematic representation of nicotine biosynthetic pathway 
as it happens in the root of nicotiana tabacum plants. Once produced, nicotine is 
unloaded in the leaf vacuoles, where it acts as a protective agent. The covalent binding 
between the pyridine and pyrrolidine ring derives from two separate processes which 
involve several enzymes (Katoh et al. 2005). Abbreviations: AO, aspartate oxidase; QS, 
quinoliate synthase; QPT, quinoliate phosphor-ribolsyltransferase; ODC, ornithine 
decarboxylase; PMT, putrscine-N-metyltransferase; DAO, diamine oxidase 
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3.2 Pharmacology and toxicology: how does nicotine act on the mammalian body?  
Nicotine, as a drug, once administered to humans and animals, exerts pharmacological and 
toxicological effects, including addiction. The main pharmacological action of nicotine is due to the 
high affinity on nAchRs, a family of ion channels-coupled receptors widely expressed in the 
mammalians central (CNS) and peripheral (PNS) nervous system, and in a great amount of other 
cell lines and tissues (muscles and cancer cells) (Gotti et al., 2009). 
Additionally, depending on different types of tobacco manufactures, nicotine absorption and its 
effects strongly differ. For example, in a particular type of tobacco, named "flue-cured" (very 
common in cigarettes), whose smoke has an acid pH (5.5-6.0), nicotine, which is a weak base 
(pKa=8.0), requires to be ionized, and this impairs the buccal absorption of this compound  
(Benowitz et al., 2009). On the other hand, the air-cured tobacco, typical of European cigarettes and 
pipe/cigar tobacco, producing its smoke more alkaline (pH=6.5), allows an improved nicotine 
absorption through the mouth (Armitage et al., 1978; Benowitz et al., 2009). 
Furthermore, different routes of administration can be an important variable to define the blood 
concentration and the absorption rate of nicotine through body tissues. In fact, according to a study 
published on Clinical Pharmacology and Therapy by Benowitz and coll. (1988), while tobacco 
smoking leads to a faster peak than intravenous administration (Benowitz et al., 1988), other 
pharmacological preparations, such as nicotine gum (2mg/piece) and oral snuff (2.5g) are slower in 
their effect, with a much more modest peak (Benowitz et al., 1988). A summary of the main 
pharmacokinetics parameters of nicotine absorption through different route of administration is 
reported in Tab 1.2 (Benowitz et al., 2009). 
Moreover, studies in humans have shown a high variability in blood concentration (10-50 ng/ml in 
the afternoon of typical smokers) and arterial peak (up to 100 ng/ml) of nicotine (Benowitz, 2009) 
in chronic smokers. This factor can vary because of individual differences in puff strength, 
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contextual environmental factors and other parameters, such as the way of smoking to optimize the 
psychoactive effect of nicotine (U.S. DHHS, 2001). Usually, nicotine blood peak declines after 20 
minutes, due to nicotine distribution in other body tissues than bloodstream, with a volume of 
distribution close to 2.6 times body weight (Benowitz and Jacob, 1984). Only less than 5% of this 
nicotine binds to plasma proteins, where, depending on the pH (7.4) of blood, it is present under 
either an ionized (69%) or unionized (31%) form. 
  
Type of nicotine administration Cmax
ng ml-1
Tmax
min
Bioavailability
%
Smoking (one cigarette 5 min, 2 mg/cigarette) 15-30 (V)
20-60 (A)
5-8 (V)
3-5 (A)
80-90 (inhaled
nicotine)
Intravenous (5.1 mg) 30 30 100
Nasal spray (1 mg) 5-8 (V)
10-15 (A)
11-18 (V)
4-6 (A)
60-80
Gum (2mg/30 min) 6-9 30 78
Sublingual tablet (2mg/20-30 min) 3.8 60ca. 65
Transdermal patch (15 mg/16 h) 11-14 6-9h 75-100
Transdermal patch (21 mg/24 h) 12-21 9-12 82
Tab 1.2 Nicotine preparations. Panel showing some of the most common route of 
administration for nicotine coupled with their main pharmacokinetic parameters. Notably, 
transdermal patch (15 mg/16h) guarantees a wide bioavailability with a very long-lasting 
Tmax (adapted from Benowitz et al., 2009). 
 
Several tissues are permeable to nicotine including kidney, liver, spleen, lungs, skeletal muscles, 
placenta, brain and with a less rate also adipose tissue (Matta et al., 2007). Liver metabolism plays a 
central role in human and mammalian degradation of nicotine and, despite the major nicotine 
metabolite known is cotinine (~75%), a wide array of less frequent compounds are products of 
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nicotine metabolism. Among them, the most found in human urines are nicotine-N-oxide (4-7%), 
nicotine glucoronide (3-5%), and other cotinine metabolites (Hukkanen et al., 2005) (fig 1.2).  
Studies carried out to compare the presence of predominant cytocrome P450 across diverse species 
have underlined that monkeys, dogs, cats and rabbits degradate nicotine primarily in cotinine, 
whereas rats and guinea pigs produce more nicotine-N-oxide than cotinine or 3-hydroxycotinine 
(Matta et al., 2007). In addition, it has been shown that mice metabolize nicotine through the 
CYP2A5, which is instead inactive in rats (Hammond et al., 1991; Nakayama et al., 1993) 
supporting the hypothesis of a genetic difference in nicotine deactivation between humans and 
animals. 
         
         
Fig 1.2 Nicotine deactivation pathways. Graphical representation of nicotine 
metabolites. Although cotinine is the main metabolite obtained by nicotine 
degradation (75%), it is followed by a wide number of minor compounds (Matta et 
al., 2007).    
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It has also been reported that parameters like urine excretion and half-life time (t1/2) consistently 
change among humans. For example, after liver metabolism a small part of nicotine is excreted by 
kidney through urines, according to their alkaline or acid pH (from 1% to 20% of the total clearance 
respectively) (Matta et al., 2007). Moreover, although the average plasma half-life elimination for 
nicotine requires roughly 2h, it has been shown an increase of the steady state of plasma nicotine 
levels over 8h in regular smokers (Matta et al., 2007).  
However, studies across species have underlined a remarkably nicotine rate of metabolism 
difference, with similarity between non-humans and humans primates (Seaton et al., 1991), but with 
a tendency to observe a faster metabolism in other animals (Gorrod and Jenner, 1975). For example, 
it has been shown that rodents, like rats and mice, have a shorter nicotine plasma t1/2 than primates, 
which is around 45 minutes and 6-7 minutes respectively (Matta et al.2007). 
In addition, other parameters, such as age, sex and ethnic group has been associated to nicotine 
metabolism variability in humans (Benowitz et al., 2002; Schoedel et al., 2004). Also environmental 
factors like stress, pathologies like kidney disorders, infective diseases (A Hepatitis), and some 
drugs like certain anticonvulsivant and oral contraceptives, might influence nicotine metabolism 
through impairing the activity of CYP2A6  (Matta et al., 2007), contributing to complicate the 
relation between nicotine consumption and individual differences. 
 
4. Neural basis of nicotine abuse and addiction  
 
The addictive property of nicotine is obviously the main reason which causes a widespread use of 
tobacco worldwide. The large expression of nAChRs mRNA in the CNS, together with nicotine-
induced increase of DA release in the nucleus accumbens (NAc), guarantee a modulation of the 
brain reward circuitry in response to nicotine administration. Hence, through its effect, nicotine 
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facilitates short- and long-term synaptic modifications leading to abuse and addiction. Furthermore, 
nicotine effect in the CNS is not only related to its rewarding properties, additionally contributing to 
enhance cognitive and locomotor activity.      
 
4.1 Nicotinic acetylcholine receptors: a physiological target for nicotine addiction  
Even though this thesis is not primary focused on nAchRs, nothing, from the body/brain effect of 
nicotine to abuse/addiction liability of this compound, could be really understood unless a 
paragraph is dedicated to them. As previously mentioned, nAchRs belong to the super-family of 
Cys-loop ligand-gated ion channels (McGehee and Role, 1995; Role and Berg, 1996; Albuquerque 
et al., 1997; Wonnacott, 1997; Jones et al., 1999; Dani, 2001; Hogg et al., 2003), selectively 
activated by the neurotransmitter acetylcholine (Ach) and widely localized within the CNS, PNS 
and neuromuscular junction (NMJ). Through their activation, nAChRs allow an intracellular influx 
of positive ions like sodium (Na+), calcium (Ca2+) and potassium (K+) (Taly et al., 2009) inducing 
a wide array of different physiological modification. 
The history related to nAChRs discovery is long and rich of memorable findings, often awarded 
with prestigious prizes. Some of the earliest hypothesis of a receptor-mediated effect of nicotine in 
the PNS came out almost ten years before the Ach discovery by Otto Loewi and Henry H.Dale, and 
is attributed to John Langley (Langley, 1905). Langley’s discovery was followed by several decades 
of enthusiastic research in the field of study of Ach and its binding sites. In fact, during the last 
century the structure of nAChRs was better studied, taking advantage from both the discovery of 
nAChRs expression in the electric organ of the Torpedo Californica, and the discovery related to 
nicotinic receptors binding affinity of α-bungarotoxin (Albuquerque et al., 2009).  
Both in the CNS and other tissues, nAchRs are assembled from five transmembrane subunits built 
around a water-filled pore located in the centre (McGehee and Role, 1995; Jones et al., 1999; 
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Karlin, 2002) with a pseudo-crystalline form primarily identified from the above mentioned 
Torpedo electric organ (Unwin et al., 2002; Unwin, 2005) (Fig 1.4a; 1.4d). However, this similar 
structure underlines a consistent difference in subunit composition across diverse organs. For 
example, on NMJ, where nAchRs are mainly located postsynaptically to transduce the motorneuron 
impulse evoked by Ach release, five different subunits have been isolated (α, β, γ and ε/θ) 
assembled each other in the same way (Mishina et al., 1986). On the other hand, within the CNS 
only α and β subunits have been identified, although organized in such a complex way to create 
over than 20 different types of pentameters, either homomeric or heteromeric (Changeux, 2010). 
Thus, this variety of subunits composition reflects a substantial difference in pharmacological and 
kinetic properties of nAChRs (Taly et al., 2009).  
In the CNS, nine types of α (α2-10) and three of β (β2-4) isoforms have been described so far, 
although α8 expression has never been reported in mammals (Gotti and Clementi, 2004; Dani and 
Bertrand, 2007; Albuquerque et al., 2009). Most of these nicotinic receptors subunits are assembled 
in a heteromeric fashion (Karlin, 2002), with a less expression of homomeric nAchRs. A putative 
stoichiometry of heteropentameric nicotinic receptor among different subunit combination has been 
described as 2α:3β (Deneris et al., 1991; Sargent, 1993). Among these possibilities, α4β2 subunit 
and α6β2 represent the most common heteromeric receptors detected in the mammalian brain, 
whereas it is quite ascertain that only α7 and α9 might form homomeric compositions in these 
vertebrates (Anand et al., 1991; Cooper et al., 1991; Vernallis et al., 1993; Gotti et al., 1994; Le 
Novere et al., 1996) (Fig 1.4c).  
Recent studies carried out through mRNA in situ hybridization techniques, have also underlined a 
marked differences both in the distribution and density of different nicotinic subunits throughout the 
mammalian brain, with an higher expression of α4, β2 and α7 and low levels of α2, α5, α6, β3 and 
β4 (Drago et al., 2003; Fowler et al., 2008).   
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Fig 1.3 Structure of nAChRs. (a) nAChR is assembled from five transmembrane subunits with 
a central pore permeable to positive ions, and lateral binding sites for its agonist 
acetylcholine (Ach). (b) Graphical representation of a typical quaternary structure (M1-
M4) of nAChRs. (c) Graphical representation of two of the most important nAchRs: the 
homomeric α7 and the heteromeric α4β2. (d) Side view of an α7 pentamer model 
(Changeux, 2010)  
 
Furthermore, due to the lack of selective agonists and antagonists for specific nicotinic receptors 
subunits, the precise distribution of different nAChRs on precise neuronal populations was largely 
unknown, unless the advantage of new tools was available. Nowadays, through techniques like real 
time-polymerase chain reaction (RT-PCR) combined to in vitro electrophysiological recordings and 
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genetic deletion of specific subunits (see below), different research groups have been investigating 
this topic.  
For example, it is now relatively well-known which are the main subunits expressed on 
dopaminergic neurons of the ventral tegmental area and on excitatory and inhibitory afferents that 
modulate their activation or inactivation (Changeux, 2010) (see below). Additionally, specific 
studies have been carried out on hippocampus cells (Sudweeks and Yakel, 2000), comprising an 
area strongly influenced by nicotine while exerting its cognitive enhancing properties.  
nAChRs subunits have a common structure revealing 4 transmembrane domains (M1-M4) with a 
long N-terminal chain and a less extended C-terminal, both facing the extracellular space (Fig 1.4b) 
(Dani and Bertrand, 2007). The M2 transmembrane domain aligns along the pore at the centre of 
the structure contributing to draw the borders of the ion channel (Dani, 1989; Revah et al., 1991; 
Bertrand et al., 1993; Karlin, 2002). 
Early studies provided evidence of two binding sites for nAChRs agonists, located between certain 
subunits (Karlin, 2002; Sine, 2002) and later, using crystals obtained from the Ach binding protein 
(AchBP) secreted by the Limnaea Stagnalis glial cells, this data has been confirmed with a <2.6 A 
resolution in a three-dimensional structure (Smit et al., 2001). Nonetheless, studies on AchBP, 
whose permeability to agonists is extended to nicotine, Ach, α-bungarotoxin, epibatidine and (+)-
tubcurarine (Karlin et al., 2002), have also contributed to understand which subunits are involved in 
the pharmacological properties of nicotine. For example, in the heterodimer α4β2, Ach binding site 
is located in a small pocket between the adjacent α4 and β2 subunits, suggesting their equal role in 
the modulation of nicotine-induced effects (Dani and Bertrand, 2007). 
Four functional nAChRs-states have been described so far: the resting state, the open state and the 
slow and fast-onset desensitized state (Katz and Thesleff, 1957; Sakmann et al., 1980; Neubig et al., 
1982; Heidmann et al., 1983; Jackson, 1989; Hess, 1993; Edelstein et al., 1996; Auerbach and Akk, 
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1998; Prince and Sine, 1999; Reitstetter et al., 1999; Grosman and Auerbach, 2001). Among them, 
only the open position is functional while the others represent closed states. The presence of a 
nAChRs agonist, such as nicotine, quickly allows a switch of these receptors from a resting state, 
which is stable without agonist, to an open state, and then to a slow or fast-onset desensitization 
(Karlin, 2002). 
Moreover, another common feature of nAChRs is that they are allosteric proteins. Basically, 
nAChRs represent the mainstream model of allosteric protein, since the origin of the name 
―allosteric‖ share with these receptors a common history. In fact, this term was coined by Jacques 
Monod and Francois Jacob in 1961 to qualify an enzymatic nonoverlapping mechanism discovered 
by a young student named Jean-Pierre Changeux (Changeux, 2009), who will have been, some 
years later, one of the most eminent researcher on nicotinic receptors. Henceforth through several 
years of study, mostly carried out by Changeux’s group, it has been demonstrated that nAChRs 
contain multiple binding sites, non-competitive antagonists sites and gates that interact with them 
modifying the quaternary structure of domains (Karlin, 2002). This allosteric property confers to 
these receptors the capability to switch from one state to the others, following different possible 
combinations. This mechanism goes beyond the simple agonist binding and it has been theorized 
and adapted to nAChRs by the Monod-Wyman-Changeux (MWC) model (Monod et al., 1965; 
Changeux et al., 1967; Karlin, 1967, , 2002). Furthermore, through this mechanism some 
compounds might behave as negative or positive effectors on nAChRs in order to modulate its 
activity. For example, 17-β-estradiol and other neurosteroids act as a positive effector on α4β2 
nAChRs (Valera et al., 1992; Paradiso et al., 2001; Curtis et al., 2002), while genistein and src-
family kinases (SFKs) act on α7 to dephosphorilate nAChRs in a different way, drastically 
modifying their Ach-evoked response (Charpantier et al., 2005; Cho et al., 2005).   
It is also worth to mention that nAChRs kinetic varies in relation to the pentamer’s assembly. For 
example, while α7 has a relatively low affinity for Ach, with half-effective concentration around 
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200 µM, α4β2 affinity is higher (low affinity: 62 µM, high affinity: 1.6 µM) (Buisson and Bertrand, 
2001) with some modification produced by repeated exposure to agonists (Sallette et al., 2005; 
Vallejo et al., 2005). As previously mentioned, agonist exposure also produces an inactive state 
known as desensitization. Due to the less affinity of α7-containing neuronal nAChRs to agonists, it 
has been demonstrated they desensitize rapidly after a high concentration of them, whereas α4β2 
have a slower inactivating kinetic (Dani and Bertrand, 2007). On the other hand, nAChRs also show 
a slow desensitization process which involves much more α4β2 subunits, when activated by a 
prolonged lower concentration of agonists, than α7. In this case α7 does not desensitize below 1µM 
concentration of agonist, while α4β2 does it below 0.1 µM (Dani et al., 2000; Quick and Lester, 
2002; Wooltorton et al., 2003). Obviously, the knowledge of this differences in subunit composition 
and desensitization time is crucial to better understand the multifaceted effect that nicotine exerts in 
the CNS. 
Moreover, the localization of nAChRs in the CNS and NMJ slightly differs. In fact, while in the 
NMJ they are mainly located on the surface of muscle cell bodies, in the CNS a number of nicotinic 
receptors are situated on the presynaptic terminal (Sargent, 1993). This surely represents a clever 
route for Ach to modulate different processes within the brain, and to confer a prominent role to 
nicotine as a cognitive enhancing drug. Thus, nAChRs play a role in neurotransmitter release 
(McGehee et al., 1995; McGehee and Role, 1995; Gray et al., 1996; Role and Berg, 1996; Alkondon 
et al., 1997; Lena and Changeux, 1997; Wonnacott, 1997; Radcliffe and Dani, 1998; Jones et al., 
1999; Luetje, 2004; Sher et al., 2004). For example, it has been shown that presynaptic nAChRs on 
glutamatergic terminals facilitate the release of glutamate when activated, contributing to modulate 
several brain functions, including synaptic plasticity (Wonnacott, 1997). Therefore, also nicotine 
application has revealed a high capability to induce the outflow of several neurotransmitters such as 
choline and acetylcholine (Grady et al., 2001), GABA (Alkondon et al., 1997), serotonin (Kenny et 
al., 2000), norepinephrine (Singer et al., 2004), endogenous opioid peptides (Pomerleau, 1998), 
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excitatory aminoacids (Schilstrom et al., 2000), and dopamine (DA) (Di Chiara and Imperato, 
1988). 
Despite this role, brain nAChRs have been also detected  in the postsynaptic space, to allow a fast 
direct nicotinic transmission, in the preterminal space and onto dendrites, axons and soma (Dani and 
Bertrand, 2007).  
In light of this consideration, nAChRs represent a substrate whose activity is not only related to 
modulate Ach transmission, being involved in several function within the CNS. Since their 
distribution is largely extended to the whole brain, it is obvious that these receptors participate in 
several functions, from learning and memory (Ji et al., 2001; Ge and Dani, 2005) to 
pathophysiological mechanism involved in Alzheimer’s disease, schizophrenia, epilepsy and 
addiction (Lena and Changeux, 1998; Court et al., 2001; Raggenbass and Bertrand, 2002; Dani and 
Harris, 2005). 
 
4.2 Neural effects of nicotine 
Recently, taking advantage of new tools and strategies in neuroscience-related field, it has been also 
clarified which nAChR subunits are involved in specific behaviors. For example, the well-known 
nicotine-induced cognitive and psychomotor enhancing effect and its rewarding properties have 
been studied with genetically modified mice lacking the gene encoding for some nicotinic subunits 
(Changeux, 2010). These results, compared to earlier evidence about the main features of nicotine 
activity in the brain, have enlarged the knowledge about this substance.     
Providing a detailed description of nicotine-induced motor and cognitive enhancing properties goes 
beyond the scope of this thesis, and a pertinent overview of this matter can be found in a number of 
excellent papers and reviews (see for example Changeux, 2010). Under this circumstance, it is only 
worth to underline how specific subunits of the nAChR have been selectively implicated in some 
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aspects of cognitive and motor control. For example, it has been demonstrated that β2 subunit is 
involved in nicotine-induced memory enhancement related to aversive stimuli (Picciotto et al., 
1995; Caldarone et al., 2000; King et al., 2003), social interaction in the resident-intruder test 
(Granon et al., 2003), and modulation of navigation and exploration in an open field paradigm 
(Maubourguet et al., 2008). Moreover, α4 and β3 subunits seem to be involved in spontaneous 
locomotor behavior and acoustic startle response in the prepulse inhibition, respectively (le Novere 
et al., 1999; Cui et al., 2003). Finally, it has been shown that, while α7 modulates the efficiency in 
attentional tasks, β3 is employed in the modulation of seizures (Salas et al., 2004; Young et al., 
2004). 
Despite the role of nAChR subunits in the modulation of locomotor activities and cognitive 
performance, nicotine also elicits an array of modifications in the brain reward circuitry leading to 
nicotine abuse and addiction. Nicotine, as an addictive substance, produces rewarding effects acting 
on the mesolimbic DA circuit, a dense pathway of midbrain projections to forebrain structures and 
cortical areas, which regulates the response to pleasant and unpleasant stimuli. Through its 
connection, this circuit, which is one of the first DA-containing pathway discovered (Marsden, 
2006), ultimately orientates goal-directed behavior.   
Addiction is only the end point of a complex series of brain modification whose features basically 
are: (1) the compulsive drug seeking and voluntary drug intake, (2) the loss of control related to this 
behavior, and (3) the drug consumption despite its side effects (Everitt and Robbins, 2005; Koob 
and Le Moal, 2008). Thus, addiction is a relapsing brain disease which can harmfully interferes 
with the quality of life and individual wellness, also because of the emerging withdrawal symptoms 
when the access to drug is prevented (Koob and Le Moal, 2008). Moreover, after a prolonged 
consumption of an addictive drug, tolerance can be developed, leading the user to increase the rate 
and dose of drug to perceive its psychotropic effect (APA, 2000).     
The activation of the brain reward circuitry by drugs of abuse concerns a wide array of short and 
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long-term modifications which vary in relation to drug exposure, triggering the neural adaptation to 
the substance (Koob and Volkow, 2010). Among these changes, it is now well-known how drugs of 
abuse modulate the synaptic strength and synaptic plasticity in some crucial brain regions, and how 
up- and down-regulation of specific receptors subunits can guide certain adaptations. In fact, 
addictive substances modify specific form of synaptic adjustment named long-term potentiation 
(LTP) and long-term depression (LTD) (Kalivas et al., 2005; Bellone and Luscher, 2006; Kauer and 
Malenka, 2007). Basically, they are two forms of plasticity that allow synaptic strengthening or 
weakening to, ultimately, fine modulate neural circuitries and to adapt behavior to a specific 
environment (Malenka and Bear, 2004). Through a long-lasting impairment of these forms of 
synaptic plasticity drugs of abuse cause addiction (Kasanetz et al., 2010). 
Currently, among different brain areas involved in modulating steps from reward-dependent 
properties of a drug to the compulsive use (addiction), five main circuitries have been isolated. It is 
worth to mention that neuroadaptation of these circuitries follows an engagement in succession 
(Koob and Volkow, 2010), underlining how time-dependent changes are fully implicated in drug 
dependence. Basically, these circuitries make up the ―brain reward circuitry‖ (fig 1.4)  and they are: 
the mesolimbic DA system, the ventral striatum, ventral striatum/dorsal striatum/thalamus circuits, 
dorsolateral frontal cortex/inferior frontal cortex/hippocampus circuitries, and amygdala (Koob and 
Volkow, 2010). 
Specifically, the mesolimbic DA system is a pathway of projections which arises from ventral 
tegmental area (VTA) DA neurons, involving as primary target the NAc, considered as the major 
component of the ventral striatum (Wise and Bozarth, 1987; Koob and Bloom, 1988). The 
activation of this pathway triggers the earliest stages of drug intake, and it is crucially implicated in 
the acute and chronic use of addictive substances. For example, it has been shown that drugs of 
abuse exposure induces short- and long-term modifications in DA neurons firing rate (Bonci et al., 
2003), and that a single in vivo exposure to psychostimulants induces AMPA-mediated LTP on DA 
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neurons (Ungless et al., 2001). The NAc, through its connection to some of the most important 
cortical and subcortical areas (e.g. the prefrontal cortex) (Groenewegen et al., 1999) plays a crucial 
role in the modulation of rewarding properties of natural stimuli and drugs of abuse, thus, directing 
the reward-seeking and goal-directed behaviors (Grace, 2000; Jongen-Relo et al., 2003; Cassaday et 
al., 2005). In fact, it has been shown that several drugs of abuse, including cocaine, morphine, 
nicotine and cannabinoids, through their effects on VTA DA neurons, enhance the release of DA in 
the NAc (Di Chiara and Imperato, 1988), and that DA increase constitutes a biological substrate for 
natural stimuli rewarding properties (Fibiger et al., 1992; Kelley, 2004). In addition, it has been 
reported that specific depletion of DA or DA receptor blockade, induce several deficits in appetitive 
learning, and in approach behavior (Di Ciano et al., 2001; Parkinson et al., 2002; Faure et al., 2005), 
while lesions of the NAc cause disruption in motivated behavior, operant and emotional learning 
and behavioral flexibility (Reading and Dunnett, 1991; Cardinal et al., 2001; Cassaday et al., 2005) 
Further modifications related to addiction have been described, involving the upregulation of NAc 
cAMP pathway and cAMP response element binding protein (CREB) in response to chronic 
administration of opiates and cocaine, whose effect contributes to reduce the rewarding value of 
these addictive substances (Chao and Nestler, 2004).  
It is worth to mention that, despite the apparent simple organization of the VTA-NAc pathway, 
several and additional subdivision have been proposed so far, which highly complicate the 
understanding of the regulation of DA release in the NAc. In fact, beyond the comprehensive 
structural property of the NAc, it is now well-known that this area is divided in two functional 
subregions: the core (CoNAc) and the shell (ShNAc). These two areas play a well-distinct role, 
being the latter much more involved in the early steps of drug of abuse response (Goto and Grace, 
2008), and strongly connected to other emotion-regulating brain areas (Ito et al., 2004). 
Nonetheless, also the architecture of VTA has been separated in distinct regions, whose response to 
drug of abuse administration strongly differs. For example, in an elegant study, Ikemoto et al. 
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(2006) demonstrated that rats self-administer nicotine in the posterior part of the VTA rather than 
anterior (Ikemoto et al., 2006), suggesting a distinct functional organization of these two VTA 
portions.   
 
 
Fig 1.4 Brain reward circuitry and neurociruitry employed in acute response to drugs of 
abuse. Sagittal view of a rodent brain with a schematic representation of the main areas 
involved in the acute response to addictive substance. As marked in red, VTA DA neurons 
work like a maestro of this process, sending projections to several cortical, limbic and 
subcortical areas. Through their connections DA modulates the primary reinforcing 
properties of drugs of abuse. Abbreviations: AC, anterior commissure; AMG, amygdala; 
ARC, arcuate nucleus; BNST, bad nucleus stria terminalis; Cer, cerebellum; C-P, caudate-
putamen; DMT, dorsomedial thalamus; FC, frontal cortex; Hippo, hippocampus; IF, inferior 
colliculus; LC, locus coeruleus; LH, lateral hipotalamus; NAcc, nucleus accumbens; OT, 
olfactory tract; PAG, periaqueductal grey matter; RPn, reticular pontine nucleus; SC, 
superior colliculus; SNr, substantia nigra reticulata; VP, ventral pallidum; VTA, ventral 
tegmental area (Koob and Volkow, 2010).  
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In addition, other theories beyond the DA-hypothesis of reward have been proposed, arguing about 
the exclusive DA enhancement role to modulate reward (Carlezon and Thomas, 2009; Koob and 
Volkow, 2010). However, the latter hypothesis still remains the best investigated, especially when it 
concerns the early stages of drug consumption. In fact, under these conditions, the prolonged and 
unregulated drug-induced DA release contributes to create an habit-learning related to drug-induced 
rewarding effects (Everitt and Wolf, 2002).  
Nicotine, as well as other addictive substances, primarily acts on the mesolimbic/mesoaccumbens 
pathway to activate the brain reward circuitry, whose earliest modification is the increase of DA 
release from the VTA to the NAc. In fact, studies carried out with the intracranial self-stimulation 
(ICSS) in animals have shown that nicotine decreases the ICSS threshold, whereas nicotine 
withdrawal exerts the opposite effect (Epping-Jordan et al., 1998). Moreover, intravenous self-
administration of nicotine is blocked by neurotoxin-specific lesions of mesolimbic DA system 
(Watkins et al., 2000), although other measures appear to act through a DA-independent mechanism 
(Laviolette et al., 2002). Additionally, it has been shown that: (1) systemic nicotine-induced 
increase of DA in the NAc is blocked by intra-VTA infusion of the nAChR antagonist 
mecamylamine (Nisell et al., 1994), (2) infusion of dihydro-β-erythroidine in the VTA decreases 
nicotine self-administration (Corrigall et al., 1994), suggesting a preferential effect of nicotine in 
this area, and (3) specific lesions of the NAc or DA receptors antagonist injections impair nicotine-
mediated reinforcing effects (Corrigall and Coen, 1991; Corrigall et al., 1992).  
To guide these modifications, nicotine acts through a common fashion to other drugs of abuse, 
enhancing the firing rate and burst firing activity of VTA DA neurons (Erhardt et al., 2002; Mameli-
Engvall et al., 2006). Basically, even under physiological conditions, VTA DA neurons exert a 
double pattern of firing activity: (1) a single-spike firing or (2) burst rhythms (Grace and Bunney, 
1984a, 1984b; Kitai et al., 1999). The latter has been associated to a larger DA release, and to the 
expression of immediately early genes within the NAc (Chergui et al., 1996; Chergui et al., 1997). 
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For this reason, a switch from tonic firing to phasic burst firing is a feature of unexpected reward or 
reward-predicting stimuli (Schultz, 2002). Since VTA DA neurons receive a wide array of 
glutamatergic (from PFC and peduncule pontine nucleus) and GABAergic projections, it has been 
shown how the burst firing modulation is due to the balance between excitatory and inhibitory 
aminoacid release to VTA DA cell bodies, with a crucial involvement of glutamatergic, and also 
cholinergic, afferents (Floresco et al., 2003; Lodge and Grace, 2006). In addition, closer analysis of 
VTA DA firing patterns in mice have revealed four different types of firing activity divided in: (1) 
high firing, high bursts; (2) high firing, low bursts; (3) low firing, low bursts; (4) low firing, high 
bursts (Mameli-Engvall et al., 2006; Changeux, 2010), and it has been demonstrated that these 
differences are due to the activation of different types of nAChR subunits. Hence, nAChRs play a 
crucial role also under physiological condition to modulate the spontaneous activity of mesolimbic 
neurons.        
Taken together, these considerations and findings drew a very complex scenario related to nicotine 
action in the brain reward circuitry, which ultimately directs nicotine addiction. Recent studies with 
knock out and lentiviral reexpressed mice have shed some light to better understand which receptor 
subunits modulate this wide array of both molecular and behavioral modification. 
Since nAChRs are widely expressed in the brain reward circuitry, it is obvious that the ultimate 
effect produced by nicotine depends on the different balance played by distinct subunits involved in 
this mechanism. A detailed schematic description of these subunits on VTA DA neurons and 
afferent projections is reported in fig 1.5. Specifically, different studies have investigated which 
subunit triggers certain physiological behaviors of VTA DA neurons, that represent the crucial start 
point to modulate the response to rewarding stimuli. A well accepted hypothesis, confirmed by 
studies in genetically modified mice, involves a central function of β2 and α7-containing nAChRs 
in the modulation of nicotine reinforcing effects. In particular, β2 subunit is considered as the 
oligomer mainly involved in the neuron switching from a resting to an excited state, and α7 as a fine 
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regulator of excited state after β2-containing receptors activation (Mameli-Engvall et al., 2006). In 
fact, it has been demonstrated that β2-/- mice only show a low-frequency, low-bursting activity 
pattern of VTA DA neurons (Mameli-Engvall et al., 2006). Moreover, VTA DA neurons do not 
respond to nicotine injection (Picciotto et al., 1998). In addition, lentiviral reexpression of β2-/- 
subunit in the VTA does not fully restore nicotine-induced excitation (Picciotto et al., 1998), being 
probable that it is necessary a functional activation of β2 also on excitatory projection to the VTA. 
On the other hand, α7-/- mice have only high frequency, high bursting mode of VTA DA neurons, 
and nicotine injection leads to a rapid excitation of these neurons followed by a rapid return to 
baseline activity, also with a tendency to a lower firing activity (Mameli-Engvall et al., 2006).  
This evidence underlines that a concomitant activation of both α7 and β2 is necessary to obtain a 
full expression of events related to nicotine reinforcement (Changeux, 2010). To confirm this 
involvement, other studies have shown that blockade of α7-containing neurons and N-metyl-d-
aspartate receptors (NMDA-Rs) in the VTA diminishes DA release to the NAc (Schilstrom et al., 
1998), and post-mortem human studies have observed an over-expression of α4β2 in smokers brain 
tissue (Benwell et al., 1988; Breese et al., 1997). Moreover, this result on humans has also been 
reported on living patients through Position Emission Tomography (Wullner et al., 2008). In 
addition, comparing systemic administration studies in animals with tobacco smoke, it has been 
reported how the overall excitation of DA neurons and LTP on glutamatergic terminals strongly 
depend to the balance between desensitization of β2 subunit in DA cell body, and enhanced 
glutamate release through α7 stimulation (Pidoplichko et al., 1997; Mansvelder and McGehee, 
2000; Mansvelder et al., 2002; Pidoplichko et al., 2004; Dani and Harris, 2005). This occurs 
because the rate of nicotine after smoking is able to desensitize faster β2 than α7 which are less 
sensitive to nicotine, especially at lower concentration (Wooltorton et al., 2003).  
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Fig 1.5 Localization of nAchRs on VTA DA neurons and its afferent projections. VTA DA 
neurons play a crucial role in the early stage of nicotine response. Nicotine acts in these 
neurons through the widespread localization of different homo- and heteropentameters 
nAChRs. Notably α4β2 subunits have a wider expression than α7 (Changeux, 2010).  
Abbreviations: Ach, acetylcholine; DA, dopamine; Glu, glutamate; LDTg, laterodorsal 
tegmental nucleus; PPTg, pedunculo-pontine tegmental nucleus; VTA, ventral tegmental 
area; PFC, prefrontal cortex; NAc, nucleus accumbens. 
 
However, not only β2 and α7 have been involved in the physiological modulation of VTA DA 
neurons and brain reward circuitry. In fact, also α4 and α6 subunits seem to modulate some aspect 
of nicotine-induced effects in the mesolimbic system. Hence, it has been demonstrated that both α4 
and α6 control striatal DA release by Ach or nicotine injection (Faure et al., 2010). In addition, it 
has been recently observed that α4, but not α6, which is mainly expressed in the terminal regions 
(Exley et al., 2008), is centrally involved in the switch from tonic to phasic VTA DA firing rate 
(Faure et al., 2010).     
Beside this clear effect of some nAChR subunit in the modulation of VTA DA neuron response, 
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other studies have evaluated the role of specific nicotinic subunit deletion using behavioral 
paradigms. For example, it has been demonstrated that mice lacking the β2, α6 or α4 subunits fail to 
self-administer nicotine, whereas α7-/- mice do not (Pons et al., 2008). Interestingly, nicotine self- 
administration is restored when a lentiviral injection elicits the reexpression of β2, α4 and α6 (Pons 
et al., 2008), suggesting a strong involvement of these subunits in the behavioral reinforcing 
properties of nicotine. Furthermore, using intra-VTA infusion of nicotine, it has been shown that β2-
/-
 mice do not self-administer nicotine while they do it when β2 subunit is reexpressed (Maskos et 
al., 2005). By contrast, α4-/- mice show an initial increase followed by a decrease of intra-VTA 
nicotine self-administration, while  α6-/- do not show any difference to wild type (Maubourguet et 
al., 2008).        
Further studies have also underlined how deletion of α5 or overexpression of β4 enhance nicotine 
self-administration and that β2 subunit efficiency, rather than α7, plays a pivotal role in nicotine-
induced conditioned place preference (Stolerman et al., 2004; Walters et al., 2006). Finally, α4 
knock-in mice show a conditioned place preference with doses of nicotine 50-folds lower than wild-
type (Tapper et al., 2004) and it has been hypothesized that α6 subunit plays a role in mediating the 
rewarding properties of nicotine (Jackson et al., 2009).   
It is, finally, worth to mention how nAChR functionality may influence the chronic administration 
of nicotine and withdrawal symptoms. Since nicotine is an abused substance, it is even more 
interesting to evaluate the role of nAChRs under physiological conditions, which can explain the 
mechanisms at the downstream of nicotine addiction. As mentioned above, chronic administration 
of an addictive drug causes a short and a long-term modification within the brain reward circuitry 
which triggers, together with other events, the switch from abuse to addiction. Nicotine does that 
through a receptor sensitization to subsequent drug exposure (Caille et al., 2009). The molecular 
basis of this process depends on a combination of different molecular changes. Among them a 
possible mechanism might involve an up-regulation, instead of down-regulation typically observed 
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when other drugs are abused (Gutkin et al., 2006; Kenny and Markou, 2006), of mainly α4β2 
nAChRs in the VTA after a long-term nicotine exposure (Nashmi and Lester, 2007; Govind et al., 
2009). Moreover, it could be possible that a change in presynaptic cholinergic transmission might 
happen to modulate this sensitization process. This second mechanism might involve a balance 
between the decreased involvement of β2 subunits and a compensatory role of the α7 after a chronic 
nicotine exposure (Besson et al., 2007). Finally, also a long-term nicotine-induced reinforcement of 
glutamatergic input from cortical regions to VTA DA neuron has been evaluated (Caille et al., 
2009). Noteworthy, it has been also reported a VTA and NAc up-regulation of glutamate receptors 
after chronic exposure to nicotine which would contribute to the long-term rewarding effect of this 
drug (Ray et al., 2009).                   
Also nicotine-induced withdrawal symptoms have been studied using knockout mice. To 
summarize, it seems that nAChRs act on both somatic and affective symptoms after quitting 
smoking with a prominent role of α2, α5, α7, β4 and β2, α6 respectively (Changeux, 2010).    
In conclusion, even though studies on genetically modified mice represent a promising strategy to 
improve the knowledge on nicotinic subunits involved in specific behaviors, some limitation of this 
model should be taken into account. In fact, it has been reported that deletions in some genes 
encoding for certain subunits cause a compensatory over-expression of other proteins, affecting 
different behavioral measures (Fowler et al., 2008). This occurs especially when the gene 
inactivation is protracted along the physical development. For example, it has been shown that α7-/- 
mice exhibit an augmented expression of α3 and α4 subunits,  and that β3-/- show an increase of α6 
(Fowler et al., 2008). Therefore, it is obvious that such kind of unplanned problem may bias against 
the reliability of measures with these models. 
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5. Final remarks  
 
In light of all these considerations tabagism appears to be a distressing problem, not easy to get 
fixed and where a wide amount of variables must be taken into account. The large expression of 
different nicotinic subunits across the brain, combined to several pharmacokinetic and 
pharmacodynamic parameters related to nicotine action in the brain and whole body, should be 
correctly evaluated to make up a pharmacotherapy to treat nicotine dependence. Currently, different 
pharmacological approaches have provided successful results in the treatment of nicotine use 
disorders. Most of them benefit from previously prescribed compounds which were  later approved 
also for nicotine addiction. Among these molecules we can include the antidepressant buproprion 
(used as a first-line therapy), the α2 noradrenergic agonist clonidine and the tricyclic antidepressant 
nortriptiline (both used as second-line therapy) (Ross and Peselow, 2009). In addition, the food and 
drug administration (FDA) have approved a wide array of nicotine replacement therapies such as 
gum, transdermal patch, inhaler etc. (Benowitz et al., 2009) although whose efficiency is quite 
limited. Finally, also the long-acting α4β2 nAChR partial agonist varenicline has been introduced as 
a drug to quit smoking, and to prevent relapse to nicotine during abstinence (Gonzales et al., 2006; 
Jorenby et al., 2006; West et al., 2008).  
Beside these compounds, some studies, either clinical and pre-clinical, are still evaluating the 
therapeutic potential of different drugs such as an immune vaccine and the cannabinoid type 1 
receptor antagonist rimonabant, clinically tested for obesity but now rejected from approval due to 
its severe side effects (Ross and Peselow, 2009). 
The hypothesis of a modulating role played by the manipulation of the endocannabinoid system in 
nicotine addiction is an intriguing topic which is captivating several research groups all around the 
world. In fact, in light of data revealing a co-morbility between tobacco and cannabis use, especially 
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in adolescents (Viveros et al., 2006), and a common neurobiological substrate where cannabinoids 
and nicotine act in the brain, a possible modulatory activity of endogenous cannabinoids on 
nicotine-induced rewarding effects should be carefully taken into account.                 
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Chapter II 
THE ENDOCANNABINOID SYSTEM: FROM CLASSICAL 
CANNABINOIDS TO NUCLEAR RECEPTORS  
  
 
Introduction 
 
The eCb system is a family of lipid molecules, enzymes and receptors whose discovery is relatively 
recent (Jonsson et al., 2006; Marsicano and Lutz, 2006). In fact, despite the old interest on 
Cannabis Sativa active principles, the essential steps which allowed the isolation of specific 
cannabinoid receptors and endogenous compounds occurred within these last 20 years (tab 2.1). 
 
1.Cannabinoid receptors 
 
Once Gaoni and Mechoulam (1964) elucidated the structure of the tricyclic dibenzopyran derivative 
Δ9-tetrahydrocannabinol (Δ9-THC; THC), the main alkaloid of Cannabis Sativa (Hollister, 1986), 
and Howlett's group in 1988 found a specific binding site for THC in the brain (Devane et al., 
1988), the intriguing possibility that neurons, and other cell lines, could express specific 
cannabinoid receptors quickly captivated more than one research group worldwide. This interest 
became something real when, the so-called cannabinoid type 1 (CB1-R) and cannabinoid type 2 
(CB2-R) receptors were cloned, in 1990 (Matsuda et al., 1990) and 1993 (Munro et al., 1993) 
respectively
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YEARS Discoveries
<1900 1964-isolation of cannabinoids from Cannabis Sativa (Woods)
1900-1950 1940-eluciadtion and synthesis of cannabinol (Todd)
1950-1970 1964-elucidation structure of THC (Gaoni and Mechoulam)
1970-1990 1984-cannabinoids decreases cyclic adenosine monophosphate (Howlett and Flemming)
1988-THC binding site in the brain (Devane)
1990-clonation of CB1-Rs (Matzuda)
>1990 1992-identification of anadamide (Devane, Mechoulam, Petrwee)
1993-identification and clonation of CB2-Rs (Murno)
1994-development of the first CB1-Rs antagonist (Rinaldi-Carmona)
1994-mechanism of cannabinoid biosynthesis (Di Marzo)
1995-identification of 2-AG (Mechoulam, Waku)
1996-clonation of FAAH (Cravatt)
1997-evidence for AEA transport (Beltramo)
1997-Neurobiology of cannabinoid dependence and withdrawal (Rodriguez De Fonseca)
1999-generation of CB1-KO mice (Ledent)
2000-AEA activates TRPV1 (Zygmund)
2001-modulation of synaptic transmission in the brain by eCbs (Kano, Wilson, Nicol)
2001-evidence about other CB-Rs (Hajos, Ledent)
2003-AEA degradation and anxiety (Kathuria)
2003-clonation of eCbs biosynthesizing enzymes (Bisogno)
TAB 2.1 Brief history of cannabinoid research.  Major breakthroughs on 
cannabinoids and endocannabinoids field of study. Notably the biggest piece of 
evidence about this topic occurred within the last 20 years (>1990).  ((Di Marzo, 
2006) with some modifications). 
 
 
Notably, progresses on this topic also stimulated a worthwhile interest regarding the 
neuropharmacology of cannabinoid receptors which, in 1994, allowed the development of SR 
141716-A (SR, rimonabant) the first and well-studied CB1-R antagonist (Rinaldi-Carmona et al., 
1994). At the state of art, after sixteen years of research, several CB1- and CB2-R agonist or 
antagonist are now available as pharmacological tools (Pertwee, 2008) (Tab 2.2).  
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L iga n d C B 1 K i va lu e (n M ) C B 2 K i va lu e (n M )
CB1 selective agonists
ACEA 1.4; 5.29 19.5; >2000
R-(+)-methAEA 17.9 to 28.3 815 to 868
Agonist without CB1-CB2
selectivity
CP55940 0.5 to 5.0 0.17 to 0.52
R-(+)-WIN55212-2 1.89 to 123 0.28 to 16.2
(-)-Δ9THC 5.05 to 80.3 3.13 to 75.3
AEA 61 to 543 279 to 1940
2-AG 58.3; 472 145; 1400
CB2 selective agonists
AM1241 280 3.4
JWH-133 677 3.4
CB1 selective antagonists
SR141716-A 1.8 to 12.3 514 to 13200
AM281 12 4200
AM251 7.49 2290
CB2 selective antagonists
SR144528 50.3 to >10000 0.28 to 5.6
AM630 5152 31.2
 
TAB 2.2 Ki values related to the most used CB-R agonists and antagonists. Data 
shown in this table are related to Ki values of some of the most important CB1 and 
CB2-Rs agonists and antagonists, whose activity has been studied for the 
displacement of [3H]-CP59940 and [3H]-HU-243 from CB-R binding sites (Pertwee, 
2008) 
 
1.1 Structure and localization of cannabinoid receptors 
Both CB1- and CB2-Rs are 7-transmembrane domain Gi-protein-coupled receptors with a 
widespread localization within the human and animal body. Human studies focused on structure of 
these receptors have reported a 44% of similarity in aminoacid sequence between CB1 and CB2-Rs  
with a splice variant of NH2 terminal in CB1 (Kano et al., 2009). In addition, despite evidence 
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suggesting the likely existence of CB1-Rs as homodimers (Wager-Miller et al., 2002), further 
studies have reported the presence of a CB1-heteromer dimerized with the dopaminergic receptor 
type 2 (D2-R) (Kearn et al., 2005; Mackie, 2005). This dimerization allows the formation of a 
CB1/D2 complex that is activated by CB1-Rs stimulation. Nonetheless, even a dimer with the 
Orexin type1 receptor has been proposed (Hilairet et al., 2003). Thus, this dimerization might 
suggest a specific cross-talk between eCb and other systems, whose functional role would be of 
interest in the pathophysiology of specific brain disorders (Kearn et al., 2005).  
 Despite the ubiquitous presence of CB-Rs in the mammalian body, there is a substantial difference 
about the localization of CB1 and CB2-Rs in the CNS and other tissues. In fact, it is now-well 
known that only a scarce amount of CB2-Rs is located in the CNS (mostly in the cerebellum and 
brain stem) (Van Sickle et al., 2005; Ashton et al., 2006), with a great abundance at the surface of 
immune cells (T and B cells, microglial cells), spleen, tonsils and peripheral tissue (Munro et al., 
1993; Galiegue et al., 1995; Piomelli, 2003). On the other hand, CB1-Rs expression is higher in the 
CNS (Howlett et al., 1990; Herkenham et al., 1991) rather than other tissues (muscles, liver, 
gastrointestinal tract, adipose tissue and pancreas) (Batkai et al., 2001). In the brain, CB1-Rs 
represent the most abundant Gi-protein-coupled receptor found (Rodriguez de Fonseca et al., 2005) 
and through their activation, cannabinoids exert their psychotropic effect and eCbs their 
physiological properties (Ledent et al., 1999; Elphick and Egertova, 2001). Early animal studies 
with the synthetic cannabinoid radioligand [3H]-CP55,940 reported an high level of CB1-Rs in 
regions like the innermost layers of the olfactory bulb, CA3 of the hippocampus, lateral part of the 
striatum, globus pallidus, substantia nigra pars reticulata, and cerebellar molecular layer 
(Herkenham et al., 1990; Herkenham et al., 1991; Mailleux and Vanderhaeghen, 1992). In contrast, 
moderate and low levels of these receptors have been found in the cerebral cortex, septum, 
amygdala, some regions of the hypothalamus, spinal dorsal horn, thalamus, brain stem and spinal 
ventral horn (Herkenham et al., 1990; Herkenham et al., 1991; Mailleux and Vanderhaeghen, 1992). 
Further investigations, carried out after the cDNA-CB1-Rs clonation (Matsuda et al., 1990), have 
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better clarified the cellular localization of these receptors and their mRNA expression through 
immunoistochemistry and in situ hybridization techniques (fig 2.1 a).   
Immunoistochemistry has revealed a double pattern of CB1-Rs mRNA-labeling across the CNS, 
with uniform response in the major neuronal population of the thalamus, striatum (Hohmann and 
Herkenham, 2000), hypothalamus, and cerebellum. Nonetheless, an un-uniform response was 
detected in some cell lines of the cerebral cortex (Marsicano and Lutz, 1999), hippocampus (Katona 
et al., 1999; Katona et al., 2000; Kawamura et al., 2006), and amygdala (Katona et al., 2001; 
McDonald and Mascagni, 2001). Moreover, a distinct dissociation between mRNA expression and 
immunoreactivity has been reported to underline a specific target of these receptors in the 
presynaptic space rather than postsynaptic (Kano et al., 2009), with a much more intense 
accumulation in the presynaptic portion of the axon (Kawamura et al., 2006). Furthermore, it has 
been well-demonstrated that CB1-Rs are preferentially distributed on the top of inhibitory synapse 
depending on specific brain region (Kawamura et al., 2006).   
 
1.2 Functional relevance of cannabinoid receptors and their involvement in signal transduction 
Among the main structural and functional characteristics of CB-Rs, it would be taken into account: 
(1) their critical involvement in the brain development where they control cell differentiation 
(Rueda et al., 2002), and (2) their full preservation throughout evolution (human, rat and mouse 
share 97-97% amino acid sequence identity) (Rodriguez de Fonseca et al., 2005). These features 
suggest that eCbs, through their affinity for CB-Rs, play a central role in cell and system 
physiology. Moreover, beyond their well-ascertained involvement in some physiological states, 
other evidence has underlined that blockade, genetic polymorphism and loss of CB-Rs (especially 
CB1) might be related to certain pathophysiological conditions and that exogenous cannabinoid 
administration might disrupt certain physiological processes. In fact, studies on genetic variants of 
CHNR1 (which encodes for CB1-R) has reported a positive correlation between gene polimorphism 
and a wide array of different pathological state (e.g. Alzheimer's disease, obesity, attentional 
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deficits, schizophrenia) (Kano et al., 2009). Additionally, also a loss of striatal CB1-Rs has been 
recently considered as a key pathogenetic factor for Hungtington’s disease(Blazquez et al., 2010) 
and an agonistic action at the level of CB1-Rs might improve some basal ganglia-related symptoms 
(Fernandez-Ruiz, 2009). 
Basically, cannabinoid receptors activation leads to a signal transduction pathway which inhibits the 
cyclic adenosinemonophosphate (cAMP) formation, causing consequently a decrease of protein 
kynase A (PKA)-dependent phosporylation process (Devane et al., 1988; Howlett et al., 1990). 
Besides the pivotal role of this mechanism, other mechanisms have been proposed to explain the 
CB-Rs signaling. For example, it has been shown that CB1 and CB2-Rs are also coupled to ion 
channels through GolfProtein, whose activation inhibits the Ca
2+
 influx at the level of N-P/Q and L 
Ca
2+
channels (Mackie and Hille, 1992; Twitchell et al., 1997), additionally causing an increase of 
inward rectifying potassium conductance and A current (Mackie et al., 1995) (fig 2.1 b). 
Furthermore, a coupling mechanism between these receptors and different species of intracellular 
cascades (e.g. mitogen activated kinase cascade and phophatidylinositol-3 kinase) have been 
suggested by several studies (Bouaboula et al., 1997; Howlett, 2002).  
Among the modifications caused by CB-R activation, the most important is the suppression of 
neurotransmitter release (Schlicker and Kathmann, 2001). Through this process, eCbs exert their 
specific neuromodulatory effect in the CNS and PNS. To facilitate this mechanism the localization 
of CB-Rs is, preferentially, presynaptic, and their activation depends on eCbs release from the 
postsynaptic neuron (see below). For example, it has been shown that CB1-Rs activation suppresses 
the release of almost all catecholamine (dopamine, norephinephrine, serotonin) (Ishac et al., 1996; 
Cadogan et al., 1997; Nakazi et al., 2000), acetylcholine (Gifford and Ashby, 1996), excitatory and 
inhibitory aminoacids (glutamate, GABA and glycine) (Levenes et al., 1998; Szabo et al., 1998; 
Jennings et al., 2001), and the neuropeptide colecistokinin (Beinfeld and Connolly, 2001), 
providing evidence about its pivotal role in several brain and peripheral functions.  
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Fig 2.1 CB1 expression and mechanism of action. (a). Medial section of a mouse brain 
where it is shown the expression of CB1-Rs through in situ hybridization techniques (source: 
Kano et al., 2009). Abbreviations: AON, anterior olfactory nucleus; Cb, cerebellum; CPu, 
caudate/putamen; DG, dentate gyrus; Hi, hippocampus; M1, primary motor cortex; MO, 
medulla oblonga; Mid, midbrain; NAc, nucleus accumbens; S1, primary sensory cortex; V1, 
primary visual cortex; VP, ventral pallidum. (b) Schematic representation of a typical CB1-
R activation pathway. When activated, CB1-Rs inhibit the adenilate cyclase (AC) activity, 
reducing the formation of cAMP. On the other hand, CB1-Rs activation behaves as a 
positive effector to allow an efflux of potassium (K+) by modulating G-protein-coupled 
inwardly rectifying potassium channel (GIRK), and as a negative modulator of Ca2+ 
channels. 
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1.3 Beyond classical cannabinoid receptors: is there anything else? 
In light of these considerations, at the first glance it seems that CB-Rs might be necessary and 
sufficient to regulate the whole eCb-dependent signaling, being largely widespread in some of the 
most important areas where eCbs act. However, recent and elegant studies have substantially 
disproved the exclusive involvement of these receptors in the modulation of eCb-mediated effects, 
hypothesizing the existence of at least other two subfamilies of CB receptors non-CB1 or CB2 
(Hajos et al., 2001; Hajos and Freund, 2002). Among the putative CBx receptors, it has been 
mentioned the so-called CB3-Rs (Hajos and Freund, 2002; Hajos et al., 2001), the transient receptor 
potential vanilloid type 1 (TRPV1) (Starowicz et al., 2007; Maccarrone et al., 2008), and the orphan 
G-protein coupled receptor GPR55 (Baker et al., 2006; Brown, 2007; Pertwee, 2007). It is worth to 
mention that also the peroxisome proliferator activated receptor (PPAR) has been considered as a 
CBx-R candidate. However, the central role in non-classical cannabinoid transmission of the latter 
receptor will be displayed below. 
 
2. Endocannabinoids: biosynthesis, release and deactivation 
 
Afterward the amazing discovery of CB1-Rs, a group of Israeli and British researchers leaded by 
Raphael Mechoulam reported the existence of the first described endocannabinoid in the brain, 
named anandamide (Devane et al., 1992). The headword anandamide ((5Z,8Z,11Z,14Z)-N-(2-
hydroxyethyl)icosa-5,8,11,14-tetraenamide, N-arachidonoylethanolamide, AEA) reminds the 
Sanskrit word "ananda" which means "bliss, delight", and it has been given in honor of its function. 
In 1995, was the turn of 2-arachidonyl-glicerol (2-AG), the second eCb found (Mechoulam et al., 
1995; Sugiura et al., 1995), and a wide amount of molecules with eCb-like activity has been 
discovered so far (see below). Through their effect on CB-Rs, and sometimes other receptors, eCbs 
exert their neuromodulatory function, providing a regulatory mechanism to guarantee the balance 
between excitatory and inhibitory neurotransmitter action within the nervous system.   
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1 mm
 
Fig 2.2.Molecular structure of AEA and 2-AG 
 
2.1 Synthesis and release of AEA and 2-AG: the fine modulation of eCbs in the brain 
The biosynthetic pathway of AEA and 2-AG is now established, although their involvement in 
other biochemical mechanisms (e.g. the cascade of arachidonic acid) complicates the scenario about 
their synthesis. Different studies have provided a description of some critical passages to obtain 
AEA and 2-AG and how they are deactivated by specific enzymes (see Kano, 2009 for a review). 
Both AEA and 2-AG are derivatives of arachidonic acid coniugated with ethanolamide or glycerol, 
respectively (Rodriguez de Fonseca et al., 2005). AEA is obtained from the 
phosphatidylethanolamide, which through the enzyme N-acyltransferase, in presence of Ca
2+
 and 
cAMP (Cadas et al., 1996; Piomelli, 2003) is transformed in N-arachidonoylphosphatidyl-
ethanolamine (NAPE). The cleavage of NAPE in AEA is obtained through a specific pospholipase 
D (NAPE-PLD), which belongs to the zinc metallhydrolase family of the β-hydrolase fold 
(Okamoto et al., 2004), and whose activity is regulated by depolarization and/or activation of 
ionotropic or metabotropic receptors (Giuffrida et al., 1999; Stella and Piomelli, 2001; Piomelli, 
2003; Cheer et al., 2007). Interestingly, NAPE-PLD mRNA immunoreactivity has been detected 
mostly on postsynaptic sites, contributing to clarify how eCbs exert their effects (see below), 
although also a presynaptic expression of this enzyme has been reported (Cristino et al., 2008; 
Egertova et al., 2008). An overall evaluation of NAPE-PLD mRNA reactivity in the brain has 
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underlined high levels of this enzyme  in the dentate gyrus of hippocampus, the Ammone’s horn, 
cortex, thalamus, hypothalamus and cerebellum (Cristino et al., 2008; Egertova et al., 2008). 
 In contrast, 2-AG synthesis does not only involve a linear pathway, but several arrays of it. The 
main pathway requires a combination of a phospholipase C (PLC) and a diacylglycerol lipase 
(DAG-L) activity. The first step is the PLC hydrolysis of arachidonic acid-containing membrane 
phospolipid to obtain arachidonic acid-containing diacylglicerol. From diacylglicerol the action of 
DAG-L yields 2-AG (Stella et al., 1997; Kondo et al., 1998; Jung et al., 2005). In addition, other 
studies have proposed the involvement of a phospholipase A1 and a lyso-PI-specific PLC (LPIPLC) 
(Ueda et al., 1993; Tsutsumi et al., 1994; Sugiura et al., 1995), which transform phospholipids in 
lysophospholipids (through PLA1) and then to 2-AG (through LPIPLC). Nonetheless, other 
biosynthesis mechanisms have been suggested (see Kano et al., 2009 for a review). 
AEA, whose chemical features resemble that of THC (Ryan et al., 1997; Seltzman et al., 1997), has 
an higher affinity for CB1-Rs (Ki: 89±10nM) than CB2-Rs (Ki: 371±102nM) (Reggio, 2002), 
showing also an affinity for TRPV1 (Ross, 2003). Sustained levels of AEA have been found 
throughout the mammalian brain and peripheral  tissues (Felder et al., 1993; 1996), with highest 
levels in the brain stem and striatum  (Bisogno et al., 1999; Yang et al., 1999). On the other hand, 2-
AG is able to bind both to CB1-Rs (Ki: 2.4µM) and CB2-Rs (Basavarajappa, 2007a), and its effect 
mimic that of THC (e.g. immobility, antinociception, immunomodulation) (Mechoulam et al., 
1995). Additionally, it has been reported that 2-AG brain levels are roughly 200 folds higher than 
AEA. However, the two eCbs display a superimposed distribution in the CNS (highest levels: 
brainstem, medulla, limbic system, striatum) (Sugiura et al., 2002). These higher levels of 2-AG in 
the brain might reflect its predominant involvement, when compared to other eCbs, in the 
modulation of certain cerebral physiological processes.         
Once synthesized, AEA and 2-AG exert their role in the CNS and PNS through a so-called ―on 
demand‖ process, which is peculiar for this class of neuromodulators. 
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The "on demand" (Di Marzo et al., 1994; Cadas et al., 1996)  release of AEA and 2-AG  is a feature 
which involves both a rapid production and a rapid degradation of eCbs, triggering their 
biosynthesis in response to several physiological and pathopysiological stimuli. The purpose of this 
mechanism is to allow a sudden eCb release from the postsynaptic neuron to activate CB-Rs located 
in the presynaptic space and, consequently, to inhibit the neurotransmitter release (Schlicker and 
Kathmann, 2001; Piomelli, 2003). This represents a clever mechanism to influence and modulate 
both the short- and long-term form of synaptic plasticity, especially in some brain regions strongly 
influenced by the role of synaptic re-modeling. For example, in the midbrain, which is crucially 
involved in reward processes and motor control (e.g. the VTA and substantia nigra), eCbs are 
released on demand after different circumstances and through a Ca
2+
-dependent fashion (Melis and 
Pistis, 2007). Some of these events, which trigger the release of eCbs, are: (1) depolarization of DA 
neurons (Melis et al., 2004a), (2) induction of burst firing (Melis et al., 2004b; Riegel and Lupica, 
2004), and (3) stimulation of excitatory afferents (Melis et al., 2004b). Thus, the final step of this 
process is to suppress GABA and glutamate release from projecting areas to midbrain DA neurons, 
modulating their activity and also protecting postsynaptic cells. This mechanism of short-term 
synaptic efficacy modulation has been named differently according to the suppression of GABA, or 
glutamate release. In fact, in the first case it is named depolarization-induced suppression of 
inhibition (DSI) (Llano et al., 1991; Pitler and Alger, 1992) and, in the second, depolarization-
induced suppression of excitation (DSE) (Kreitzer and Regehr, 2001) . DSI was the first mechanism 
recognized, and was primarily isolated in the cerebellum (Llano et al., 1991), whereas the specific 
acronym was given by Pitler and Alger (1992). In fact, they found a particular DSI mechanism in 
the hippocampus, acting through a Ca
2+
-dependent mechanism and that would have involved a 
retrograde messenger, whose primary candidate was glutamate (Pitler and Alger, 1992). Finally, in 
2001 eCbs where found to be responsible of GABA release suppression, since DSI was blocked by 
the CB1-R antagonists SR141716-A, and AM251 or AM281 (Ohno-Shosaku et al., 2001; Wilson 
and Nicoll, 2001). 
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 Additionally, in the same year, Wilson and Nicoll demonstrated that eCb release occurs without the 
presence of a vescicular transport (Wilson and Nicoll, 2001), suggesting a mechanism which differs 
from the classic neurotransmitter behavior. Among other evidence which strongly suggested that 
the messenger responsible for DSI was an eCb, it is worth to mention that: (1) CB1-R agonists 
enhance DSI and selectively reduce the inhibitory post-synaptic currents (IPSCs) in the 
hippocampus and cerebellum (Katona et al., 1999; Hoffman and Lupica, 2000; Takahashi and 
Linden, 2000; Ohno-Shosaku et al., 2001; Wilson et al., 2001; Wilson and Nicoll, 2001); (2) DSI is 
absent in CB1
-/-
 mice (Wilson et al., 2001; Yoshida et al., 2002), and (3) GABA interneurons, 
involved in DSI, express an high level of CB1 in their axon terminals (Katona et al., 1999).  
Afterwards was the hand of DSE discovery, by Kreitzer and Regeher, which includes the same 
aspect of DSI, but acting on glutamate release instead of GABA (Kreitzer and Regehr, 2001). Also 
in this case, different studies have reported: (1) an absence of DSE in CB1-KO mice (Ohno-
Shosaku et al., 2002), (2) a modulatory effect exerted by CB1-R agonists and antagonists (Kreitzer 
and Regehr, 2001; Maejima et al., 2001), and (3) a massive suppression of excitatory post-synaptic 
currents (EPSCs) mediated by eCbs release (Melis et al., 2004b). This mechanism has been studied  
in some brain areas such as the VTA (Melis et al., 2004b), where it seems that eCb-mediated DSE 
is triggered by the activation of D2-Rs in the postsynaptic cell (Melis et al., 2004b). A schematic 
representation of eCb-mediated DSE is reported in fig 2.3.    
Despite the central role played by DSI and DSE in the modulation of eCb-mediated synaptic 
plasticity, also long-term forms of synaptic remodeling have been assigned to eCbs. In fact, 
different eCb-induced LTDs have been described so far, together with heterosynaptic form of LTP 
(where eCbs act indirectly). Throughout these mechanisms the eCb system plays a pivotal role in 
some specific processes which require a long-lasting change in synaptic strengthening, or 
weakening. For example, in the hippocampus, LTD and LTP are critical for  learning/memory 
consolidation and a common feature of cannabinoids, such as THC, is to impair these cognitive 
functions. 
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Fig 2.3.eCb signaling in the brain. Graphical representation of a typical AEA-mediated 
DSE. AEA (green) is produced on demand following the influx of Ca2+ through the 
stimulation of AMPA receptors by glutamate (grey). Afterward AEA is released to bind to 
CB1-Rs located in the axon terminal of presynaptic excitatory afferents. The result is a 
massive inhibition of glutamate release. Afterward, AEA is reuptaken by a putative carrier 
protein (sky-blue) and, then, brought to the postsynaptic space where it encounters a 
FAAH-dependent deactivation process.     
 
 
These long-term changes affect the synaptic strength, involving modifications whose time length 
varies from few minutes to several days, and they include a fine regulation of cellular adaptation 
(e.g.: receptor density; synaptic remodeling) (Piomelli, 2003; Kreitzer, 2005; Chevaleyre et al., 
2006; Safo et al., 2006). LTD has been intensively studied and it represents a typical feature of eCb-
mediated long-lasting effect. Providing a detailed description of eCb-mediated LTD goes beyond 
the scope of this thesis, and excellent reviews on this topic are now available (Heifets and Castillo, 
2009). The first evidence of this modulatory mechanism of synaptic plasticity emerged in 2002 
through studies carried out by Lovinger’s group (Gerdeman et al., 2002) that demonstrated an eCb-
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mediated LTD at excitatory synapses in the dorsal striatum. Further studied have extended the brain 
localization of this mechanism to the NAc (Robbe et al., 2002), amygdala (Marsicano et al., 2002; 
Azad et al., 2004; Chevaleyre et al., 2007), the above mentioned hippocampus (Chevaleyre and 
Castillo, 2003; Edwards et al., 2008; Lafourcade and Alger, 2008), PFC (Lafourcade et al., 2007), 
VTA (Pan et al., 2008) and other areas, where synthesis and postsynaptic release of eCbs trigger 
this specific eCb-mediated plasticity. For example, in the VTA and NAc, whose high relevance for 
this thesis has been already discussed, it has been shown that moderate in vitro stimulations for 5-10 
minutes, evoke an eCb-mediated LTD on inhibitory and excitatory afferents, respectively (Robbe et 
al., 2002; Hoffman et al., 2003; Soler-Llavina and Sabatini, 2006). This effect causes a consequent 
long-lasting reduction of GABA and glutamate release from presynaptic neurons. 
Even though the involvement of the eCb system in drug addiction will be better explained below, it 
is worth to mention that repeated exposures to drugs of abuse modulate eCb-LTD both in VTA and 
NAc (Fourgeaud et al., 2004; Mato et al., 2004; Pan et al., 2008),  underlining a strict relationship 
between the eCb system activation and drugs of abuse-induced long-term effect responsible of the 
switch from abuse to addiction.  
In light of these findings, it seems to be quite established that through these fine mechanisms 
(DSI/DSE, LTP/LTD etc…), the activation of the eCb system guarantees a reliable modulatory 
assemble to regulate several functions in the CNS, which would also include the information 
processing and brain protection to injuries (Melis et al., 2006).             
 
2.2 Transport and metabolism of eCbs 
Similarly to other neurotransmitter systems, eCbs possess a putative reuptake mechanism and an 
array of enzymes which inactivate and degrade them. Currently, little is known about AEA and 2-
AG membrane transporter. In fact, despite the fact that different models have been proposed, a 
specific uptake mechanism has not been found yet. Among them, the highest recognized possibility 
remains the transport of AEA into the postsynaptic cell through a putative carrier protein (Fegley et 
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al., 2004; Ligresti et al., 2004), but also the hypothesis of simple passive diffusion and endocytosis-
induced by a caveolae-related uptake process have been suggested (McFarland and Barker, 2004; 
McFarland et al., 2004). A very recent study carried out by Vincenzo di Marzo's group has 
elegantly provided evidence to the first hypothesis, measuring the activity of TRPV1 channels as 
biosensor of AEA cellular reuptake together with exploiting nanotechnology in TRPV1-
overexpressing HEK-293 cells (Ligresti et al., 2010).   
For what concerns 2-AG, there are less studies focused on the investigation of uptake mechanism. 
Mounting evidence suggests the involvement of the same mechanism discussed above for AEA 
(Beltramo and Piomelli, 2000; Bisogno et al., 2001), or a shared mechanism for AEA and 2-AG 
(Hermann et al., 2006).   
On the other hand, it is quite ascertained that AEA and 2-AG do not share the same metabolizing 
proteins. In fact, two different enzymes have been involved in AEA and 2-AG degradation, named  
fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAG-L), respectively. Although 
the main route to deactivate these eCbs is the hydrolization through the above mentioned enzymes, 
other mechanisms, such as the oxydation by lipoxigenases and cycloxygenases, have been involved 
in endocannabinoids degradation (Kano et al., 2009). 
FAAH, cloned from the rat liver, but identified also in the brain (Cravatt et al., 1996), is a 
membrane-bound enzyme belonging to the family of amidase proteins (Basavarajappa, 2007b). 
FAAH, whose structure comprises a chain formed by 579 aminoacids, is able to recognize an array 
of fatty acids, although AEA is its preferred substrate, hydrolyzing it in arachidonic acid and 
ethanolamine (Kano et al., 2009). Recently, it has been demonstrated a role of FAAH in 
deactivating the n-acylethanolamides (NAEs) oleoylethanolamide (OEA) and palitoylethanolamide 
(PEA) (see below) (Kathuria et al., 2003), whose levels, together with AEA, are drastically 
increased after pharmacological blockade of FAAH by URB597 (Fegley et al., 2005).  In fact, the 
development of genetically modified mice lacking the gene encoding for FAAH (FAAH-knock out, 
FAAH-KO) has shown a more responsiveness to the exogenous administration of AEA in these 
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animals compared to wild type (WT) (Cravatt et al., 2010). Moreover, also an endogenous level of 
AEA and other fatty acid ethanolamines higher over ten folds than control mice has been reported 
in FAAH KO (Cravatt et al., 2001). 
Nonetheless, beside FAAH activity, AEA is also metabolized by other enzymes. In fact, also the 
involvement of cyclooxigenases, such as the COX-2, LOX-2, and the cytochrome P450 has been 
reported as putative inactivating mechanism for AEA (see Basavarajappa, 2007a for a review).  
 On the other hand, MAG-L, first cloned from mouse adipocytes cDNA library (Karlsson et al., 
1997), plays a pivotal role in the degradation of 2-AG, although some studies have underlined a 
circumscribed FAAH capability to hydrolyze this eCb (Di Marzo et al., 1998). MAG-L, whose 
expression has been found in many tissues and cells, works metabolizing 2-AG  in arachydonic acid 
and glycerol (Beltramo and Piomelli, 2000; Maccarrone et al., 2001), and it is formed by 303 
aminoacids in several species of animals and in humans (Karlsson et al., 1997; Karlsson et al., 
2001). Further information about the critical steps to 2-AG deactivation and metabolism can be 
found in several excellent reviews (Basavarajappa, 2007b). In addition, it is worth to mention that a 
substantial difference between site of action of FAAH and MAG-L has been reported. In fact, while 
FAAH activity is concentrated in the postsynaptic terminal, which requires a transport of eCbs from 
the presynaptic membrane to the postsynaptic space, MAG-L acts within the presynaptic membrane 
(Choi and Lovinger, 1997; Dinh et al., 2004). This evidence suggests that MAG-L has a role in 
terminating retrograde signaling at presynaptic neurons (Kim and Alger, 2004).    
 
3. Not only anandamide: toward the discovery of new endocannabinoids 
 
As already mentioned, the discovery of CB-Rs has not definitely closed the discussion to the 
beguiling world of receptors activated by eCbs. The hypothesis of the so-called CBx, or CB3-R, and 
the suggested involvement of TRPV1 as binding site for the eCb AEA, combined with unfitting 
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studies carried out in knock-out mice for the CB1-Rs, have disproved the exclusive role of classic 
cannabinoid receptors in eCb-mediated signaling (Wiley and Martin, 2002).  
In addition, mounting evidence about the not exclusive affinity of CB1 and CB2-R agonist for their 
respective binding sites, have underlined the possibility that other systems and oligomers might 
interact with the classic eCb system to complicate its profile of action in the CNS and PNS. For 
example, it has been shown that, at concentration of 1 µM, AEA activates TRPV4 and blocks 
TRPV8, while HU-210 and CP55940 act as agonists of the orphan receptor GPR55 (Pertwee, 
2008). In addition, there is evidence about the presence of non-CB1/CB2 or V1-Rs in the brain, 
which can be activated by methAEA and the synthetic cannabinoid WIN55212-2 (Pertwee, 2008).  
Moreover, despite the well-characterized presence of AEA and 2-AG in the brain, other eCb-like 
molecules have been described in the CNS and PNS. Among them, other eCbs are the 2-
arachidonyl-glyceryl ether (nolandin, 2-AGE), O-arachidonyl-ethanolamine (virodhamine), N-
arachidonyl-dopamine (NADA), dihomo-γ-linoleonyl ethanolamide, and docostetraenoyl 
ethanolamide (Hanus et al., 1993; Hanus et al., 2001; Huang et al., 2002; Porter et al., 2002).  
In particular, a recent interest has been dedicated to OEA and PEA (fig 2.2), two NAEs, whose 
pharmacological profile remained elusive until the discovery of their agonistic action on a family of 
nuclear receptors and transcription factor known as peroxisome proliferator activated receptors 
(PPARs) (Fu et al., 2003).  
 
3.1 n-acylethanolamides, cognate molecules of classic encocannabinoids 
Even though the interest for these compounds has grown up in these years, PEA and n-
acylethanolamides were already known several decades ago, when it was found that PEA had an 
antinflammatory activity in guinea pig, and it was present in peanuts, soybean and egg yolk 
(Hansen, 2010). Additionally, early studies provided the existence of these NAEs as endogenous 
compounds in the mammalian brain (Bachur et al., 1965).   
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OEA and PEA share with AEA a common metabolizing substrate, which is the FAAH enzyme, and 
it has been demonstrated that pharmacological blockade of FAAH by the irreversible inhibitor 
URB597 increases the levels of both AEA and OEA/PEA (Kathuria et al., 2003) (see above). 
OEA and PEA, as well as AEA, belong to the family of NAEs, representing a monounsaturated and 
saturated form of them, respectively. The most peculiar feature of these endogenous NAEs is that 
they are devoid of cannabinoid-like activity, being ineffective either on CB1 or CB2-Rs,  and 
sharing affinity for the α-type PPAR (PPAR-α) (O'Sullivan, 2007). Furthermore, even PPAR-α was 
considered an orphan receptor for a long time unless it has been discovered its affinity for OEA and 
PEA (Pistis and Melis, 2010).  
Recently, a large interest has been dedicated to a putative cross talk between the eCb system and 
PPAR activation in the modulation of several brain functions. 
To corroborate this hypothesis, different studies have demonstrated that CB-R agonists and PPAR 
ligands play an opposite effect each other in the regulation of certain physiological aspects. For 
example, weather it is well-known the appetite stimulant properties of the CB1-R agonist THC 
(Fride et al., 2005), OEA activity is implicated in appetite suppression and weight loss (Fu et al., 
2003). Moreover, while THC and CB1-R agonists negatively modulate learning and memory 
(Sullivan, 2000; Davies et al., 2002), OEA and PEA are involved in different aspects of memory 
enhancement (Campolongo et al., 2009; Mazzola et al., 2009). Nonetheless, other studies have 
suggested a co-activation of these two parallel systems in the modulation of specific response both 
in the CNS and PNS. In fact,  it has been recently reported that several CB1-Rs agonists exert their 
neuroprotective action through activation of PPAR-α (Sun et al., 2006; Sun et al., 2007). 
Furthermore, NAEs significantly contribute to the anti-nociceptive and anti-inflammatory action of 
endocannabinoids (LoVerme et al., 2006; Jhaveri et al., 2008; Sagar et al., 2008). In addition, an 
intriguing synergistic effect between CB1-R activation and PPAR-α have been suggested to explain 
the cognitive enhancing properties of the FAAH inhibitor URB597 (Mazzola et al., 2009).  
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Fig 2.3 Non-classical eCbs and biosynthesis of NAEs. (a) Among the large family of eCb-
like molecules, a current specific interest has been dedicated to oleoylethanolamide 
(OEA) and palmitoylethanolamide (PEA), whose chemical structure is represented in this 
panel. (b) Different enzymatic pathways for formation of n-acylethanolamide (NAE) from 
n-acylphosphatidylethanolamine (NAPE) (Hansen, 2010). Although different pathways are 
involved in NAE formation, the most studied remains the NAPE-PLD-dependent process. In 
addition, NAEs can be also syntesized through a phospholipase C (PLC)-, a phosphatase- 
and a phospholipase B (Abh4)+phosphodiesterase (GDE1)-dependent process. NAEs can 
be hydrolyzed by a fatty acid amide hydrolase (FAAH), or a NAE-hydrolyzing acid 
amidase (NAAA). 
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NAEs, whose presence has been reported in the brain with a concentration in the rat CNS around or 
above 100 pmol/g each  (Hansen, 2010), share with AEA a lipophylic structure with high log P 
values. The latter parameter gives a reason to their low solubility in water (OEA=6.12±0.64; 
PEA=5.56±0.58) (Bojesen and Hansen, 2003). NAE synthesis and catabolic process occur 
independently of classical eCbs, and crucial stimuli at the upstream of their biosynthesis are not 
fully understood (Pistis and Melis, 2010). Some evidence suggests that, similarly to AEA and 2-
AG, these molecules are released on demand in response to certain physiological processes 
concerning injuries and inflammation (Hansen et al., 1997), contributing to modulate physiological 
response to external threats. The main biosynthesis pathway of OEA and PEA is basically the same 
observed and discussed for AEA (see above), involving NAPE-PLD (Pistis and Melis, 2010) (fig 
2.3). 
Interestingly, NAPE-PLD
-/-
 mice show a reduction in Ca
2+
-dependent conversion of NAPE to NAEs 
(Hansen and Diep, 2009) with a decrease in OEA and PEA levels, but not AEA (Leung et al., 
2006), suggesting an involvement of parallel systems and/or compensatory adaptation for AEA 
biosynthesis in this mouse strain. In addition, since it is well-known that NAPE-PLD mRNA 
immunoreactivity (see above) has been highly reported on postsynaptic space, it is possible that 
NAE synthesis might be functional to allow an autocrine signaling on PPARs expressed in the same 
cell, although they can also act as modulator of synaptic plasticity once produced in the presynaptic 
axon terminal (Pistis and Melis, 2010).  
Finally, even though it has been already mentioned that FAAH represents the main metabolic 
substrate for NAEs (see above), at least other 2 enzymes have been considered capable to deactivate 
these molecules: FAAH-2 and NAE-hydrolyzing acid amidase (NAAA) (Tsuboi et al., 2005; Wei et 
al., 2006).     
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3.2 Nuclear receptors: new targets for endocannabinoid-like molecules 
As already cited, the affinity of OEA and PEA is basically confined to PPARs, showing no binding 
properties on CB-Rs. In fact, although it is still under evaluation the possible involvement of other 
receptors not fully characterized (e.g. GPR55) (Borrelli and Izzo, 2009; Godlewski et al., 2009) in 
OEA and PEA-mediated effects, PPARs obviously represent the most studied biological target to 
understand where NAEs act. 
The PPAR subfamily is composed in three isoforms: α, γ, and β/δ, whose encoding genes are 
separated. Belonging to the family of nuclear receptors, PPARs possess a modular structure with 
two different domains: (1) a DNA-binding domain and (2) a large ligand-binding domain which 
interacts with a  great number of different ligands (e.g. fatty acids, NAEs, eicosanoids, antidiabetic 
synthetic agonists thiazolidinediones and fibrates) (Laudet et al., 1992; Escriva et al., 1998; 
Desvergne and Wahli, 1999).  Binding studies have confirmed that OEA has an higher half-
maximal concentration (EC50) for PPAR β/δ than α (1.1 µM vs. 120 nM), being much more active 
on the latter and showing no effect on γ subfamily of PPARs (Fu et al., 2003). By contrast, PEA 
shows affinity only for PPAR α (3 µM), but not for PPAR γ and β/δ (Bouaboula et al., 2005; Lo 
Verme et al., 2005). Also AEA has been reported as a putative PPAR-α and γ agonist, although 
studies have been carried out only through in vitro techniques and in transfected systems (Sun et al., 
2007). 
Providing a full description of PPAR activity in the brain, where the localization of these receptors 
(especially PPAR α) is ubiquitous (Moreno et al., 2004), is beyond the scope of this thesis. 
However, recent reviews have been focusing on this topic (see Pistis and Melis, 2010 for a review). 
In this section it is only worth to mention that PPAR-α is a lipid sensor implicated in the 
metabolism of fatty acids (Pistis and Melis, 2010). Thus, PPAR-α is expressed in several tissues 
involved in the regulation of metabolic aspect such as kidney, liver, brown fat, CNS (Braissant et 
al., 1996; Mandard et al., 2004; Moreno et al., 2004; Galan-Rodriguez et al., 2009), and in other cell 
lines (e.g. monocytes, vascular endothelium) (Chinetti et al., 1998) where its presence is mainly 
61 
 
involved in the negative modulation of inflammatory response. By contrast, γ-type PPAR 
participates in the regulation and expression of DA-Rs and DA signaling, neuroprotection and 
inflammation, while β/δ line is involved in homeostasis control, reproductive capacity in females, 
tissue repair, and cell proliferation (Wang et al., 2003; Michalik et al., 2006). Taken together, these 
studies provide an interesting profile of these receptors in the regulation of several physiological 
functions, mainly connected with metabolism. 
Similarly to other members of the nuclear receptor family, they mainly act as gene transcription 
regulators (Berger and Moller, 2002), with a tendency to develop conformational changes 
promoting the association of coactivators and corepressor proteins (Pistis and Melis, 2010). Briefly, 
they take part in gene transcription with an heterodimerization with the retinoid X receptor (RXR) 
and then binding to specific regions of the DNA called ―peroxisome proliferator response element‖ 
(PPRE). In addition, beside this conventional genomic effect of PPARs, it has been suggested also a 
non-genomic effect responsible of short-term modification induced by receptor activation (Gardner 
et al., 2005; Ropero et al., 2009). 
Some studies have provided evidence of this non-genomic mechanism. Among them it has been 
shown that (1) PPAR activity is still conserved in presence of protein and mRNA synthesis inhibitor 
(Ropero et al., 2009), (2) they possess a rapid onset (2-5 min) (Ropero et al., 2009) and (3) PPAR 
activation induces production of cytosolic effectors such as reactive oxygen species (Melis et al., 
2008). 
 
4. Endocannabinoids from reward to addiction: do they play a role in the mesoaccumbens 
pathway? 
 
In light of previous considerations, at a first glance it seems that eCb-mediated fine modulatory 
action might be an intriguing topic, when it concerns complicated phenomena like drug abuse and 
addiction. In the first chapter some space was dedicated to draw the hallmarks of the brain reward 
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circuitry and the main steps that trigger drug dependence. Furthermore, already in the introduction it 
was highlighted how the manipulation of the eCb system might modulate drug-induced effects in 
some specific areas related to responses to pleasurable stimuli.      
Recently, interest has been dedicated to the putative role of the eCb system in the midbrain DA 
neuron physiology, where it might play a pivotal function in rewarding processes and addiction. It 
has been already reported how the activation of the so-called brain reward circuitry is crucial in 
early stages of reward seeking and goal-directed behavior. In addition, it has also been underlined 
how a malfunction of this system could trigger drug dependence.  
The first evidence of a cannabinoid action in the VTA and in the neighbor substantia nigra pars 
compacta (SNc) arises from the effect of the exogenous CB1-R agonist THC, acting on VTA DA 
neurons as an abused substance (French et al., 1997; Gessa et al., 1998). This effect was mimicked 
by the CB1-Rs synthetic agonist WIN 55212-2. Both of them cause an increase of VTA DA neuron 
firing rate and bust firing, which allows an enhancement in DA release from the VTA to its 
projecting areas such as the NAc (Tanda et al., 1997; Cheer et al., 2004) and prefrontal cortex 
(Chen et al., 1990; Pistis et al., 2002b).  
Since the levels of CB1-R  mRNA in the VTA and SNc are low (Herkenham et al., 1991; Matsuda 
et al., 1993), it has been suggested that exogenous synthetic and natural agonists act on DA neurons 
through a CB1-Rs mediated inhibition of GABA and glutamate release from inhibitory and 
excitatory projections, respectively (Mechoulam et al., 1995; Marsicano and Lutz, 1999). This 
represents the already mentioned eCb-mediated DSI and DSE, whose functional relevance was 
already described. To confirm this hypothesis, several electrophysiological studies have indirectly 
demonstrated that inhibitory and excitatory projections to mesolimbic DA neurons express CB1-Rs 
(Melis et al., 2004b; Melis et al., 2004a; Riegel and Lupica, 2004), and that perfusion of CB1-Rs 
agonists depresses excitatory and inhibitory post-synaptic currents on VTA DA neurons (Szabo et 
al., 2002; Melis et al., 2004a; Marinelli et al., 2007). Moreover, direct evidence of CB1-R 
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expression on GABAergic terminals was reported by studies carried out through electron 
microscopic investigation (Katona et al., 1999).  
 
              
1 mm
 
Fig 2.3 localization of CB1-Rs in the brain reward circuitry. The eCb system is considered as 
a suitable candidate to modulate the brain reward circuitry response to pleasant stimuli, 
such as those produced by administration of drugs of abuse. In this graphical 
representation CB-Rs are preferentially located at the top of excitatory and inhibitory 
presynaptic buttons which project to the mainstream neurons of the mesocorticolimbic 
system. Abbreviations: BLA, basolateral amygdala; HIP, hippocampus; NAc, nucleus 
accumbens; VTA, ventral tegmental area; PFC, prefrontal cortex (Maldonado et al., 2006) 
 
 
In addition, it has been elegantly shown that DA neurons release eCbs after depolarization induced 
by the enhanced Ca
2+
 postsynaptic influx (Melis et al., 2004b; Riegel and Lupica, 2004) and that, 
among different eCbs implicated in this mechanism, 2-AG plays a more relevant role than AEA 
(Melis et al., 2004b). 
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Moreover, it has been demonstrated that the eCb system exerts a modulatory effect beyond the VTA 
to regulate the whole activity of the mesoaccumbens pathway. In fact, electrophysiological studies 
in rats have shown that both THC and synthetic cannabinoids depress BLA and PFC-evoked 
excitation of GABAergic medium spiny neurons (MSNs) of the ShNAc (Pistis et al., 2002a), which 
represent a common feature of drug of abuse administration. Nonetheless, it has been clearly 
elucidated that eCbs are necessary to induce LTD in the NAc and neostriatum, taking part in the 
critical steps from reward-dependent drug intake to compulsive consumption (Gerdeman et al., 
2002; Robbe et al., 2002; Robbe et al., 2003).  
Several studies have also demonstrated that the eCb system modulates drug-induced response in the 
reward pathway, providing evidence regarding its possible role in the pharmacotherapy of addiction 
(Parolaro and Rubino, 2008). For example, it has been clearly elucidated that the eCb system 
interacts with the rewarding properties of some, but not all, drugs of abuse. In fact, it has been 
shown that cannabinoids attenuate both morphine and methadone withdrawal signs while SR 
141716-A (SR, rimonabant) precipitates morphine abstinence in addicted rats (Hine et al., 1975; 
Vela et al., 1995; Yamaguchi et al., 2001; Del Arco et al., 2002; Maldonado, 2002). Moreover, an 
interplay between opioid and eCb system has been confirmed by studies showing that the opioid µ-
antagonist naloxone precipitates abstinence in THC-tolerant rats (Kaymakcalan et al., 1977), and 
that SR-precipitated withdrawal is attenuated by morphine (Lichtman et al., 2001). Moreover, using 
self-administration (SA) and conditioned place preference (CPP) paradigms in animals, it has been 
demonstrated that (1) CB1
-/-
 mice do not show morphine-induced CPP and SA at a dose capable to 
induce rewarding effects in WT (Ledent et al., 1999; Martin et al., 2000; Cossu et al., 2001), and (2) 
the same effect was observed treating rats with the CB1-R antagonist SR  (Navarro et al., 2001; De 
Vries et al., 2003; Fattore et al., 2003). Finally, a cannabinoid-dependent mechanism has been 
reported in the reinstatement of heroin seeking behavior after a long period of abstinence (Fattore et 
al., 2003).  In line with these findings, which tend to be less compelling across different studies as 
concerns CPP in CB1
-/-
 (Parolaro and Rubino, 2008), also opioid receptor KO mice do not show 
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rewarding response to THC (Castane et al., 2003). Furthermore, even the involvement of the eCb 
system in alcohol dependence has been evaluated. In fact, using a genetically selected strain of 
animals called Sardinian Preferring (SP) rats, it has been shown that SR blocks the voluntary 
alcohol consumption in these animals (Colombo et al., 1998) and that SP rats show a spontaneously 
reduced eCb-mediated DSI with a general less effect of CB1-Rs agonists on GABA IPSCs as 
compared with controls (Melis et al., 2009). In addition, electrophysiological studies on BLA 
glutamatergic neurons have demonstrated that SR prevents ethanol-induced inhibition on these 
neurons, underlining an active involvement of CB1-Rs on alcohol-mediated effects in this 
subcortical area (Perra et al., 2008).     
On the other hand, these results have not been replicated with cocaine and psychostimulants, 
leading to a controversial argumentation about the ineffective role of the eCb system in the 
modulation of cocaine and amphetamine-induced response in the VTA. In fact, although cocaine 
and amphetamine-induced SA and CPP are not blocked by either SR or genetic deletion of CB1-Rs 
(Martin et al., 2000; Cossu et al., 2001; Braida et al., 2005; Lesscher et al., 2005) and CB1-Rs 
blockade does not prevent cocaine-induced increase in DA release in the NAc (Soria et al., 2005), 
other investigations have reported opposite results. For example, according to some studies the eCb 
system plays a pivotal role in the acquisition of an operant response to self-administrable cocaine 
(Soria et al., 2005), SR is able to revert the breakpoint of cocaine-SA in rats under long access 
sessions (Orio et al., 2009) and SR has a preventive effect on cue and drug induced relapse to 
cocaine (De Vries et al., 2001; Filip et al., 2006; Wiskerke et al., 2008).    
In addition, in recent years the possibility that eCb system manipulation might interfere also with 
nicotine-induced rewarding effects in animals and humans was also evaluated. This possibility has 
attracted attention, since both THC and nicotine are usually taken in combination by humans, and 
that reciprocally can interact with each other in several behavioral paradigms and physiological 
processes. For example, interactions between THC and nicotine were studied on locomotion, 
anxiety, nociception and heart rate (Pryor et al., 1978; Valjent et al., 2002) and it was also reported 
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that nicotine potentiated some THC-induced effects such as hypothermia, bradycardia (Pryor et al., 
1978) and anxiolitic-like responses (Valjent et al., 2002). In addition, it was shown that co-
administration of THC and nicotine leaded to an higher enhancement of c-Fos immunoreactivity in 
some of the most important areas of the brain reward circuitry (e.g. ShNAc, BNST, basolateral 
amygdala) (Valjent et al., 2002).  
 Furthermore, it was postulated a type of interaction between the eCb system and nicotine addiction. 
This hypothesis has been strengthened by results showing a rewarding effect of co-infusion of 
subthreshold doses of THC and nicotine using CPP measures (Valjent et al., 2002) and that THC 
reduced the incidence of withdrawal signs caused by nicotine (Balerio et al., 2004).  
Moreover, in line with results obtained with morphine, it has been demonstrated that CB1-KO mice 
do not show any CPP for nicotine and that nicotine-induced CPP is blocked by the administration of 
SR (Le Foll and Goldberg, 2004). Conversely, other high impact studies have ruled out the 
involvement of CB1-Rs in nicotine SA under fixed-ratio schedule (Cossu et al., 2001; Castane et 
al., 2002). These findings seem to be in sharp contrast to other evidence about the action of 
rimonabant on nicotine-induced behavioral effects, and nicotine-induced DA release in the ShNAc 
(Cohen et al., 2002; Cohen et al., 2005; Cheer et al., 2007).   
Finally, very recently it has been shown that pharmacological manipulation of the eCb system, 
through the inhibition of FAAH by URB597, negatively modulated nicotine-induced behavioral 
effects such as the CPP, SA and nicotine-induced DA release in the ShNAc (Scherma et al., 2008), 
thus, opening a new avenue in the study on how eCbs modulate drug addiction. 
As mentioned before, one of the most intriguing characteristic of FAAH activity and its 
pharmacological inhibition is the capability to modulate the endogenous levels of NAEs and eCbs 
like AEA. Since FAAH blockade  not only elevates AEA, but also NAEs levels (e.g. OEA and 
PEA) it is possible that at least a part of URB597 effect might  be ascribed to NAEs rather than 
AEA, raising an interesting perspective in the pharmacological treatment of tobacco addiction.      
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5. Final remarks and purpose of our study 
 
At  first glance, all these findings underline a possible role of eCbs in the common neurobiological 
mechanism underlying drug addiction. As a matter of fact, beside the vast literature focused on 
eCbs, a current interest on the interaction between the eCb system and the effect of addictive 
substances is growing up. One reason which explains this specific attention might be ascribed to the 
lack of pharmacological strategies to treat an insidious and relapsing disorder like drug addiction. 
Hence, the possibility that manipulation of an endogenous system modulates drug-induced response 
might represent a new avenue for drug development. 
As previously mentioned (chapter I), nicotine dependence might be a suitable candidate to test this 
possible involvement. This is due to different reasons, most of them discussed above, including 
previously described encouraging results obtained with CB1-R antagonists. 
Even though in the present study it was first evaluated the actions of rimonabant on nicotine-
induced excitatory effects on VTA DA neurons, we subsequently moved to the pharmacological 
inhibition of FAAH enzyme, since previous findings had shown a unexpected effect of URB597 on 
nicotine action (Scherma et al., 2008). Next, we focused on MSNs of the ShNAc, which are the 
main targets of DA released by VTA neurons, to evaluate whether FAAH inhibition modulates 
nicotine’s action on these cells. To this aim, we carried out in vivo single unit extracellular 
recording from VTA DA neurons and MSNs of the ShNAc in urethane anaesthetized  rats. Our 
results showed that FAAH inhibition modulates nicotine effects both in the VTA and in the NAc. 
Furthermore, we discovered that NAEs, rather than classical endocannabinoids, are involved, 
suggesting the possibility of an intriguing cross talk between CB1-R and PPAR-α activation. These 
results have been sequentially presented under abstract form in several conferences (e.g. Luchicchi 
et al., 2008; 2009a; 2009b; 2009c; 2010), and in three peer reviewed articles (Melis et al., 2008; 
Luchicchi et al., 2010; Mascia et al., 2010) (see appendix). 
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Chapter III 
MATERIALS AND METHODS 
 
 
Experiments were performed in strict accordance with the Guidelines for the Care and Use of 
Mammalian  in Neuroscience and Behavioral Research (National Research Council 2004) and EEC 
Council Directive of 24 November 1986 (86/609). We made all efforts to minimize pain and 
suffering, and to reduce the number of animals used. Male Sprague Dawley albino rats (250–350 g) 
(Harlan) were housed in groups of three to six in standard conditions of temperature and humidity 
under a 12 h light/dark cycle (with lights on at 7:00 A.M.), with food and water available ad 
libitum.  
 
1. Experiments in the VTA 
 
Animals were anaesthetized with urethane (1300 mg/kg, i.p.), their femoral vein was cannulated for 
intravenous administration of pharmacological agents, and they were placed in the stereotaxic 
apparatus (Kopf) with their body temperature maintained at 37±1°C by a heating pad. Thereafter, 
the scalp was retracted and two burr holes were drilled above the VTA (-6.0 mm anteroposterior 
from bregma, 0.3-0.6 mm lateral from midline) for the placement of a recording electrode and 
above the medial part of the ShNAc (+1.5 mm anteroposterior from bregma; 1 mm lateral from 
midline) for the placement of stimulating electrode. Since only cells identified as projecting to the 
ShNAc were isolated, we delivered electrical stimuli from the ipsilateral medial ShNAc through a 
formvar-coated stimulating stainless steel bipolar electrode (250μm tip diameter) (fig 4.1). 
For intracerebroventricular drug administration, a guide cannula (23 gauge stainless steel) was 
placed into the ventricle ipsilateral to the recording side (1.0 mm posterior, 1.4 mm lateral to 
bregma and 4.0 mm ventral to the cortical surface). Structures were localized according to the 
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stereotaxic atlas of Paxinos and Watson (1997). Intracerebroventricular injections were made 
through a prefilled inner cannula (30 gauge stainless steel tubing) connected to a 50 µl Hamilton 
microsyringe, and extending 1.0 mm below the tip of the guide into the ventricle. Infusion rate was 
set at 2.5 µl/min by an electrically driven mini-pump. 
Single unit activity of neurons located in the VTA (V 7.0–8.0 mm from the cortical surface) was 
recorded extracellularly with glass micropipettes filled with 2% pontamine sky blue dissolved in 0.5 
M sodium acetate (impedance 2–5MΩ). Single unit activity was filtered (bandpass 500–5000 Hz), 
and individual spikes were isolated by means of a window discriminator (Digitimer), displayed on a 
digital storage oscilloscope (TDS 3012, Tektronics), and digitally recorded. Experiments were 
sampled on line and off line with Spike2 software (Cambridge Electronic Design) by a computer 
connected to CED 1401 interface (Cambridge Electronic Design). Single units were isolated and 
identified according to already published criteria (Grace and Bunney, 1983, , 1984a; Ungless et al., 
2004). To evaluate their selective projection to the ShNAc, we deliver a 1Hz electrical stimulation 
through the stimulating electrode to observe an antidromic response on VTA DA neurons. Since 
only one cell was recorded per rat, VTA DA neurons were selected when all criteria for 
identification were fulfilled: firing rate <10 Hz, duration of action potential >2.5 ms, inhibitory 
responses to hind paw pinching. Bursts were defined as the occurrence of two spikes at an 
interspike interval ≤80 ms, and terminated when the interspike interval exceeded 160 ms (Grace and 
Bunney, 1983). At the end of each recording section, direct current (10µA for 15 min) was passed 
through the recording electrode to eject Pontamine sky blue, which allowed the identification of the 
recorded cells. Brains were removed and fixed in 8% formalin solution. The position of the 
electrodes was microscopically identified on serial sections (60 μm) stained with cresyl violet. 
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Fig 3.1. Experiments in the VTA. Schematic representation showing the protocol carried out 
for in vivo electrophysiological recordings from VTA DA neurons. Two burr holes are drilled 
above the VTA and ShNAc for the placement of a recording and stimulating electrode, 
respectively. When a neuron is isolated, current from the ShNAc is applied in order to 
evaluate the antidromic response of VTA DA neuron to NAc stimulation.   
 
 
2. Experiments in the ShNAc 
 
We recorded extracellularly single-unit activity of neurons located in the medial part of the NAc 
(shell) (1.5 mm anterior from bregma, 0.8–1.3 mm lateral from the midline, 6.5–7.0 mm ventral 
from cortical surface) using the same instruments previously described for the VTA experiments. In 
addition, because MSNs of the ShNAc do not fire spontaneously in anaesthetized animals, we 
delivered electrical stimuli in the basolateral amygdala (BLA) to evoke spike firing in the NAc cell. 
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For this reason, we inserted a formvar-coated stimulating stainless steel bipolar electrode with an 
inclination of 15° anteroposterior on the coronal plane (250 μm tip diameter) in the ipsilateral BLA 
(3.2 mm posterior from bregma, 5.0 mm lateral from the midline, 7.0 mm ventral from the cortical 
surface) (fig 4.2), which is a major excitatory projecting area to the NAc. After the glass electrode 
had been positioned to the dorsal limit of the NAc, we searched cells that responded to the 
stimulation of the BLA. Stimuli (~0.5 mA) were delivered to the BLA at 1-second intervals, while 
the microelectrode was lowered incrementally through the NAc. When a cell was detected, we 
adjusted the position of the microelectrode in order to maximize the spike amplitude relative to 
background noise. We identified neurons that responded to BLA stimulation by their robust 
excitatory response (latency range 10–25 ms). We did not include in this study cells whose latencies 
were longer than 26 ms following BLA stimulation because they could exhibit a polysynaptic 
response component (Mulder et al., 1998). A graphical representation of BLA-evoked excitation of 
MSNs is reported in fig 3.2. The experimental protocol was essentially that published by Floresco et 
al. (2001) (Floresco et al., 2001) with some modifications (Pistis et al., 2002a). When we isolated a 
cell, we adjusted stimulation currents to approximately half-maximal intensity, such as ~50% of 
electrical stimuli (1 Hz) in the BLA elicited an action potential in the recorded cell. We calculated 
evoked spike probability by dividing the number of action potentials observed by the number of 
stimuli administered in 100-second periods. Once stable levels of evoked spike probability were 
achieved (< 10% changes over 10-15 minutes), we administered drugs intravenously and assessed 
spike probability every 100 seconds. Changes in spike probability were an index of changes 
induced by the studied compounds over the excitation of NAc cells evoked by BLA stimulation. As 
well as for VTA experiments, we recorded only one cell per rat. 
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Fig 3.2. Experiments in the Shell of the NAc. Since medium spiny neurons (MSNs) of the 
ShNAc do not fire spontaneously in anaesthetized animals, a current was applied from the 
basolateral amygdala (BLA) in order to elicit an evoked spike firing of NAc neurons. For this 
reason the current was adjusted to obtain a 50% of probability to evoke a MSNs firing rate 
after BLA stimulation.  
 
 
 
3. Statistical analysis 
 
For VTA experiments, we calculated drug-induced changes in firing rate and pattern by averaging 
the effects after drug administration (2 minutes), and normalizing them to the predrug baseline. For 
ShNAc experiments, we determined predrug spike probability baseline as the mean of at least three 
consecutive assessments (100 seconds) over 10 minutes before drug administration. We generated 
73 
 
peristimulus time histograms (1-ms bins, 100 cumulative sweeps) by CED Spike2 software 
(Cambridge Electronic Design). Following drug administration, we calculated spike probability 
every 100 seconds, and normalized it to the predrug baseline. All the numerical data are given as 
mean±standard error of the mean. Data were compared and analyzed by using two-way analysis of 
variance (ANOVA) for repeated measures (treatment vs. time), or one-way ANOVA, or Student’s t-
test for repeated measures, when appropriate. Post hoc multiple comparisons were made using the 
Dunnett’s, or Bonferroni’s tests. We performed statistical analysis by means of the NCSS program 
(Kaysville, UT, USA). The significance level was established at P < 0.05. 
 
4. Drugs 
 
Nicotine [(–)-nicotine hydrogen tartrate] was purchased from Sigma (St. Louis, MO). Morphine 
chloridrate and cocaine chloridrate were purchased from S.a.l.a.r.s (Como, Italy), and Akzo 
Pharmadivision Diosynth (Oss, the Netherlands). SCH 23390 was purchased from Sigma/RBI, and 
L-sulpiride was purchased from Ravizza (Latina, Italy). Rimonabant (SR141716-A) was a generous 
gift of Sanofi-Aventis Recherche (Montpellier, France). URB597 was purchased from Alexis 
(Lausen, Switzerland). OEA, WY14643, MK886, methAEA, and fenofibrate, and clofibrate were 
purchased from Tocris (Bristol, UK). MethOEA was a generous gift of Dr. Steven R. Goldberg 
(NIDA, Baltimore, MD, US). We diluted nicotine, SCH 23390, L-sulpiride, cocaine and morphine 
in saline. We adjusted nicotine solution to pH = 7 with NaOH. We emulsified rimonabant in 
1%Tween80 (Sigma, St Louis, MO, USA), then we diluted in saline and sonicated. We dissolved 
URB597 in dimethylsulfoxide (DMSO) (100 mg/ml) and diluted to the final concentration in saline. 
The final concentration of DMSO was 0.1%. We emulsified methOEA, WY14163, MK886, 
fenofibrate and clofibrate in 10% of Tween80, dissolved in 20% of DMSO and then diluted to the 
final concentration in distilled water. For i.c.v. administration, either OEA or methAEA were 
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dissolved in 40% w/v 2-hydroxypropyl-β-ciclodextrin, while methAEA for i.v. injection was 
dissolved in 2% of Tween80 and 2% of ethanol, and then diluted in saline.  
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Chapter IV 
RESULTS 
 
 
1. Blockade of CB-1Rs did not affect nicotine-induced effects on VTA DA neurons 
 
We first addressed whether the electrophysiological effect of nicotine on VTA DA neurons is 
prevented by the CB1-R antagonist SR141716-A (SR, rimonabant). To this aim, we recorded the 
electrical activity of single VTA DA neurons in anaesthetized animals, and we selected neurons 
only when they fulfilled all the criteria already reported in literature (see methods). A typical VTA 
DA neuron waveform, acquired from a digital storage oscilloscope, is presented in fig 4.1. Only one 
cell was recorded per rat. Moreover we restricted our sample to cells which responded to the 
stimulation of ShNAc. A total of 183 VTA DA neurons were recorded. We recorded the 
spontaneous activity of VTA DA neurons for at least 5 minutes, followed by a single administration 
of vehicle. Then, after 4 minutes of acquisition we administered nicotine (0.2 mg/kg i.v.). 
As previously reported in literature (Mereu et al., 1987; Erhardt et al., 2002; Mameli-Engvall et al., 
2006), nicotine (0.2 mg/kg i.v.) enhanced the firing rate (144.2±24.2% of baseline firing rate; 
F(5,71)=4.06; n=23; p<0.05; one-way ANOVA for repeated measures and Dunnett’s test vs. baseline) 
and burst firing (+10.6±3.8% of baseline; F(5,71)=2.89; n=23; p<0.05; one-way ANOVA for repeated 
measures and Dunnett’s test vs. baseline) of VTA DA neurons identified as projecting to the ShNAc 
(fig 4.1 c, d), while the administration of vehicle was ineffective per se (data not shown). This 
stimulatory effect, which is common to other drugs of abuse (e.g. opioids, cannabinoids and 
alcohol) enables the activation of the mesolimbic circuitry and allows the release of DA in the NAc. 
The administration of the CB1-R antagonist SR (0.5 mg/kg i.v.), 4 minutes before nicotine 
administration, did not abolish nicotine-induced activation of VTA DA neurons (F(1;103)=1.10, n=11; 
p>0.05; two-way ANOVA and Bonferroni’s test vs. controls) (fig 4.1 c, d). This result is in sharp 
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contrast to previous findings obtained through other techniques, where it was found that SR blocks 
neurochemical and behavioral effects of nicotine when tested with paradigms suggestive of 
addicting properties (Cohen et al., 2005; Cheer et al., 2007).  
 
2. URB597 fully prevented nicotine-induced effects on VTA DA neurons: involvement of CB1-
Rs and PPAR-α 
 
Since it has been already reported that FAAH blockade by URB597 fully prevents nicotine-induced 
self administration, nicotine-induced conditioned place preference and nicotine-induced increase of 
DA release in the ShNAc (Scherma et al., 2008), our next step was to evaluate whether FAAH 
inactivation might also modulate the electrophysiological effects of nicotine on the VTA DA 
neurons. Surprisingly, URB597 pretreatment (0.1 mg/kg i.v., 1-2 hours before recording) abolished 
nicotine-induced excitation of VTA DA neurons both on firing rate (74.1±6.2% of baseline firing 
rate; F(1,95)=4.95; n=6; p<0.01; two-way ANOVA and Bonferroni’s test vs. controls) and burst firing 
(-16.8±4.1% of baseline burst firing; F(1,107)=7.98; n=6; p<0.01; two-way ANOVA and Bonferroni’s 
test vs. controls) (fig 4.1 c, d) causing, on the other hand, a transient inhibition (firing rate: 
F(3,23)=3.73; n=6; p<0.001; one-way ANOVA for repeated measures vs. baseline; burst: F(3,23)=9.44; 
n=6; p<0.01; one-way ANOVA for repeated measures vs. baseline). The administration of 
URB597, per se, did not induce any change in spontaneous firing activity of VTA DA cells (firing 
rate: 3.7±0.26 Hz; n=48, in control animals vs. 3.9±0.14; n=14, in URB597 pretreated animals; 
p>0.05; Student’s T test; burst firing: 22.6±3.64% of spikes in burst; n=48, in control animals vs. 
23.0±5.15%; n=14, in URB597 pretreated animals; p>0.05; Student’s T test) (fig 4.1 e). 
Next, we addressed whether URB597-induced effects were due to the activation of CB1-Rs by  
AEA. To this aim, we pretreated animals with the CB1-R antagonist SR (0.5 mg/kg i.v., 1 minute 
before URB597). In fact, SR prevented URB597 effect on firing rate of VTA DA neurons 
(123.7±11.5% of baseline; F(1,23)=11.04; n=9; p<0.01; two way ANOVA and Bonferroni’s test vs. 
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UB597) but was ineffective on burst firing (-18.4±8.0% of baseline; F(1,23)=2.30; n=9; p>0.05; two 
way ANOVA and Bonferroni’s test for repeated measures vs. URB597) (fig 4.2 a, b). The CB1-R 
antagonist AM251 (1.0 mg/kg i.v., 1 min before URB597) mimicked the effect of SR (firing: 
F(1,61)=10.96; n=6; p<0.01; two way ANOVA and Bonferroni’s test vs.URB597; burst: F(1,75)=0.00; 
n=6; p>0.05; two-way ANOVA vs.URB597) (fig 4.2 a, b). Since URB597 does not only enhance 
AEA levels, but also OEA and PEA levels, we asked whether the lack of effect of SR and AM251 
on burst activity was due to the activation of PPAR-α. In fact, as discussed in chapter II, both OEA 
and PEA do not show affinity for CB1-Rs, but can be considered endogenous ligands for PPAR-α, a 
member of nuclear receptor transcription factor family widely expressed in the brain (Moreno et al., 
2004). Hence, the pretreatment with the PPAR-α antagonist MK886 (3 mg/kg i.p.,15 min before 
URB597) fully prevented the effect of URB597 on nicotine-induced burst firing, showing no effect 
on firing rate (firing: F(1,75)=0.00; n=13; p>0.05; two-way ANOVA and Bonferroni’s test 
vs.URB597; burst: 10.5±3.5% of baseline; F(1,72)=4.90; n=13; p<0.05; two-way ANOVA and 
Bonferroni’s test vs.URB597) (fig 4.2 a, b). These results draw a more complicated scenario, which 
involves new aspects to take into account when studying the effects of nicotine on VTA DA 
neurons.      
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Figure 4.1. Effects of rimonabant and URB597 on activation of VTA dopamine neurons by 
nicotine. (a) Average trace, acquired from a digital storage oscilloscope, showing the 
typical waveform of a VTA DA neuron recorded from an anaesthetized rat. (b) 
Representative firing rate histograms illustrating effects of intravenous nicotine (NIC, 
injected at arrowheads) on discharge activity of individual VTA DA neurons recorded from 
anaesthetized rats. The top panel shows the typical response to 0.2 mg/kg nicotine in 
control conditions following intravenous injection of vehicle (VEH). The middle panel 
illustrates the lack of effect of rimonabant (SR, 0.5 mg/kg i.v.) on spontaneous firing rate of 
dopamine neurons and on the subsequent effects of nicotine. The bottom panel shows 
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the effect of nicotine in a URB597 pretreated animal, where nicotine induced a transient 
inhibition of firing activity. (c; d) Graphs illustrating the time course of nicotine’s actions on 
firing rate and burst firing of VTA DA neurons. Pretreatment with URB597 (0.1 mg/kg, i.v.), 
but not rimonabant (0.5 mg/kg, i.v.), prevented the nicotine-induced increases in firing 
rate (c) and burst firing (d) of VTA dopamine neurons. (e) Histograms showing that URB597 
pretreatment does not affect the baseline activity of recorded VTA DA cells (p>0.05, 
Student’s t-test). Results are means, with vertical bars representing the SEM of firing rates 
and burst firing, expressed as a percentage of, or difference from, baseline (BAS) values. 
Arrows represent time of nicotine injection. *p<0.05 versus baseline (one-way ANOVA for 
repeated measures and Dunnett’s test); # p<0.01 versus controls (two-way ANOVA and 
Bonferroni’s test) 
 
 
                        
 
Figure 4.2. Contribution of CB1 receptors and PPAR-α to URB597’s reversal of nicotine’s 
effects. (a) The CB1 receptor antagonists rimonabant (SR, 0.5 mg/kg i.v.) or AM251(AM, 1.0 
mg/kg, i.v.) reversed URB597’s blockade of nicotine-induced increase in firing rate of VTA 
dopaminergic neurons (NIC, 0.2 mg/kg), whereas the PPAR-α antagonist MK886 (MK, 3 
mg/kg, i.p.) was ineffective. (b) In contrast, MK886 administration reversed URB597’s 
blockade of nicotine-induced increase in bursting activity of VTA dopamine neurons, 
whereas SR and AM251 were ineffective. Results are means, with vertical bars representing 
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the SEM of firing rates and burst firing, expressed as a percentage of, or difference from, 
baseline (BAS) values. Arrows represent time of nicotine injection. # p<0.05, SR and AM251 
versus controls (two-way ANOVA and Bonferroni’s test); § p<0.05, MK versus controls (two-
way ANOVA and Bonferroni’s test) 
 
 
 
3. Oleoylethanolamide (OEA), but not methyl-anandamide (methAEA) mimicked URB597 
effects 
 
To determine the precise contribution of CB1-R and PPAR-α in the modulation of nicotine effects 
on VTA DA neurons, we next addressed whether the FAAH resistant analogue of AEA, methAEA 
prevented the actions of nicotine. To this aim we injected methAEA at doses of 1 and 5 mg/kg i.v. 
or 5µg/5µl i.c.v. Interestingly, methAEA did not mimic the effects of URB597 (i.e. blockade of the 
excitatory effect of nicotine) (methAEA 5mg/kg firing: F(3,234)=0.68; n=6; p>0.05; two-way 
ANOVA and Bonferroni’s test vs. controls) (fig 4.3 b), suggesting that CB1-Rs are scarcely 
involved in the modulation of nicotine-induced effects on VTA DA neurons. 
Furthermore, to test the involvement of PPAR-α, we administered the PPAR-α endogenous agonist 
OEA. Since OEA is metabolically unstable, we chose to inject it in the lateral ventricle (20 μg/5μl) 
4 minutes before nicotine. OEA experiments were compared with controls receiving the same 
vehicle used to dilute OEA (40% w/v 2-hydroxypropyl-β-cyclodextrin). Interestingly, OEA, 
without producing any effect per se, fully prevented nicotine-induced excitation of VTA DA 
neurons both on firing rate (92.7±13.5% of baseline; F(1,99)=5.61; n=6; p<0.05; two-way ANOVA 
and Bonferroni’s test vs. controls), and burst firing (F(1,107)=4.28; n=6; p<0.05; two-way ANOVA 
vs. controls). Moreover, the PPAR-α antagonist MK886 (3 mg/kg i.p., 30 minutes before recording) 
blocked the effects of OEA (firing: 122.8±7.2; F(1,55)=6.06; n=8; p<0.005; two way ANOVA and 
Bonferroni’s test vs. OEA) (fig 4.3 d), thus restoring the excitatory action of nicotine. These data 
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strongly highlight the contribution of PPAR-α in the modulation of nicotine effect on mesolimbic 
DA neurons. 
 
                    
 
 
Figure 4.3. OEA, but not methAEA, prevented increases in firing rate of VTA dopaminergic 
neurons produced by nicotine. (a) Representative firing rate histograms showing the 
effects of nicotine (NIC, 0.2 mg/kg i.v., injected at arrowheads) on the discharge activity 
of individual VTA dopamine neurons recorded following injection of methAEA(1 mg/kg, 
i.v.). (b) Graph illustrating that nicotine-induced excitation of VTA dopamine neurons was 
not changed following the administration of methAEA, either intravenously (1 and 5 
mg/kg) or intracerebroventricularly (5µg/5µl). (c) Representative firing rate histograms 
showing the effects of nicotine (0.2 mg/kg i.v., injected at arrowheads) on the discharge 
activity of individual VTA dopamine neurons recorded following injection of OEA (20 
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µg/5µl, i.c.v.; top). MK886 (MK, 3 mg/kg, i.p.) reversed the OEA-induced blockade of 
nicotine’s effects (bottom). Neither OEA nor vehicle (40% w/v 2-hydroxypropyl-β-
cyclodextrin) produced significant changes in spontaneous firing rate or burst firing. (d) 
Graph depicting that nicotine-induced excitation of VTA dopamine neurons was 
abolished by OEA. MK886 (MK, 3 mg/kg, i.p.) reversed the OEA-induced blockade of 
nicotine’s effects. Results are means, with vertical bars representing SEM of firing rates, 
expressed as a percentage of baseline (BAS) values. Arrows represent the time of 
intravenous injections. The horizontal bar represents the time of intracerebroventricular 
administration. # p<0.05, OEA versus controls (two-way ANOVA and Bonferroni’s test); § 
p<0.05, MK+OEA versus OEA (two-way ANOVA and Bonferroni’s test). 
                    
 
4. The hydrolysis resistant analogue of OEA, methyl-oleoylethanolamide (methOEA) 
abolished nicotine effects on VTA DA neurons 
 
Our next aim was to test the actions of different PPAR-α agonists to confirm our previous results 
with the endogenous NAE, OEA. For these studies, in control experiments the administration of 
nicotine was preceded by a single injection of the vehicle used to dilute different PPAR-α agonists 
(see methods), which was ineffective per se. 
Consistent with previous results, the administration of the FAAH resistant analogue of OEA, 
methOEA (5 and 10 mg/kg i.v.) abolished nicotine-induced effects on VTA DA neurons (Firing 
rate: F(1,48)=5.24; n=7; p<0.05; two-way ANOVA vs. controls; burst: F(1,52)=4.73; n=7; p<0.05 two-
way ANOVA and Bonferroni’s test vs. controls) (fig 4.4 b, c),  without affecting the baseline firing 
rate, or burst firing per se (3.18±0.5 Hz for methOEA 5 mg/kg vs. 3.24±0.2 Hz for controls; p>0.05; 
Student’s T test 3.11±0.4 Hz for methOEA 10 mg/kg vs. 3.24±0.2 Hz for controls; p>0.05; 
Student’s T test).  
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5. The synthetic PPAR-α agonist WY14643 (WY) abolished the effects of nicotine in the VTA 
 
Our next step was to pretreat animals with the PPAR-α agonist WY14643 (WY). WY (40 mg/kg 
i.p., 1-2 hours before recording) blocked nicotine-induced enhancement of firing rate (95.76±5.71% 
of baseline; F(1,48)=20.36; n=7; p<0.01; two-way ANOVA and Bonferroni’s test vs. controls), and 
burst firing (F(1,48)=5.98; n=7; p<0.05; two-way ANOVA and Bonferroni’s test vs. controls) (fig 4.4 
e, f).  WY pretreatment had any effect neither on firing rate nor burst firing of VTA DA neurons 
(3.2±0.6 Hz for WY 20 mg/kg vs. 3.24 ±0.2Hz for controls; p>0.05; Student’s T test; 3.3±0.6 for 
WY 40 mg/kg vs. 3.24±0.2 for control; p>0.05; Student’s T test). Moreover, pre-administration of 
the PPAR-α antagonist MK886 (MK, 3 mg/kg i.p., 15 min before WY) abolished the effect of WY 
on these cells (firing: F(1,60)=16.57; n=5; p<0.01; two-way ANOVA  and Bonferroni’s test vs. WY; 
burst: F(1,60)=18.24; n=5; p<0.05; two-way ANOVA and Bonferroni’s test vs. WY) (fig 4.4 e, f), 
thus confirming that WY acts through a PPAR-α dependent-mechanism. A lower dose of WY (20 
mg/kg i.p.) partially, and not significantly, attenuated the effects of nicotine action (data not 
shown).   
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Figure 4.4. The PPAR-α agonists inhibited nicotine-induced activation of VTA dopamine 
neurons in anaesthetized rats. (a, d) Histograms showing the effects of  PPAR-α agonists on 
discharge activity of  individual VTA dopamine neurons after nicotine (Nic) administration. 
(b, c) The PPAR-α agonist meth-oleoylethanolamide (methOEA) (5 and 10 mg/kg 
intravenously injected 4 minutes before nicotine) significantly blocked nicotine-induced 
increases in firing rate and burst firing. (e, f) In line with methOEA experiments,  WY1463 (40 
mg/kg i.p. > 30 minutes before the start of recordings) blocked nicotine-induced increases 
in firing rate, and burst firing and the PPAR-α antagonist MK886 (3 mg/kg injected >45 
minutes before the start of recordings) significantly abolished the effects produced by 
WY14643.  Results are presented as mean ± SEM of firing rates and burst firing, expressed as 
percentages of, or differences from, baseline values, respectively. Arrows indicate time of 
drug injections.* p<0.01 versus baseline (one-way ANOVA and Dunnett’s test); # p<0.05 
versus controls (two-way ANOVA and Bonferroni’s test); § p<0.05 versus WY (two-way 
ANOVA and Bonferroni’s test) Nic, nicotine; MK, MK886; mOEA, methOEA; WY, WY14643. 
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6. Fenofibrate and clofibrate abolished nicotine effect in the VTA through a PPAR α-
dependent mechanism 
 
In addition, we tried to block nicotine action on mesolimbic DA neurons taking advantage of two 
PPAR-α agonists, fenofibrate and clofibrate, already used in clinical practice for the treatment of 
lipid disorders. Fenofibrate (200 mg/kg i.p., >1hour before recordings) abolished nicotine effects on 
VTA DA neurons (firing rate: 83.27±17.21% of baseline; F(1;32)=6.59; n=5; p<0.05; two-way 
ANOVA and Bonferroni’s test vs. controls; burst: -6.79±3.45; F(1;36)=5.16; n=5; p<0.05; two way 
ANOVA and Bonferroni’s test vs. controls) (fig 4.5 a, b) through a PPAR-α dependent mechanism, 
since this effect was reverted by the pre-administration of MK (3 mg/kg i.p., 15 minutes before 
fenofibrate) (firing rate: 149.78±11.14% of baseline; F(1;32)=6.59; n=5; p<0.05; two-way ANOVA 
and Bonferroni’s test vs. fenofibrate; burst: 21.62±9.42% of baseline; F(1;32)=5.14; n=5; p<0.05; 
two-way ANOVA and Bonferroni’s test vs. fenofibrate) (fig 4.5 a, b). Clofibrate (300 mg/kg i.p., 
>1 hour before recordings), consistently, prevented nicotine-induced increase in firing rate 
(97.00±5.04% of baseline; F(4;48)=17.59; n=7; p<0.01; two-way ANOVA and Bonferroni’s test vs. 
controls), and burst firing (F(4;44)=4.480; p<0.01; two-way ANOVA and Bonferroni’s test vs. 
controls) of VTA DA neurons (fig 4.5 c, d). These data suggest PPAR-α agonists as possible new 
treatment  of tobacco addiction.   
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Figure 4.5. Fenofibrate and clofibrate blocked nicotine-induced effects on VTA dopamine 
neurons.  (a, b) The PPAR-α agonist fenofibrate (200 mg/kg i.p., >1 hour before recordings) 
blocked nicotine effects on VTA DA neuron firing rate and burst firing. The administration of 
MK886 (MK; 3 mg/kg i.p., 15 minutes before fenofibrate) abolished the effects produced 
by fenofibrate. (c, d) In line with fenofibrate experiments, also clofibrate (300 mg/kg i.p., 
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>1 hour before recordings) prevented nicotine-induced effect both on firing rate, and 
burst firing of VTA DA neurons. (e) Representative firing rate histograms showing the action 
of nicotine in a fenofibrate- (left panel) and a MK+fenofibrate-pretreated rat (right panel).  
Results are presented as mean ± SEM of firing rates and burst firing, expressed as 
percentages of or differences from baseline values, respectively. Arrows indicate time of 
drug injections. # p<0.05 versus controls (two-way ANOVA and Bonferroni’s test); § p<0.05 
versus fenofibrate (two-way ANOVA and Bonferroni’s test); *p<0.05 versus controls (two-
way ANOVA and Bonferroni’s test). 
 
 
7. URB597 did not revert cocaine- and morphine-induced effects on VTA DA neurons 
 
Since our previous results have shown that  PPAR-α can modulate nicotine-induced effects, our 
next aim was to better clarify whether this effect was specific for nicotine or can be extended to 
other drugs of abuse. For this reason, we carried out experiments on VTA DA neurons to evaluate 
whether URB597 modified their electrophysiological response to the psychostimulant cocaine and 
the μ-opioid receptor agonist morphine.  
Cocaine, in line with previous findings (Einhorn et al., 1988), depressed the firing rate and burst 
firing of VTA DA neurons in a long-lasting manner (firing: 61.62±9.35% of baseline; F(5;30)=5.996; 
n=6; P<0.001; one-way ANOVA for repeated measures and Dunnett’s test vs. baseline; burst: -
16.42±6.14 of baseline level; F(5;25)=4.659; n=6; P<0.01; one-way ANOVA for repeated measures 
and Dunnett’s test vs. baseline) (fig 4.6 b, c). Using the above reported protocol of pretreatment, 
URB597 (0.1 mg/kg i.v.) did not prevent cocaine effects on VTA DA neurons (66.5±9.98% of 
baseline level; F(1;60)=0.0003; n=6, P>0.05; two-way ANOVA and Bonferroni’s test vs. 
vehicle+cocaine) (fig 4.6 b, c).  
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Figure 4.6. Effects of URB597 on the responses of VTA dopamine neurons to cocaine. (a) 
Representative firing rate histograms showing the decrease in firing rate of an individual 
VTA dopamine neuron produced by intravenous cocaine (COC, 1 mg/kg injected at 
arrowheads) in control conditions (left panel), and after URB597 (0.1 mg/kg i.v.) 
pretreatment (right panel). The injection of vehicle (VEH) is ineffective. (b, c) Graphs 
illustrating the time course of cocaine’s effects on firing rate and burst firing of VTA DA 
neurons with and without URB597 pre-treatment. Results are means, with vertical bars 
representing the standard error of the mean of firing rates and burst firing, expressed as a 
percentage of, or difference from, the baseline (BAS). *p < 0.01 versus baseline (one-way 
ANOVA and Dunnett’s test). 
 
 
Morphine, consistently with the literature (Matthews and German, 1984), enhanced the firing rate 
and burst firing of DA neurons in the VTA (139.46±8.17% of baseline level; F(4;20)=3.299; n=5; 
P<0.05; one-way ANOVA for repeated measures and Dunnett’s test vs. baseline) (fig 4.7 b, c). 
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Pretreatment with URB597 failed to modify this effect (firing: 159.63±9.06 of baseline level; 
F(1;40)=2.76; n=5, P=0.13 vs. vehicle+morphine; two-way ANOVA and Bonferroni’s test; burst: 
+15.34±5.13 of baseline level; F(1;40)=0.12; n=5, P>0.05 vs. vehicle+morphine; two-way ANOVA 
and Bonferroni’s test) (fig 4.7 b, c). These results support the hypothesis that the effects of PPAR-α 
agonists are specific for nicotine. 
 
  
             
 
Figure 4.7. Lack of effect of URB597 on morphine-induced increases in firing rate and burst 
firing of VTA dopamine neurons. (a) Representative firing rate histograms showing that 
intravenous injection of morphine (MORPH, 4 mg/kg) enhances firing rate of VTA DA 
neurons in control conditions (left panel) and that this effect is not blocked by the 
administration of URB597 (0.1 mg/kg, i.v.,1- 2 hours before the recordings). (b, c) Graphical 
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depiction of the time course of firing rate (b) or burst firing (c) of VTA dopamine neurons 
following intravenous administration of morphine (MORPH, 4 mg/kg). Pre-treatment with 
URB597 (0.1 mg/kg, i.v.) did not alter the effects of morphine either on firing rate or burst 
activity of VTA dopamine neurons. Results are means, with vertical bars representing the 
standard error of the mean of firing rates and burst firing, expressed as a percentage of, or 
difference from, the baseline (BAS). *p < 0.05 versus baseline (one-way ANOVA and 
Dunnett’s test). 
 
 
8. URB597 abolished nicotine-induced inhibition of MSNs in the ShNAc 
 
In the third part of our study, we addressed whether the ―classical‖ and ―non-classical‖ eCb systems 
may affect the actions of  nicotine, cocaine, and morphine on medium spiny neurons (MSNs) of the 
ShNAc. The ShNAc is a crucial area of the reward circuitry, receiving an abundant projection from 
VTA DA neurons, and modulating the primary reinforcing properties of natural stimuli and drugs of 
abuse.  A total number of 59 MSNs isolated in the medial part of the ShNAc were recorded. These 
neurons are normally quiescent in anaesthetized animals, and are excited by basolateral amygdala 
(BLA) stimulation, which is one of the major excitatory afferents. BLA stimulation evoked firing in 
MSNs of the ShNAc with a mean latency of 18.4±0.7 ms (fig 4.8 a). The average baseline spike 
probability following BLA stimulation was 46.3±1.5%. We recorded evoked activity of MSNs of 
the ShNAc for 300 seconds before the administration of nicotine, morphine, or cocaine. We 
recorded only one neuron per rat.  
As previously described in literature (Hakan et al., 1993), nicotine (0.2 mg/kg i.v.) depressed the 
excitability of MSNs evoked by BLA stimulation (64±12% of baseline level; F(5;40)=3.44, n=6, 
P<0.01; one-way ANOVA for repeated measures and Dunnett’s test vs. baseline) in a long-lasting 
manner (fig 4.8 b). This inhibitory effect is due to a combination of activation of  DA receptor type-
1 and type-2 (D1-Rs, D2-Rs). Hence, the simultaneous administration of the D1R antagonist SCH 
23390 (SCH; 1 mg/kg i.v.), and the D2-Rs antagonist L-sulpiride (10 mg/kg i.v.) abolished the 
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inhibitory response of these neurons after nicotine injection (122.5±10.6% of baseline level; 
F(1;80)=14.09; n=6; P<0.001 vs. control; two-way ANOVA and Bonferroni’s test) (fig 4.8 c). By 
contrast, neither the single injection of SCH nor L-sulpiride was able to revert nicotine effect on 
MSNs (SCH23390: F(1;70)=0.05, n=6, P>0.05; L-sulpiride: F(1;70)=0.02, n=6, P>0.05; two-way 
ANOVA and Bonferroni’s test) (fig 4.8 c).  
    
          
 
Figure 4.8. Nicotine depresses the excitability of (MSNs) in the shell of the nucleus 
accumbens (ShNAc). (a) Superimposed traces acquired from a digital storage 
oscilloscope showing a relatively constant latency of the orthodromic responses of a 
representative MSN after basolateral amygdala (BLA) stimulation. The arrowhead 
indicates the artifacts produced by BLA stimulation; the arrow shows evoked action 
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potentials of a MSN. Once a cell was isolated, the current applied to the BLA was adjusted 
to obtain ~50% of probability to elicit an action potential after a single pulse stimulation. 
(b) Representative peristimulus time histograms displaying the typical inhibitory response of 
a MSN in the ShNAc after BLA stimulation and injection of nicotine (0.2 mg/kg, i.v.). (c) 
Graph showing the time course of nicotine-induced inhibition of spike firing of MSNs. (d) 
Graphical depiction illustrating that nicotine-induced inhibition was prevented by the 
combined administration (at arrow), but not by the separate injection, of the D1-R 
antagonist SCH23390 (SCH, 1 mg/kg, i.v.) and the D2-R antagonist L-sulpiride (L-Sulp, 10 
mg/kg, i.v.). Results are means, with vertical bars representing the standard error of the 
mean of evoked spike firing, expressed as a percentage of the baseline (BAS). *p < 0.05 
versus baseline (one-way ANOVA and Dunnett’s test); #p < 0.05 versus controls ( two-way 
ANOVA and Bonferroni’s test) 
 
 
To test whether the eCb system might modulate nicotine-induced inhibitory effect in the ShNAc, 
we first  carried out experiments with the CB1-Rs antagonist SR. In line with VTA experiments, the 
administration of SR (0.5 mg/kg i.v., 200 seconds before nicotine) failed to prevent nicotine-
induced depression of MSNs excitability, suggesting that CB1-Rs are not involved (data not 
shown). 
On the other hand, consistently with the results obtained in the VTA, URB597 pretreatment (0.1 
mg/kg i.v., 1-2 hours before recording) abolished nicotine action in the ShNAc (126.6±15.6% of 
baseline level, F(1;70)=9.03, P<0.01 vs. control; two-way ANOVA and Bonferroni’s test) (fig 4.9 b). 
URB597 pretreatment did not show any effect per se on spike firing excitability of MSNs 
(1.52±0.16 mA vs. 1.9±0.4 mA, respectively; n=6; P>0.05; Student’s T test), while nicotine 
administration after URB597 caused an increase in BLA-evoked MSNs excitability (F(8;40)=3.32, 
n=6, P<0.01; one-way ANOVA for repeated measures and Dunnett’s test vs. baseline). 
These data prove that increasing levels of NAEs and eCbs, rather than CB1-R inactivation, is 
related to the modulation of nicotine rewarding properties in a crucial pathway of the brain reward 
circuitry. 
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9. SR141716-A and MK886 antagonized URB597 effects in the ShNAc  
 
Next, we investigated whether the effects of URB597 depend on activation of CB1-R or PPAR-α. 
To this aim, we pretreated a group of animals with the CB1-R antagonist SR and another group 
with the PPAR-α antagonist MK886, both of them injected 15 minutes before URB597 
administration. 
In line with VTA experiments, both SR (0.5 mg/kg i.v.) and MK (3 mg/kg i.p.), unable to produce 
any effect per se (data not shown), reverted URB597 action on MSNs after nicotine administration 
(rimonabant+URB597 vs. URB597: 63.5±21.8% of baseline level; F(1;63)=10.3, n=5, P<0.05, 
MK886+URB597 vs. URB597: 56.8,±16% of baseline level; F(1;70)= 5.462, n=6, P<0.05, two-way 
ANOVA and Bonferroni’s test) (fig 4.9 b, c). These results might suggest a possible cross-talk 
between classical eCb system and NAEs (see discussion).      
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Figure 4.9. URB597 suppresses nicotine’s action on MSNs in the ShNAc. (a) Exemplificative 
peristimulus time histograms showing that nicotine-induced decrease of MSN excitability is 
reversed by URB597, whereas the CB1-R antagonist rimonabant (SR, 0.5 mg/kg) and the 
peroxisome proliferator-activated nuclear receptor-a antagonist MK886 (3 mg/kg), 
administered 15 minutes before URB597, prevented the effects of the fatty acid amide 
hydrolase inhibitor, and restored nicotine-induced inhibition of MSN responses to 
basolateral amygdala (BLA) stimulation in the ShNAc. (b,c) Graphical depiction illustrating 
that URB597 pre-treatment prevented nicotine-induced inhibition of MSNs, and that this 
inhibition by nicotine was reversed by rimonabant (SR, 0.5 mg/kg, i.v.) (b), or MK886 (3 
mg/kg, i.p.) (c). Results are means, with vertical bars representing the standard error of the 
mean of evoked spike firing, expressed as difference percentage of the baseline (BAS). 
#p < 0.05 versus controls (two-way ANOVA and Bonferroni’s test),§ and §§ p < 0.001 versus 
URB597 (two-way ANOVA and Bonferroni’s test). 
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10. URB597 blocked cocaine effects in the NAc 
 
Since URB597 blocked nicotine effect on MSNs of the NAc, our last step was focused on testing 
whether the enhanced levels of eCbs and NAEs might also modulate cocaine and morphine action 
on these neurons.  
In line with the literature (Hakan et al., 1987),  we did not manage to obtain a stable time course of 
morphine on GABAergic MSNs. For this reason we carried out our experiments only with cocaine.  
Cocaine (1 mg/kg i.v.), as already demonstrated (White et al., 1993), exerted a strong and long-
lasting inhibitory effect on BLA-evoked MSN excitability (37.06±27.7% of baseline level; 
F(6;48)=7.28, n=7, P<0.001, one-way ANOVA for repeated measures and Dunnett’s test vs. baseline) 
(fig 4.10 b). Interestingly, URB597 pretreatment (0.1 mg/kg i.v.) abolished cocaine-induced effect 
on MSNs without affecting the baseline mean current applied to evoke a MSN excitation 
(95.3±15.1% of baseline level; F(1;77)=11.97, n=6, P<0.01 vs. control, two-way ANOVA and 
Bonferroni’s test) (fig 4.10 b).  
This result strongly differs from those observed in the VTA experiment, where URB597 was not 
able to block cocaine, thus pointing to the involvement of different mechanisms by which FAAH 
blockade may act to prevent cocaine effects.        
 
11. MK886 but not SR141716-A reverted URB597 effect on cocaine in the NAc. 
 
Finally, we tried to elucidate the mechanism by which URB597 acts in the ShNAc to abolish 
cocaine-induced effects. In contrast, the effects of URB597 depended on the activation of PPAR-α, 
since the pretreatment with MK (3 mg/kg i.p., 15 minutes before URB597) (58.02±15.59% of 
baseline level; F(1;70)=7.028, n=6, P<0.05 vs. URB597 pretreated animals, two-way ANOVA and 
Bonferroni’s test) (fig 4.10 d), but not with SR (0.5 mg/kg i.v., 15 min before recording) 
(98.34±18.45% of baseline; F(1;70)=0.04, n=6, P>0.05 vs. URB597 pretreated animals, two-way 
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ANOVA and Bonferroni’s test) (fig 4.10 c), reverted URB597 action on cocaine response in the 
ShNAc. This last result provides evidence about a possible involvement solo of PPAR-α activation, 
which could opens the way for considering these receptors as modulators of reward-seeking 
behavior. 
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Figure 4.10. URB597 suppresses cocaine’s action on MSNs of the shell of the ShNAc. (a) 
Representative peristimulus time histograms showing the response of recorded ShNAc 
MSNs after BLA stimulation. The probability of evoking MSN responses after BLA stimulation 
decreased after cocaine administration. Pre-treatment with URB597 reversed cocaine-
induced inhibition of MSNs. The peroxisome proliferator-activated nuclear receptor-a 
antagonist MK886 blocked URB597 effect and restored cocaine-induced inhibition of 
MSNs. (b–d) Graphical depictions of the time course of cocaine’s effects on MSN 
excitability in the ShNAc. Cocaine depresses the excitability of MSNs in a long-lasting 
manner (b). This effect was blocked by URB597, which fully prevented cocaine-induced 
inhibition (b). Pre-treatment with the CB1-R antagonist rimonabant (SR; 0.5 mg/kg, i.v.) did 
not alter URB597’s blockade of cocaine’s effect (c), whereas MK886 (3 mg/kg, i.p.) (d) 
completely prevented URB597’s blockade of cocaine’s actions and restored cocaine-
induced inhibition of MSNs. Results are means, with vertical bars representing the standard 
error of the mean of evoked spike firing, expressed as a percentage of the baseline (BAS). 
98 
 
*p < 0.05 versus baseline, one-way ANOVA and Dunnett’s test); #p < 0.05 versus controls, 
§P < 0.05 versus URB597 (two-way ANOVA and Bonferroni’s test). 
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Chapter V 
GENERAL DISCUSSION 
 
 
In this thesis, it was shown that the manipulation of the eCb system, through inhibition of the 
enzyme FAAH, blocked nicotine addictive properties by the activation of both the conventional eCb 
and the ―parallel‖ eCb-like systems, the latter comprising NAEs and their nuclear receptors.  
In fact, the inhibition of FAAH by the carbamic acid derivate URB597abolished nicotine-induced 
enhancement of firing rate and burst firing of VTA DA neurons. The functional consequence of this 
effect are of importance, since mesolimbic DA neurons play a pivotal role in the acute responses to 
natural rewarding stimuli and drugs of abuse. Hence, increased DA neuron discharge rate and/or 
DA release in terminal areas such as the NAc, are among the first steps of the complex and 
multifaceted neural mechanisms and cellular pathways that lead to addiction (see chapter I).    
Previous studies were focused on the involvement of the eCb system in the modulation of nicotine 
rewarding properties. For instance, early reports showed that the CB1-R antagonist rimonabant 
decreases nicotine-induced enhancement of DA outflow from the VTA to the NAc (Cohen et al., 
2002; Cheer et al., 2007), and conditioned place preference (Le Foll and Goldberg, 2004). However, 
the electrophysiological data here reported do not support this hypothesis, since URB597 but not 
rimonabant, abolished the effects of nicotine on VTA DA neurons. This finding suggests that 
enhanced levels of eCbs, rather than blockade of cannabinoid receptors exert a preventive action on 
nicotine-induced effects in mesolimbic DA neurons. The reasons of the discrepancy between the 
lack of effects by rimonabant on neuronal responses to nicotine and its effects on neurochemical 
and behavioral actions of the drug are currently unknown. However, it might be possible that the 
suppression by rimonabant of evoked DA release may be independent from the inhibition of firing 
activity of DA neurons in the VTA, and may be an effect primarily involving their terminal regions 
or local circuits within the NAc.  
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Behavioral experiments carried out by Scherma and coll. (2008) support our electrophysiological 
results, since they demonstrated a significant effect of FAAH inhibition by URB597 in preventing 
the development of nicotine-induced conditioned place preference (CPP), acquisition of nicotine 
self-administration, nicotine reinstatement, and nicotine-induced increase of DA release in the 
ShNAc in rats (Scherma et al., 2008).  
It must be pointed out that, despite the role of FAAH in the deactivation of the CB1-R agonist 
AEA, this enzyme also metabolizes other NAEs like the monounsaturated fatty acid 
oleoylethanolamide (OEA), and the saturated palmitoylethanolamide (PEA) (Kathuria et al., 2003; 
Fegley et al., 2005). Interestingly, even though OEA and PEA belong to the family of eCb-like 
molecules, they are devoid of CB1-R affinity, being ligands at the α-type peroxisome-proliferator 
activated receptors (PPAR-α), a subfamily of nuclear receptors and transcription factors highly 
implicated in several metabolic processes (Pistis and Melis, 2010) (see chapter II).      
In line with these findings, in our study we observed that the conventional eCb system is not 
primarily involved in the mechanism of action of URB597. In fact, despite rimonabant prevented 
the effects mediated by URB597 on VTA DA neuron firing rate after nicotine administration, 
further experiments showed that the stable analogue of AEA, methAEA failed to mimic the action 
of the FAAH inhibitor. Conversely, we discovered that OEA blocked nicotine-induced 
electrophysiological effects on VTA DA cells. This result highlights the role of PPAR-α in the 
modulation of nicotine rewarding properties. Notably, this finding was also corroborated by patch-
clamp experiments in vitro, where it was shown that OEA and PEA completely prevented nicotine-
induced excitation of VTA DA neurons (Melis et al., 2008).  
These results draw a very complex scenario which goes beyond our early hypothesis about the 
modulatory role of the ―classic‖ eCb system in drug-induced effects, and they provide one of the 
first evidence about a potential, functional role of nuclear receptors in the pathophysiology of CNS 
diseases. In fact, although it has been recently demonstrated that PPAR-α is ubiquitously expressed 
in the brain (Moreno et al., 2004), and that OEA and PEA are identified as its endogenous ligands 
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(Fu et al., 2003), the characterization of its central function and role in brain physiology and 
pathophysiology remained widely unknown (Hansen, 2010). Similarly, centrally mediated effects of 
the PPAR-α agonist NAEs have been poorly investigated. Evidence suggests that OEA and PEA 
might be part of an independent eCb-like system, which exerts modulatory actions by the activation 
of PPAR-α, rather than CB1-Rs. Moreover, to support this observation, several studies underlined 
how NAEs are synthesized, released and inactivated independently to conventional eCbs (Hansen et 
al., 1995; Stella and Piomelli, 2001; Mackie and Stella, 2006). 
The findings that the effects of OEA are blocked by the PPAR-α antagonist MK886, and  mimicked 
by the synthetic agonist WY14643 (WY) and by the stable analogue of OEA, methOEA, give 
further support to the hypothesis that a PPAR-α-mediated mechanism is involved in the modulation 
of nicotine effects on mesolimbic DA neurons. Notably, also the modulatory effect of fibrates 
(fenofibrate and clofibrate), already used in the clinical treatment of dyslipidemia, on nicotine-
induced actions strongly suggests that these compounds might possess a pharmacological spectrum 
that goes beyond the lipid sensor ability of PPAR-α (see chapter II). 
In line with these results, it has been recently reported that WY and methOEA block the acquisition 
of nicotine self-administration, and suppress the reinstatement to nicotine seeking behavior in rats 
and squirrel monkeys through a direct effect on PPAR-α (Mascia et al., 2010).  
Noteworthy, different studies by Sun and coll. (Sun et al., 2006; Sun et al., 2007) showed that also 
AEA displays affinity as an agonist for PPAR-α. However, our results do not support the idea that 
AEA might act as a PPAR-α agonist on DA neurons since, as already mentioned above, differently 
from OEA, methAEA did not suppress the effects of nicotine, and further in vitro experiments with 
AEA have confirmed our observation in vivo (Melis et al., 2008). In addition, other studies 
performed in an animal model of analgesia, have disconfirmed that AEA activates PPAR-α, given 
that the analgesic properties of this eCb  were still preserved in PPAR-α-/- mice, whereas the effects 
of OEA and PEA were abolished (LoVerme et al., 2006). These discrepancies might arise from the 
fact that the studies of Sun and coll. were carried out in HeLa cells transiently transfected with 
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PPAR-α, raising the issue that these investigations should be performed under more physiological 
conditions, and possibly in neurons, to confirm their results.  
Besides the activation of PPAR-α, another alternative explanation of our observations might involve 
a noncompetitive antagonistic action of AEA and NAEs on nAChRs, as it was reported by several 
studies (Butt et al., 2002; Oz et al., 2003; Barrantes, 2004; Spivak et al., 2007; Butt et al., 2008). 
However, also in these cases studies were performed in Xenopus oocytes, or in mouse thalamic 
synaptosomes. We tend to exclude this hypothesis since our results show that chemically unrelated 
PPAR-α agonists are similarly effective, and that their actions are blocked by pharmacological 
antagonism of PPAR-α. 
In this thesis it was also demonstrated that the modulation of both FAAH blockade and PPAR-α 
activation on VTA DA neurons is specifically associated to nicotine action, since URB597 had no 
effect on cocaine- and morphine-induced decrease and increase of DA neurons electrical activity, 
respectively. This finding suggests that PPAR-activation might exclusively target nAChRs 
(discussed below).   
However, we found that the inhibition of FAAH does not specifically target nicotine action in the 
shell of the NAc, where URB597 blocked both nicotine- and cocaine-induced depression of MSN 
excitability after BLA stimulation. The ShNAc is crucially involved in the modulation of primary 
reinforcing properties of natural stimuli and drugs of abuse and reward-seeking behavior (Goto and 
Grace, 2008). A common electrophysiological feature of GABAergic MSNs is that they are 
depressed by the administration of the main addictive substances, including nicotine and cocaine 
(Carlezon and Thomas, 2009). This inhibitory action exerted by drugs of abuse  has an important 
functional role since, by impairing GABAergic transmission to downstream areas encoding for 
hedonic qualities of stimuli, it disinhibits structures such as the ventral pallidum and VTA, and 
augment the rewarding value of the incentive (Carlezon and Thomas, 2009). 
For this reason, our finding is of particular interest as it shows a modulatory role exerted by 
increased levels of conventional and unconventional eCbs in drug-induced response of MSNs.  
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Notably, our study in the ShNAc showed that URB597 action on nicotine-induced effects was 
prevented by either the administration of SR or MK886, underlining that URB597 effects might 
require both CB1 and PPAR-α activation. These data extend our results on VTA DA neurons, 
where both CB1 and PPAR-α played a role in URB597-mediated effect. Thus, this findings sheds 
some light into the probable cross-talk between these two systems, a possibility already taken into 
account to explain the effects of URB597 as a cognitive enhancer (Mazzola et al., 2009) . 
Further electrophysiological studies have provided additional evidence about a synergistic effect 
between the eCb system and PPAR-α activation to explain how FAAH inhibition might modulate 
nicotine-induced effect. In fact, neither methAEA nor methOEA, affect nicotine-induced depression 
on BLA-evoked MSNs spike firing (Luchicchi, Goldberg and Pistis, work in progress). This lack of 
effect would suggest that URB597 modulation in the NAc might need the combined activation of 
both CB1-R and PPAR-α to exert its suppressant action.  
Surprisingly, here it was also shown that after URB597 pretreatment, nicotine effect became 
excitatory rather than inhibitory, in the NAc. This enhancement of BLA-evoked excitability of 
MSNs might be parsimoniously explained by calling up a combination of different factors. Among 
them, it is likely that reduction of nicotine-induced DA release from the VTA to the NAc (Scherma 
et al., 2008), together with activation of CB1-Rs in the ventral striatum by AEA and the consequent 
depression of nicotine-induced GABA release, may unmask the increase of glutamate release 
induced by nicotine (Reid et al., 2000), which ultimately excites MSNs.  
The finding that URB597 modulates the effects of cocaine in the ShNAc was rather unexpected, 
since FAAH blockade did not prevent cocaine action on VTA DA neurons. For this reason, this 
result makes the scenario of cocaine-eCb interactions quite complicated. In fact, studies have 
shown that (1) CB1
-/-
 mice self-administer cocaine (Cossu et al., 2001), (2) rimonabant does not 
modify the development of cocaine induced CPP (Martin et al., 2000), and (3) URB597 does not 
alter cocaine self-administration in squirrel monkeys (Justinova et al., 2008). On the contrary, other 
investigations provided opposing results. For example, Cheer et al. (2007) demonstrated that SR 
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prevents cocaine-induced increase in DA levels in the NAc, and Orio et al. (2009) that rimonabant 
increases the breakpoint for cocaine self-administration under a fixed-ratio schedule in rats under 
long access sessions.  
One possible explanation for the discrepancy between our study and that of Justinova and coll. 
might involve differences in experimental subjects (rats vs. monkeys), and the substantial difference 
in the experimental protocol used. In fact, while in self-administration studies the injection of 
cocaine followed 1-h session protocol, and URB597 effect was examined over three consecutive 
daily sessions, in our study we examined electrical responses of neurons from specific brain areas 
(ShNAc) to an acute intravenous dose of cocaine. This effect might suggest that URB597 acts by 
impairing drug-induced electrophysiological effect in discrete manner, whereas it is ineffective on 
drug-induced associated behavior. Another possibility is that URB597 might prevent the initial 
acute effects of cocaine. In line with this hypothesis, a recent study has shown that URB597 reduces 
cocaine reinstatement in abstinent animals, but not the initial cocaine self-administration 
(Adamczyk et al., 2009). 
In the present experiments, some evidence indicating that CB1-Rs are not involved in the 
modulation exerted by URB597 on cocaine-induced effect in the ShNAc was also provided. In fact, 
this effect seems to be correlated more to the activation of PPAR-α, since the pretreatment with 
MK886 abolishes URB597 effects on MSNs. These data indicate that under these circumstances, 
FAAH inhibition results in the activation of both surface cannabinoid (by AEA) and nuclear 
receptors (by OEA/PEA).   
Taken together, these findings provide evidence of a role for PPAR-α in the CNS, alone or in 
combination with CB1-Rs, in the modulation of drug-induced effects in the mesoaccumbens 
pathway, a circuit which mediates the rewarding response to addictive substances and, ultimately, 
produces some neurobiological changes that leads to abuse and addiction. 
Finally, it is worth to mention that, even though the mechanism by which PPAR-α may modulate 
neuronal response to nicotine and cocaine in the VTA and ShNAc has not been clarify yet, different 
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hypothesis might be proposed to explain this effect. First of all, the rapid onset of agonist action 
suggests that PPAR-α may act through a non-genomic mechanism. In fact it is hard to reconcile our 
result with a classic genomic process of nuclear receptors, which requires a longer timeframe to 
produce an effect. In addition, studies in vitro carried out by our group strongly suggest that PPAR-
α activation on DA neurons negatively modulate somatodendritic nAChRs by phosphorylating them 
(Melis et al., 2008; Melis et al., 2010). In fact, it was previously shown that functional properties of 
specific nAChRs subunits (such as α7) depend on the status of tyrosine phosphorylation of the 
receptor (Charpantier et al., 2005), and that phosphorylation/dephosphorylation of tyrosine residues 
in nAChRs controls the number of functional surface receptors (Cho et al., 2005).  
For this reason it is likely that PPAR-α activation may trigger the phosphorylation of specific 
subunits of nAChRs on DA neurons by a tyrosin kinase-dependent mechanism.  This hypothesis is 
confirmed by findings in vitro using the tyrosine kinases inhibitor genistein (Melis et al., 2008). 
Hence, inhibition of tyrosine kinases restores the excitatory properties of nicotine in the presence of 
PPAR-α agonists. Although we cannot identify which specific tyrosin kinase is involved in this 
mechanism, the nAchR subunits primarily involved in the interaction with PPAR-α have been 
identified. Indeed, in an elegant experimental design utilizing both patch-clamp experiments in rats 
and lentiviral expression mice, Melis and coll. (2010) demonstrated that PPAR-α decreases both 
DA neurons activity and VTA net output by negatively modulating the β2 subunit of nAChRs 
expressed in DA neurons. β2 subunits of nAChRs are critically involved in the switch from regular 
to activate state of DA neurons (Mameli-Engvall et al., 2006; Melis et al., 2010) and their negative 
modulation might reduce the responsiveness of DA neurons to external information (Melis et al., 
2010). This effect might also explain why URB597 suppresses nicotine-induced depression of MSN 
in the ShNAc, which is a DA-dependent effect.  
How PPAR-α modulated acute neuronal responses to cocaine in the present experiments is not 
known. Among possible explanations, a conservative hypothesis may involve a negative 
modulation exerted by PPAR-α agonists, such as OEA and PEA, on cholinergic transmission within 
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the ShNAc. In fact, cholinergic interneurons of the NAc were shown to modulate the response of 
MSNs (de Rover et al., 2002). In that study, the authors hypothesized that this effect occurred 
through an increase of GABAergic interneuron activity within the ventral striatum. These neurons 
receive inputs from the cholinergic neurons mediated by nAChRs, and their synapses impinge 
directly to MSNs. Moreover, other studies have demonstrated an increase in acetylcholine release in 
the NAc after psychostimulant exposure (Guix et al., 1992; Imperato et al., 1992; Bickerdike and 
Abercrombie, 1997). Since PPAR-α, activated by endogenous agonists OEA and PEA, specifically 
modulates nAChRs by inducing their inactivation through phosphorylation (Melis et al., 2008), by 
analogy, it is likely that PPAR-α activation within the NAc might modulate cocaine’s response 
through inactivation of nAChRs in GABAergic interneurons. This should results in an impairment 
of GABA transmission to the MSNs that could explain the lack of inhibitory effect of cocaine on 
MSNs after URB597 pretreatment. Interestingly, interactions between OEA and PEA and 
acetylcholine transmission might be bidirectional, given that their biosynthesis is increased after 
stimulation of muscarinic receptors (Stella and Piomelli, 2001), which are present in the terminal 
regions of GABAergic interneurons (de Rover et al., 2002). 
A schematic representation of PPAR-α dependent modulation on nicotine and cocaine effects is 
shown in fig 5.1.      
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Fig 5.1. A possible mechanism of action by which PPAR-α activation modulates nicotine-
induced effects on VTA DA neurons and cocaine-induced depression of MSNs excitability 
in the ShNAc. (a) Schematic diagram illustrating the proposed mechanism of PPAR-α 
activation, and modulation of responses of DA neurons to nicotine, by the 
noncannabinoid fatty acid ethanolamides OEA and PEA. Their action is mimicked by the 
synthetic PPAR-α  agonist WY14643, and blocked by the PPAR-α antagonist MK886. 
URB597 enhances brain levels of OEA and PEA in vivo by inhibiting their major catabolizing 
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enzyme, FAAH. It is proposed that activated PPAR-α stimulates the activity of tyrosine 
kinases (Tyr Kin) through a nongenomic mechanism. Tyrosine kinases, in turn, induce the 
phosphorylation (P) of nAChRs, which reduces their responses to the agonists, or promotes 
rapid internalization. (b). Possible mechanisms underlying the modulation by PPAR-α on 
cocaine-induced effect in the ShNAc. Cocaine, by blocking DA transporters (DAT), 
increases DA levels in the NAc. In turn, activation of D1-Rs by DA on Ach interneurons (Ach 
intern) evokes increases of the release of acetylcholine (Ach), which activates GABA 
interneurons (GABA intern) through the activation of postsynaptic nAChRs (de Rover et al., 
2002).  Excitation of GABA interneurons depresses the excitability of MSNs. Hence,  PPAR-α 
activation might modulate nAChRs activity by reducing Ach-mediated excitation of 
GABA interneurons, and modifying the subsequent GABA release to MSNs. This figure also 
shows that activation of muscarinic receptors (mAChRs) triggers the biosynthesis of OEA 
and PEA (Stella and Piomelli, 2001), contributing to create a bidirectional interaction 
between NAEs and acetylcholine transmission.      
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CONCLUSIONS AND FINAL REMARKS 
 
 
Altogether, these findings suggest that FAAH inhibition, and the consequent PPAR-α activation by 
increased levels of FAAH substrates, one can abolish neurochemical, electrophysiological and 
behavioral effects of nicotine. Importantly our data are also corroborated by previous results 
obtained through different techniques (Melis et al., 2008; Scherma et al., 2008; Mascia et al., 2010; 
Melis et al., 2010). Overall, these observations provide a strong preclinical rationale and are 
predictive of a potential use of PPAR-α agonists in the treatment of tobacco addiction in humans. 
Since fibrates prevent nicotine-induced effects on VTA DA neurons, it seems reasonable to test 
these drugs, already used in the clinical treatment of metabolic disorders, for detoxification of 
nicotine addicted patients. Currently, there is no evidence about this possible effect of fibrates in 
humans, and doubts might arise whether these drugs do effectively reach appropriate concentration 
in the brain. However, a recent study by Porta and coll. (2009) has demonstrated that fenofibrate 
possesses anticonvulsant properties in rats (Porta et al., 2009), suggesting that these drugs might 
cross the blood-brain barrier and directly act in the CNS through a PPAR-α-dependent mechanism. 
Consistently, neuroprotective effects of PPAR agonists in CNS diseases such as Alzheimer, 
Parkinson and stroke have been reported (Heneka and Landreth, 2007). Indeed, among fibrates, 
fenofibric acid (the active metabolite of fenofibrate) does cross the blood-brain barrier though 
slowly (Deplanque et al., 2003), and its levels in the cerebrospinal fluid might actually be higher 
than generally expected. Noteworthy, Chikaisa and coll. (2008) report that a two-week feeding of 
bezafibrate phase advanced sleep-wake rhythm of about 2-3 h, increased the EEG delta-power in 
non-REM sleep, and attenuated its daily amplitude, thus ultimately supporting the central effects of 
fibrates (Chikahisa et al., 2008). 
Therefore, fibrates might represent a new interesting avenue as a strategy for smoking cessation. 
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However, studies are needed to ascertain the possibility that patients already treated with fibrates, 
and with an history of tabagism, show a reduced intake of nicotine after a short- and long- term 
treatment with these drugs. 
Additionally, a very recent study published in the journal Obesity has shown an interesting link 
between a common NAPE-PLD haplotype polymorphism and smoking cessation (Wangensteen et 
al., 2010), which may provide the first clinical evidence of an interaction between levels of NAEs 
and vulnerability to nicotine addiction.  
Irrespective of whether or not studies on humans would confirm the hypotheses of the feasibility of 
PPAR-α activation as a pharmacological tool for quitting cigarette smoking, our studies identified 
new unsuspected players in the complex interplay between neurotransmitter and neuromodulators, 
which govern neuroadaptations induced by drugs of abuse, leading to addiction. 
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APPENDIX 
Cellular/Molecular
Endogenous Fatty Acid Ethanolamides Suppress Nicotine-
Induced Activation of Mesolimbic Dopamine Neurons
through Nuclear Receptors
MiriamMelis,1* Giuliano Pillolla,1* Antonio Luchicchi,1 Anna Lisa Muntoni,2 Sevil Yasar,3 Steven R. Goldberg,4 and
Marco Pistis1
1B. B. Brodie Department of Neuroscience, and 2Consiglio Nazionale delle Richerche Institute of Neuroscience, University of Cagliari, 09042 Monserrato,
Italy, 3Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224,
and 4Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, Department of Health and Human
Services, National Institute on Drug Abuse–National Institutes of Health, Baltimore, Maryland 21224
Nicotine stimulates the activity ofmesolimbic dopamine neurons, which is believed tomediate the rewarding and addictive properties of
tobacco use. Accumulating evidence suggests that the endocannabinoid systemmight play amajor role in neuronal mechanisms under-
lying the rewarding properties of drugs of abuse, including nicotine. Here, we investigated the modulation of nicotine effects by the
endocannabinoid systemondopamineneurons in theventral tegmental areawith electrophysiological techniques in vivoand in vitro.We
discovered that pharmacological inhibition of fatty acid amide hydrolase (FAAH), the enzyme that catabolizes fatty acid ethanolamides,
among which the endocannabinoid anandamide (AEA) is the best known, suppressed nicotine-induced excitation of dopamine cells.
Importantly, this effect was mimicked by the administration of the FAAH substrates oleoylethanolamide (OEA) and palmitoylethanol-
amide (PEA), but not methanandamide, the hydrolysis resistant analog of AEA. OEA and PEA are naturally occurring lipid signaling
molecules structurally related to AEA, but devoid of affinity for cannabinoid receptors. They blocked the effects of nicotine by activation
of the peroxisomeproliferator-activated receptor- (PPAR-), a nuclear receptor transcription factor involved in several aspects of lipid
metabolism and energy balance. Activation of PPAR- triggered a nongenomic stimulation of tyrosine kinases, which might lead to
phosphorylation and negative regulation of neuronal nicotinic acetylcholine receptors. These data indicate for the first time that the
anorexic lipidsOEAandPEApossess neuromodulatory properties as endogenous ligands of PPAR- in the brain andprovide a potential
new target for the treatment of nicotine addiction.
Key words: dopamine neurons; nicotine; electrophysiology; endocannabinoids; fatty acid amide hydrolase; patch clamp; peroxisome
proliferator-activated receptor
Introduction
Nicotine is the main active component in tobacco smoke, which
initiates and sustains tobacco addiction. Hence, nicotine induces
drug-seeking behavior in animals and many additional effects
commonly seen with addictive drugs (Stolerman and Shoaib,
1991). Among these effects, stimulation ofmesolimbic dopamine
(DA) transmission is considered to be one of the hallmarks to
define the addicting potential of nicotine, being one of the com-
mon features of all abused drugs (Di Chiara and Imperato, 1988;
Wise, 2004). By acting at neuronal nicotinic acetylcholine recep-
tors (nAChRs), nicotine activates ventral tegmental area (VTA)
DA neurons (Mereu et al., 1987; Pidoplichko et al., 1997) and
induces DA release in the nucleus accumbens (Di Chiara and
Imperato, 1988).
Among medications aimed at achieving smoking cessation,
antagonists at the cannabinoid type-1 (CB1) receptors show
promise, based on preclinical data indicating that these com-
pounds, such as rimonabant (SR141716A) or AM251, reduce
nicotine self-administration or conditioned place preference
(CPP) (Cohen et al., 2002; Le Foll and Goldberg, 2004; Forget et
al., 2005; Shoaib, 2008), nicotine-induced DA release in the nu-
cleus accumbens (Cohen et al., 2002; Cheer et al., 2007), or smok-
ing cessation in humans (Cahill and Ussher, 2007). These data
strongly point to a facilitatory effect of the endocannabinoid sys-
tem in the motivational and DA-releasing properties of nicotine.
Indeed, endogenous cannabinoids, such as arachidonoylethano-
lamide (anandamide, AEA) and 2-arachidonoylglycerol, andCB1
receptors are involved in the neuronal mechanisms underlying
the rewarding effects of most drugs of abuse, including nicotine
(Castan˜e´ et al., 2005; Le Foll and Goldberg, 2005; Le Foll et al.,
2008; Solinas et al., 2008).
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The present study was designed to investigate modulation of
nicotine effects by the endocannabinoid system, and to clarify the
role of DA neurons in the mediation of the antiaddicting prop-
erties of CB1 antagonists. To this aim, the electrophysiological
responses of DAneurons to nicotine administrationwere studied
following either blockade of CB1 receptors or, conversely, en-
hancement of brain endocannabinoid levels by inhibiting fatty
acid amide hydrolase (FAAH) (Kathuria et al., 2003; Fegley et al.,
2005), the major hydrolyzing enzyme for AEA and other endog-
enous fatty acid ethanolamides (FAEs), such as the N-acylamines
oleoylethanolamide (OEA) and palmitoylethanolamide (PEA).
Unlike AEA, bothOEA and PEA have no affinity for cannabinoid
receptors, but bind to the peroxisome proliferator-activated re-
ceptor (PPAR), a family of nuclear receptor transcription factors
(Fu et al., 2003; Lo Verme et al., 2005). Three subtypes of PPARs
(, / and ) play important roles in lipid metabolism, insulin
sensitivity, glucose homeostasis and inflammation (Berger and
Moller, 2002). Through PPAR-, OEA and PEA are peripherally
acting satiety signals that modulate feeding, body weight and
lipid metabolism (Rodriguez de Fonseca et al., 2001; Fu et al.,
2003) and have antinociceptive effects in visceral and inflamma-
tory pain models (Lo Verme et al., 2005; D’Agostino et al., 2007;
Suardiaz et al., 2007).
We discovered that, contrary to our expectations, enhance-
ment of brain FAE levels, rather than blockade of CB1 receptors,
inhibited the responses of DA neurons to nicotine. More impor-
tantly, the noncannabinoid FAEs OEA and PEA play a novel and
unsuspected role, as PPAR- agonists, in the negative regulation
of neuronal responses to nicotine.
Materials andMethods
Electrophysiology: single unit recordings. We performed the experiments
in strict accordance with the Guidelines for the Care and Use of Mam-
mals in Neuroscience and Behavioral Research (National Research
Council 2004) and EEC Council Directive of 24 November 1986 (86/
609). We made all efforts to minimize pain and suffering and to reduce
the number of animals used.
Male Sprague Dawley rats (250–350 g) (Harlan) were housed in
groups of three to six in standard conditions of temperature and humid-
ity under a 12 h light/dark cycle (with lights on at 7:00 A.M.) with food
and water available ad libitum.
Animals were anesthetized with urethane (1300 mg/kg, i.p.), their
femoral vein was cannulated for intravenous administration of pharma-
cological agents, and theywere placed in the stereotaxic apparatus (Kopf)
with their body temperature maintained at 37  1°C by a heating pad.
Thereafter, the scalp was retracted and one burr hole was drilled above
the VTA (6.0 mm anteroposterior from bregma, 0.3–0.6 mm lateral
from midline) for the placement of a recording electrode. For intracere-
broventricular drug administration, a guide cannula (23 gauge stainless
steel) was placed into the ventricle ipsilateral to the recording side (1.0
mm posterior, 1.4 mm lateral to bregma and 4.0 mm ventral to the
cortical surface). Structures were localized according to the stereotaxic
atlas of Paxinos and Watson (1997). Intracerebroventricular injections
were made through a prefilled inner cannula (30 gauge stainless steel
tubing) connected to a 50 l Hamilton microsyringe and extending 1.0
mm below the tip of the guide into the ventricle. Infusion rate was set at
2.5 l/min by an electrically driven mini-pump.
Single unit activity of neurons located in the VTA (V 7.0–8.0 mm
from the cortical surface) was recorded extracellularly with glass mi-
cropipettes filled with 2% pontamine sky blue dissolved in 0.5 M sodium
acetate (impedance 2–5 M). Single unit activity was filtered (bandpass
500–5000 Hz) and individual spikes were isolated bymeans of a window
discriminator (Digitimer), displayed on a digital storage oscilloscope
(TDS 3012, Tektronics) and digitally recorded. Experiments were sam-
pled on line and off line with Spike2 software (Cambridge Electronic
Design) by a computer connected to CED 1401 interface (Cambridge
Electronic Design).
Single units were isolated and identified according to already pub-
lished criteria (Grace and Bunney, 1983, 1984; Ungless et al., 2004). Since
only one cell was recorded per rat, VTA DA neurons were selected when
all criteria for identificationwere fulfilled: firing rate10Hz, duration of
action potential 2.5 ms, inhibitory responses to hindpaw pinching.
Bursts were defined as the occurrence of two spikes at an interspike
interval 80 ms, and terminated when the interspike interval exceeded
160 ms (Grace and Bunney, 1983).
At the end of each recording section, direct current (10A for 15min)
was passed through the recording electrode to eject Pontamine sky blue,
which allowed the identification of the recorded cells. Brains were re-
moved and fixed in 8% formalin solution. The position of the electrodes
was microscopically identified on serial sections (60 m) stained with
cresyl violet.
Electrophysiology: patch-clamp recordings. The preparation of VTA
slices was as described previously (Johnson and North, 1992). Briefly,
male Sprague Dawley rats (10–28 d) were anesthetized with halothane in
a vapor chamber and killed by decapitation. A block of tissue containing
themidbrainwas rapidly dissected and sliced in the horizontal plane (300
m) with a vibratome (Leica VT1000S) in ice-cold low-Ca2 solution
containing (in mM): 126 NaCl, 1.6 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 0.625
CaCl2, 18 NaHCO3, and 11 glucose. Slices were transferred to a holding
chamber with artificial CSF (ACSF, 37°C) saturatedwith 95%O2 and 5%
CO2 containing (in mM): 126 NaCl, 1.6 KCl, 1.2 NaH2PO4, 1.2 MgCl2,
2.4 CaCl2, 18NaHCO3, and 11 glucose. Slices were allowed to recover for
at least 1 h before being placed in the recording chamber and superfused
with the ACSF (37°C) saturated with 95% O2 and 5% CO2. Cells were
visualized with an upright microscope with infrared illumination (Ax-
ioskop FS 2 plus, Zeiss), and whole-cell patch-clamp recordings were
made by using an Axopatch 200B amplifier (Axon Instruments). Both
voltage- and current-clamp experimentsweremadewith electrodes filled
with a solution containing the following (in mM): 117 KCl 144, 10
HEPES, BAPTA 3.45, CaCl 1, 2.5 Mg2ATP, and 0.25 Mg2GTP (pH 7.2–
7.4, 275–285 mOsm). Experiments were begun only after series resis-
tance had stabilized (typically 15–40 M). Series and input resistance
were monitored continuously on-line with a 5 mV depolarizing step (25
ms).Datawere filtered at 2 kHz, digitized at 10 kHz, and collected on-line
with acquisition software (pClamp 8.2, Axon Instruments). DA neurons
from the posterior VTA were identified by the presence of a large Ih
current (Johnson and North, 1992) that was assayed immediately after
break-in, using a series of incremental 10mV hyperpolarizing steps from
a holding potential of 70 mV. Each slice received only a single drug
exposure.
Drugs.Nicotine (()-nicotine hydrogen tartrate) was purchased from
Sigma. OEA, PEA, methanandamide (mAEA), AM281, AM251, capsaz-
epine, WY14643, MK886, genistein, PP2 were purchased from Tocris.
Rimonabant (SR141716A) was a generous gift of Sanofi-Aventis Recher-
che (Montpellier). Nicotine was diluted in saline (pH  7). For i.c.v.
administration, OEA or mAEA were dissolved in 40% w/v
2-hydroxypropyl--cyclodextrin. mAEA for i.v. injections was dissolved
in 2% Tween 80 and 2% ethanol and then diluted in saline. Rimonabant
was emulsified in 1% Tween 80, then diluted in saline solution and
sonicated. URB597 and MK886 were dissolved in DMSO (100 g/l)
and diluted to the final concentration in saline. All drugs for patch-clamp
experiments were dissolved in DMSO as stock solutions and then dilute
to the final volume in ACSF (final concentration0.01%).
Statistical analysis. Drug-induced changes in firing rate and pattern
were calculated by averaging the effects after drug administration (2 min
or 30 s bins for in vivo and in vitro electrophysiology, respectively) and
normalizing to the predrug baseline. All the numerical data are given as
mean  SEM. Data were compared and analyzed by using two-way
ANOVA for repeatedmeasures (treatment time), or one-way ANOVA
or Student’s t test for repeated measures, when appropriate. Post hoc
multiple comparisons were made using the Dunnett’s test. Statistical
analysis was performed by means of the NCSS program. The signifi-
cance level was established at p  0.05.
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Results
Effects of rimonabant and URB597 on activation of VTA
dopamine neurons by nicotine in vivo
We recorded the activity of VTA DA neurons in urethane anes-
thetized rats. Cells were recorded only when they fulfilled all
established criteria for VTADA neuron identification (seeMate-
rials and Methods). A typical DA neuron broad waveform is
shown in Figure 1A. Consistent with previous in vivo studies
(Mereu et al., 1987; Erhardt et al., 2002), nicotine (0.2mg/kg, i.v.)
enhanced firing rate of VTA DA neurons to 144.2  24.2% of
baseline and burst firing to 10.6 3.8% (F(5,71) 4.06, n 23,
p 0.05; F(5,71) 2.89, n 23, p 0.05, respectively, one-way
ANOVA for repeated measure) (Fig. 1B–
D). As previously reported, nicotine-
induced excitation was short lasting, being
significant 2 and 4min following adminis-
tration (Dunnett’s post hoc). Injections of
all the different vehicles (either intraperi-
toneal, intravenous, or intracerebroven-
tricular) that were used in all subsequent
experiments neither significantly changed
the discharge activity of DA neurons nor
modulated the effect of the subsequent
nicotine administration. Therefore, all con-
trol experiments with nicotine were pooled.
We first studied the effect of CB1 recep-
tor blockade on nicotine-induced excita-
tion of DA neurons. Rimonabant
(SR141716A, 0.5 mg/kg, i.v. 4 min before
nicotine) did not modify the excitatory re-
sponse of DA neurons to nicotine com-
pared with vehicle (F(1,103) 1.10, n 11,
p  0.3, two-way ANOVA for repeated
measures) (Fig. 1B–D). Next, we investi-
gated the effect of enhancement of endog-
enous endocannabinoid tone. Rats were
pretreated between 60 and 120 min (aver-
age 72.4 min) before electrophysiological
recordings with URB597 (0.1 mg/kg, i.v.),
an irreversible FAAH inhibitor. The inter-
val between URB597 administration and
recordings varied among experiments,
nevertheless, this dose ofURB597 is within
the range of doses shown to enhance per-
sistently (6 h) brain AEA levels (Kathu-
ria et al., 2003; Fegley et al., 2005), with
maximal effects 1–2 h following adminis-
tration (Fegley et al., 2005). URB597 did
not change spontaneous baseline firing
rate (3.7  0.26 Hz, n  48, in control
animals; 3.9  0.14, n  14, in URB-
pretreated animals, p  0.36, Student’s t
test) or burst firing (22.6  3.64% of
spikes in bursts, n  48, in control ani-
mals; 23.0  5.15%, n  14; in URB-
pretreated animals, p  0.96, Student’s t
test) of VTA DA neurons assessed before
nicotine administration, but, unexpect-
edly, it completely prevented nicotine’s ef-
fects on DA neuronal activity (74.1 
6.2% and 16.8  4.1% of baseline, for
firing rate and burst firing, respectively)
(Fig. 1B,C,D). Two-way ANOVA showed
a highly significant effect of URB597 treatment on the effects of
nicotine on firing rate (F(1,95)  4.95, n  6, p  0.01) and burst
firing (F(1,107) 7.98, n 6, p 0.01). Hence, following URB597
pretreatment, nicotine transiently inhibited, rather than excited, fir-
ing rate and burst firing of DA neurons (F(3,23) 3.73, p 0.001,
n 6; F(3,23) 9.44, p 0.01, one-way ANOVA for repeatedmea-
sures) (Fig. 1B,C,D).
Contribution of CB1 receptors and PPAR- to URB597
antagonism of nicotine effects in vivo
URB597 has been shown to increase not only AEA, but also OEA
and PEA levels (Kathuria et al., 2003). We first investigated
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Figure 1. Effects of rimonabant and URB597 on activation of VTA dopamine neurons by nicotine. A, Average trace, acquired
from a digital storage oscilloscope, showing the typical, broad, notched waveform of a VTA dopamine neuron recorded from an
anesthetized rat.B, Representative firing ratehistograms showingeffects of intravenousnicotine (NIC, injectedat arrowheads) on
discharge activity of individual VTA dopamine neurons recorded from anesthetized rats. The top panel shows the typical response
to 0.2 mg/kg nicotine in control conditions following intravenous injection of vehicle (VEH). The middle panel shows the lack of
effect of rimonabant (SR, 0.5 mg/kg, i.v.) on spontaneous firing rate of dopamine neurons and on the subsequent effects of
nicotine. The bottom panel shows the effect of nicotine in a URB597 pretreated animal, where nicotine induced a transient
inhibition of firing activity. C, D, Graphs illustrating the time course of nicotine’s effects on firing rate and burst firing of VTA
dopamine neurons. Pretreatment with URB597 (0.1 mg/kg, i.v.), but not rimonabant (0.5 mg/kg, i.v.), prevented the nicotine-
induced increases in firing rate (C) and burst firing (D) of VTA dopamine neurons. Results aremeans, with vertical bars represent-
ing the SEMof firing rates andburst firing, expressed as a percentage of or difference frombaseline (BAS) values. Arrows represent
time of nicotine injection. *p 0.05 versus baseline (one-way ANOVA for repeated measures and Dunnett’s test).
Melis et al. • PPAR-Modulates Neuronal Responses to Nicotine J. Neurosci., December 17, 2008 • 28(51):13985–13994 • 13987
whether AEA mediates URB597’s antagonism of nicotine effects
by acting at CB1 receptors. For this purpose, we administered the
CB1 antagonist rimonabant together with URB597. Rimonabant
(0.5 mg/kg, i.v. 1 min before URB597) significantly reduced the
ability of URB597 to block nicotine-induced stimulation of DA
neuron discharge rate (123.7  11.5% of baseline), but not of
burst firing (18.4  8.0% of baseline) (F(1,23)  11.04, n  9,
p  0.01; F(1,23)  2.30, n  9, p  0.2, respectively, two-way
ANOVA for repeated measures) (Fig. 2A,B). The CB1 receptor
antagonist AM251 (1.0 mg/kg, i.v. 1 min before URB597, n 5)
fully replicated the effects of rimonabant (Fig. 2A,B) (firing rate:
F(1,61) 10.96, n 6, p 0.01; burst firing: F(1,75) 0.00, n 6,
p 0.9, two-way ANOVA for repeated measures). This dissoci-
ation between URB597 effects on nicotine-induced increases in
firing rate and burst firing was further analyzed by assessing the
contribution of the noncannabinoid FAEs (OEA and PEA),
which are ligands at PPAR- (Fu et al., 2003). We asked whether
the effect of URB597 could be antagonized by the synthetic selec-
tive PPAR- antagonist MK886 (3 mg/kg, i.p.). MK886 signifi-
cantly prevented URB597 from altering nicotine-induced stimu-
lation of bursting (10.5 3.5% of baseline) (F(1,72) 4.90, n
13, p 0.05, two-way ANOVA for repeated measures) (Fig. 2B),
but not firing rate (F(1,75)  0.0, n  13, p  0.95, two-way
ANOVA for repeated measures) (Fig. 2A). These results suggest
that diverse FAEs may modulate nicotine effects on DA neurons
through different mechanisms.
Oleoylethanolamide blocks nicotine effects in vivo
via PPAR-
To determine the precise contribution of either CB1 or PPAR-
receptors in the observed effects, we assessed whether mAEA, the
metabolically stable analog of AEA, and OEA modulated the re-
sponse to nicotine of VTADA neurons. mAEAwas administered
intravenously at doses of 1 and 5 mg/kg (n 6 each group) (Fig.
3A,B), or i.c.v. at a dose of 5 g/5 l (n  6) (Fig. 3B) 4 min
before nicotine administration. These doses, which exert CB1
receptor-mediated behavioral effects in vivo (Solinas et al., 2006,
2007), did not affect either baseline firing rate or burst firing of
DA neurons or modulate the excitatory response to nicotine ad-
ministration, compared with vehicle (F(3,234) 0.68, n 6, p
0.57, two-way ANOVA for repeated measures). Due to the poor
metabolic stability of OEA, we chose to administer it (20 g/5
l), or a corresponding volume of vehicle (40% w/v
2-hydroxypropyl--cyclodextrin), into the lateral ventricle 4min
before nicotine. In contrast tomAEA,OEA completely prevented
the activation of DA neurons induced by nicotine (92.7 13.5%
of baseline at 2 min postnicotine) (Fig. 3C,D), whereas vehicle
injectionwas inactive (n 6, data not shown). Two-wayANOVA
showed a significant effect of OEA treatment on nicotine-
induced stimulation of firing rate and burst firing (F(1,99) 5.61,
n  6, p  0.05; F(1,107)  4.28, n  6, p  0.05, respectively,
two-way ANOVA for repeated measures). Neither OEA nor ve-
hicle produced significant changes in the spontaneous firing rate
or burst firing of DA neurons (Fig. 3C,D). Next,MK886 pretreat-
ment (3 mg/kg, i.p., 30 min before recordings) prevented the
blockade byOEA of nicotine’s excitatory effects (122.8 7.2%of
baseline at 4 min postnicotine), when compared with OEA alone
(F(1,55)  6.06, n  8, p  0.05, two-way ANOVA for repeated
measures) (Fig. 3C,D), thus highlighting the role of PPAR- in
the effects of OEA.
Blockade of nicotine-induced excitation of dopamine neurons
in vitro by noncannabinoid fatty acid ethanolamides
We next asked whether modulation of nicotine effects by
PPAR- could be studied in brain slices containing the mesen-
cephalon by using whole-cell patch-clamp recordings. The effect
of nicotine was studied on posterior VTADAneurons. Figure 4A
(top) shows a typical action potential of a representative DA neu-
ron, when recorded in the current-clamp mode, with its typical
low threshold, broad action potential, and prominent afterhyper-
polarization. The second derivative of this action potential orig-
inates the waveform (Fig. 4A, bottom) that has been used for cell
identification of DA neurons inmany in vivo extracellular studies
(Grace and Bunney, 1983, 1984; Ungless et al., 2004), and quali-
tatively corresponds to the typical action potential recorded in
vivo and shown in Figure 1A. DA neurons recorded under
current-clampmode displayed an average frequency of 1.8 0.1
Hz (n 102) and fired spontaneously in a clock-like, single-spike
mode. Consistent with the literature (Pidoplichko et al., 1997),
DA neurons responded to bath-applied nicotine (1 M, 2 min)
with a transient excitation of discharge rate (	40%) (Fig. 4B–D).
This excitation peaked (137 12.8% of baseline, n 6), and was
statistically significant (F(6,41)  8.03, p  0.0001, one-way
ANOVA), during the first minute of application. Under voltage-
clamp mode (Vholding 70 mV), nicotine caused a transient
inward current of 40.3  5.6 pA (n  6) (Fig. 4F), due to rapid
activation and desensitization of nAChRs (Pidoplichko et al.,
1997). We next examined the effects of the three different FAEs
(i.e., mAEA, OEA and PEA) on nicotine induced excitation of
VTA DA neurons. These drugs were applied for 5 min to assess
whether they per se modulated spontaneous firing of DA neu-
rons, and then coapplied with nicotine (1 M). mAEA was tested
at two different concentrations, 30 nM and 1 M. The lower con-
centration of mAEA did not significantly affect spontaneous dis-
charge rate of DA neurons or modulate nicotine-evoked excita-
tion (the peak of nicotine with mAEA was 147.7  13.7% of
baseline firing rate, p 0.58, t test, vs nicotine alone) (Fig. 4E,G).
Since this concentration of mAEA might have been too low, we
next tested a concentration of 1 M, which itself significantly
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Figure 2. Contribution of CB1 receptors and PPAR- to URB597’s reversal of nicotine’s ef-
fects in vivo.A, TheCB1 receptor antagonists rimonabant (SR, 0.5mg/kg, i.v.) or AM251 (AM,1.0
mg/kg, i.v.) reversed URB597’s blockade of nicotine-induced increases in firing rate of VTA
dopaminergic neurons produced by nicotine (NIC, 0.2mg/kg), whereas the PPAR- antagonist
MK886 (MK, 3 mg/kg, i.p.) was ineffective. B, In contrast, MK886 administration reversed
URB597’s blockade of nicotine-induced increase in bursting activity of VTA dopamine neurons,
whereas rimonabant and AM251 were ineffective. Results are means, with vertical bars repre-
senting the SEM of firing rates and burst firing, expressed as a percentage of or difference from
baseline (BAS) values. Arrows represent time of nicotine injection. *p 0.05 versus baseline
(one-way ANOVA for repeated measures and Dunnett’s test).
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enhanced firing rate of DA neurons to 370.6 110% of baseline
level (F(5,125)  21.74, n  6, p  0.0001, one-way ANOVA for
repeated measures; data not shown). We asked whether mAEA-
induced stimulation was due to activation of CB1 and/or TRPV1
receptors. The CB1 receptor antagonist AM281, at a concentra-
tion (500 nM) that fully reverses activation of CB1 receptors by
maximal concentrations of agonists (Melis et al., 2004), had no
effect on mAEA-induced stimulation of DA neuron firing rate
(F(1,72)  0.67, n  5, p  0.4365, two-way ANOVA; data not
shown). However, this stimulation was completely blocked by
the TRPV1 receptor antagonist capsazepine (10 M, F(1,171) 
8.13, n  5–6, p  0.019, two-way ANOVA; data not shown).
This observation is consistent with other studies showing that
TRPV1 agonists stimulate DA neuron activity by enhancing glu-
tamatergic synaptic transmission onto DA
neurons (Marinelli et al., 2005). To isolate
the agonistic activity of mAEA at CB1 re-
ceptors, or possibly at PPAR-, and avoid
TRPV1-induced excitation ofDA cells that
could mask or confound the effects of the
subsequent application of nicotine, we ap-
plied nicotine in the presence of capsaz-
epine. Under these circumstances, excita-
tory effects of nicotine were unmodified
comparedwith controls (151.4 13.5%of
baseline, t 0.77, n 6, p 0.4563, t test)
(Fig. 4G), suggesting that CB1 receptor
stimulation did not affect nicotine-
induced excitation of DA neuron firing
and that mAEA did not activate PPAR-
(see below).
Next, we tested two different noncan-
nabinoid FAEs, OEA and PEA. Interest-
ingly, OEA (0.3, 1 and 3 M) dose-
dependently prevented nicotine-induced
excitation (97.44 5% and 92.01 7% of
baseline at 1 and 3 M, respectively; 1 M:
n 5, t 2.65, p 0.01; 3 M: n 7, t
3.22, p 0.04) (Fig. 4H), without affecting
DA neuron spontaneous activity during
preapplication (Fig. 4E). The effects of
OEA were mimicked by PEA (10 M,
101.9  3% of baseline, n  6, t  2.66,
p 0.01) (Fig. 4E,G). Consistently, under
voltage-clampmode (Vholding70mV),
the nicotine-induced inward current was
completely abolished when nicotine was
perfused in the presence of OEA (3 M, 5
min preapplication:0.3 3.4 pA, n 6,
t  7.13, p  0.0004, paired t test) (Fig.
4F), or PEA (10M, 5min preapplication:
0.6  7.5 pA, N  5, t  4.442, p 
0.001, paired t test) (Fig. 4F). During pre-
application, OEA and PEA did not induce
inward or outward currents onto DA neu-
rons (data not shown).
Based on these results, we expected that
the PPAR- antagonist MK886 would
block the actions of OEA and PEA on
nicotine-induced excitation. As predicted,
when OEA or PEA were coapplied with
MK886 (300 nM), nicotine’s effects on fir-
ing rate of DA neurons were restored
(155.8 16.6% and 163.8 11.3% of baseline in the presence of
OEA and PEA, respectively; OEAMK886 vs OEA alone: F(2,323)
 7.59, n 8, p 0.004, two-way ANOVA; PEAMK886 versus
PEA alone: F(1,228)  4.84, n  8, p  0.04, two-way ANOVA)
(Fig. 5A,B,C). MK886 when perfused either alone or in combi-
nation with OEA/PEA did not alter spontaneous firing rate of
VTA DA neurons (Fig. 5C). However, MK886 significantly en-
hanced nicotine-induced activation of DA neurons (207 27%
of baseline, MK886nicotine vs nicotine: t 2.167, n 7, p
0.05, t test) (Fig. 5B).
Next, we determined whether the synthetic PPAR- agonist
WY14643 would alter the effects of nicotine on DA cells.
WY14643 (300 nM) was per se ineffective on DA neuronal firing
rate, but fully prevented nicotine-induced excitation (83.7 
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Figure 3. OEA, but not mAEA, prevented increases in firing rate of VTA dopaminergic neurons produced by nicotine. A,
Representative firing ratehistograms showing theeffects of nicotine (NIC, 0.2mg/kg i.v., injectedat arrowheads) on thedischarge
activity of individual VTAdopamineneurons recorded following injection ofmAEA (1mg/kg, i.v.).B, Graph showing that nicotine-
induced excitation of VTA dopamine neuronswas not changed following the administration ofmAEA, either intravenously (1 and
5mg/kg) or intracerebroventricularly (5g/5l). C, Representative firing rate histograms showing the effects of NIC (0.2mg/kg
i.v., injected at arrowheads) on the discharge activity of individual VTA dopamine neurons recorded following injection of OEA (20
g/5l, i.c.v.; top).MK886 (MK, 3mg/kg, i.p.) reversed theOEA-inducedblockadeof nicotine’s effects (bottom).NeitherOEAnor
vehicle (40% w/v 2-hydroxypropyl--cyclodextrin) produced significant changes in spontaneous firing rate or burst firing. D,
Graph showing that nicotine-induced excitation of VTA dopamine neurons was abolished by OEA. MK886 (MK, 3 mg/kg, i.p.)
reversed the OEA-induced blockade of nicotine’s effects. Results are means, with vertical bars representing SEM of firing rates,
expressed as a percentage of baseline (BAS) values. Arrows represent the time of intravenous injections. The horizontal bar
represents the timeof intracerebroventricular administration. *p0.05 versus baseline (one-wayANOVA for repeatedmeasures
and Dunnett’s test).
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14.7% of baseline, n  9, t  2.54, p  0.02) (Fig. 5D,E). The
effect ofWY14643was also reversed byMK886 (167.7 22.7%of
baseline;WY14643MK886vsWY14643 alone:F(1,228)5.30,n
5, p 0.05, two-way ANOVA) (Fig. 5D,E), confirming the role of
PPAR- in the modulation of DA neuron responses to nicotine.
Mechanisms downstream of PPAR- activation in the
modulation of nicotine effects: involvement of tyrosine
kinases
Although it is well established that PPAR- regulates gene ex-
pression (Berger and Moller, 2002), the effects of OEA, PEA and
WY14643 observed in the present studywere fairly rapid in onset,
thus ruling out gene induction as a possible mechanism, and
suggesting a more likely nongenomic (Gardner et al., 2005)
mechanism occurring in such a short time scale. Among many
diverse pathways, we chose to investigate the regulation of ty-
rosine kinases, because PPAR- agonists have been shown to
activate several tyrosine kinases, such as the Src family kinase
(SFK) (Gardner et al., 2005), which phosphorylates and nega-
tively regulates 7 nAChRs (Charpantier et al., 2005).
We hypothesized that phosphorylation of nAChRs could ac-
count for PPAR- mediated inhibition of nicotine effects. To
explore this possibility, we incubated slices with the general ty-
rosine kinase inhibitor genistein (10 M), which has indirect ef-
fects on nAChRs arising from the inhibition of intracellular phos-
phorylation pathways. Experiments were conducted under
voltage-clamp mode on nicotine-induced inward currents, since
genistein had aspecific channel blocker properties which led to a
complete blockade of action potential generation (data not
shown). Genistein was able to prevent OEA blockade of nicotine
effects andrestorednicotine-evoked inwardcurrents (37.84.4pA,
n 6, t 6.79, p 0.0001) (Fig. 6A,B), demonstrating that inhibi-
tion of tyrosine kinases reverses the effect of PPAR- activation.
To investigate which tyrosine kinase phosphorylates and neg-
atively modulates nAChRs, we focused on SFKs, on the basis of
previous reports highlighting the role of SFK in the regulation of
7 nAChRs (Charpantier et al., 2005). We predicted that inhibi-
tion of SFKwould reverse the effects of OEA. To test this hypoth-
esis, slices were incubated (1 h) and continuously perfused with
the SFK inhibitor PP2 (10 M). This treatment did not change
electrophysiological features of recorded DA neurons (data not
shown). However, PP2 failed to reverse OEA blockade of nico-
tine’s effects on DA cells under both voltage- and current-clamp
modes. Indeed, in the presence of PP2, OEA abolished nicotine-
induced inward currents (1.4  5.7, n  5, t  0.16, p  0.5)
(Fig. 6A,B) as well as the nicotine-induced enhancement of firing
rate (100.9  7.1% of baseline, F(1,108)  0.06, n  6, p  0.8,
two-way ANOVA) (Fig. 6C,D), suggesting that SFK is not involved
in the negative modulation of nAChRs by PPAR- agonists.
A
1s
50
 m
v
0 60 120 180 240
0
100
200
* *
nic+
mAEA
30 nM
nic+
mAEA
1µM
nic+
PEA
0
100
200
nic
*
(6)
(6)(5)
(6)
300
a
b
c
Fi
rin
g 
ra
te
 (%
 o
f b
as
el
in
e)
Time (min)
0 5 10 15
# 
of
 e
ve
nt
s
0
100
200
300
C D
Fi
rin
g 
ra
te
 (%
 o
f b
as
el
in
e)
100
200
0
0.3 1 3
OEA (µM)
(5)
(6)
(7)
Fi
rin
g 
ra
te
 (%
 o
f b
as
el
in
e)
**
Time (s)
G
basal
nic
wash out
nic
nic
nic+
OEA
*(7)
10 ms20
 m
V
10 ms
B
E
0
100
200
300 mAEA
OEA
PEA
Time (min)
0 5 1510 20F
iri
ng
 ra
te
 (%
 o
f b
as
el
in
e)
F
100 s
20
 p
A75
50
-25
25
0I
ho
ld
in
g 
(p
A
)
****
OEA PEAC
H
Figure 4. Activation of dopamine neurons by nicotine is prevented by OEA and PEA in vitro.A, Typical action potential waveformof a dopamine neuron recorded under current-clampmode (top)
and its second derivative (bottom).B, Representative traces of a dopamine neuron spontaneous activity during baseline level (top), nicotine application (nic, 1M for 2min;middle), andwash out
(bottom). C, Rate histogram depicting an example of the effect of nicotine on dopamine neuron firing rate. The horizontal bar represents the time of nicotine application. D, Time course of the
excitatory effect of nicotine on dopamine neuron discharge rate (30 s bins). E, OEA (3M) and PEA (10M), but not mAEA (30 nM), blocked nicotine-induced activation of dopamine neurons. The
dashedand the solidbars represent the timesof fatty acid ethanolamide (OEA,PEA, ormAEA)ornicotineapplication, respectively.F, Thebargraph shows thatOEA (3MandPEA10M)alsoblocked
nicotine-induced inward currents (Iholding) when dopamine neurons were recorded under the voltage-clamp mode (Vhold70 mV). The inset shows that nicotine (black line) caused a 47 pA
inward current under voltage-clampmode, which was completely abolished in the presence of OEA (3M; OEA’s effect on Iholding is superimposed in light gray for comparison). The horizontal bar
represents the time of nicotine application.G, Bar graph summarizing the actions of mAEA (30 nM and 1M), OEA (3M), and PEA (10M) on nicotine-induced enhancement of dopamine neuron
discharge rate (average of the first minute of nicotine perfusion). mAEA at 1Mwas perfused in the presence of capsazepine (CPZ, 10M) to prevent the vanilloid-induced excitation of dopamine
neurons. H, Dose-effect relationship of OEA’s blockade of nicotine-induced excitation of dopamine neurons. Numbers above bars indicate the n values for each group of experiments. Data are
expressed as mean SEM. *p 0.05, **p 0.01.
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Discussion
The present study revealed that naturally occurring noncannabi-
noid FAEs can modulate the responses of VTA DA neurons to
nicotine via PPAR-, possibly by phosphorylation of nAChRs.
This is the first evidence of an important functional role of this
family of nuclear receptor transcription factors in the brain. It
also highlights the role of FAEs, devoid of cannabinoid actions, in
the regulation of neuronal functions.
Centrally mediated effects of the noncannabinoid FAEs have
been poorly characterized, although OEA and PEAmight consti-
tute an independent endocannabinoid-like system. This view is
supported by the findings that their synthesis and inactivation
occurs independently of “classic” endocannabinoids, although in
a similar on demand manner (Hansen et al., 1995; Stella and
Piomelli, 2001; Mackie and Stella, 2006). The molecular targets
underlying their pharmacological effects have remained elusive
until the discovery of their agonistic actions at PPAR- (Fu et al.,
2003). These nuclear receptors are ubiquitously distributed in the
CNS (Moreno et al., 2004), but their roles in neuronal physiol-
ogy, or in pathophysiological mechanisms of brain disorders, are
largely unknown.
Indirect enhancement of brain FAEs levels obtained by block-
ade of their major hydrolyzing enzyme, FAAH, by URB597
(Kathuria et al., 2003) has been reported to produce antidepres-
sant, anxiolytic and analgesic effects in rodents (Kathuria et al.,
2003; Gobbi et al., 2005; Piomelli et al., 2006; Russo et al., 2007).
All of these effects are prevented by treatment with CB1 receptor
antagonists, and have been ascribed to increased AEA levels, thus
suggesting that augmented levels of OEA and PEA do not con-
tribute significantly. However, a PPAR- antagonist was recently
reported to block the peripheral analgesic effects of URB597,
suggesting that analgesia may be mediated by FAEs binding at
PPAR- (Jhaveri et al., 2008). In the present experiments, we
discovered that inhibition of FAAH, rather than blockade of CB1
receptors, suppresses nicotine-induced activation of DA neu-
rons. The lack of effect by rimonabant was unexpected in light of
recent reports that CB1 antagonists decrease DA release evoked
by nicotine in the nucleus accumbens (Cohen et al., 2002; Cheer
et al., 2007). One can argue, however, that the suppression by
rimonabant of evoked DA release may be independent from the
inhibition of firing activity of DA neurons in the VTA, and may
4
Figure 5. OEA and PEA block nicotine activation of dopamine neurons through a PPAR--
mediatedmechanism.A, Representative traces of the spontaneous activity of a dopamine neu-
ron during baseline (top), OEA (3M) plus the PPAR- antagonist MK886 (0.3M) preappli-
cation (5 min, second panel), subsequent nicotine application (1M, 2 min, third panel), and
wash out (bottom).B, Bar graph illustrating the effect ofMK886 on nicotine-induced activation
of VTA DA neurons and on OEA- and PEA-mediated inhibition of nicotine excitation (average of
the first minute of nicotine perfusion). Note that activation of dopamine neurons by nicotine
was fully restored when either OEA or PEA were coapplied with MK886. Notably, MK886 itself
significantly potentiated nicotine-induced excitation. C, Time course of the effect ofMK886 (0.3
M), aloneor in combinationwitheitherOEAorPEA, onnicotine inducedexcitation. Thedashed
bar represents the time of fatty acid ethanolamide (OEA, PEA) plus MK886 or MK886 alone
application. The solidbar represents the timeofnicotineapplication.D, Representative traces of
dopamine neuron firing rate showing that the PPAR- agonist WY14643 (300 nM) mimicked
the actions of OEA and PEA by preventing nicotine-induced excitation (top), which was then
restored by the coapplication of MK886 (bottom). E, Time course of the effect of nicotine on
dopamine neuron firing rate in the presence of WY14643 (open symbols) or WY14643 plus
MK886 (closed symbols). The dashed and the solid bars represent the times of PPAR- agonist/
antagonist or nicotine application, respectively. In the inset, the bar graph summarizes the
effects of WY14643 (WY) on nicotine-induced excitation of dopamine neuron firing rate (FR)
with or without MK886. Numbers above bars indicate the n values for each group of experi-
ments. Data are expressed as mean SEM. *p 0.05.
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be an effect primarily involving their ter-
minal regions or local circuits within the
nucleus accumbens. Hence, presynapti-
cally located nAChRs potently regulateDA
release in the striatum, including the nu-
cleus accumbens (Zhou et al., 2001). The
effect of URB597 was even more surpris-
ing, since it contradicts the notion that the
endocannabinoid system exerts a facilita-
tory effect on nicotine reward and addic-
tion. Consistent with the present results,
recent findings indicate that URB597 pre-
vents the development of nicotine-
induced CPP, acquisition of nicotine self-
administration and nicotine-induced
reinstatement in both CPP and self-
administration models of relapse
(Scherma et al., 2008).
Here, we found that the effects of
URB597 were not entirely dependent on
CB1 receptor stimulation, since nicotine-
induced increases in DA neuron bursting
were not reversed by rimonabant or
AM251, whereas increases in firing rate
were. The PPAR- antagonist MK886 re-
versed URB597’s blockade of nicotine-
induced bursting in DA neurons, suggest-
ing that FAEs, other than AEA, play a role
in antagonizing the effects of nicotine.
More importantly, OEA, but not mAEA,
blocked the effects of nicotine on DA neu-
rons in vivo. These results were substanti-
ated by the findings that both OEA and
PEA, but not mAEA, completely pre-
vented nicotine-induced excitation of DA
neurons in vitro. Additionally, OEA and
PEA actions via PPAR- were confirmed
by the antagonism exerted byMK886, and
by the observation that the PPAR- ago-
nist WY14643 mimicked the actions of
noncannabinoid FAEs. Although AEA has
been reported to display binding affinity
for PPAR- (Sun et al., 2006, 2007), our
results are not consistent with those find-
ings, since mAEA had no effects on
nicotine-induced excitation of DA neu-
rons, contrary to OEA and PEA. However,
the studies of Sun et al. (2006, 2007) were
performed in HeLa cells transiently trans-
fected with PPAR-, thus other investiga-
tions are necessary to confirm the binding properties of AEA at
PPAR- under more physiological conditions and, more impor-
tantly, in neurons. Remarkably, the analgesic properties ofmAEA
are fully preserved in PPAR- knock-out mice, suggesting a
PPAR--independent mechanism of action, whereas those of
OEA and PEA are abolished (LoVerme et al., 2006).
Studies on recombinant or native nAChRs expressed inXeno-
pus oocytes or in mouse thalamic synaptosomes, respectively,
have demonstrated that AEA (Oz et al., 2003; Spivak et al., 2007;
Butt et al., 2008) or fatty acids (Butt et al., 2002; Barrantes, 2004)
can modulate nAChR function as noncompetitive antagonists.
Our results tend to exclude this possibility. In fact, they strongly
support the notion that OEA and PEA effects are specifically
mediated by PPAR-, since they are blocked by the selective syn-
thetic antagonist and mimicked by the agonist. Additionally, we
found that mAEA did not alter nicotine-induced DA neuron ex-
citation, making its action as nAChR antagonist unlikely.
As mentioned above, rimonabant revealed a significant com-
ponent mediated by CB1 receptors in the effects of URB597. This
piece of evidence is apparently difficult to reconcile with the re-
sults obtained with mAEA. Hence, mAEA does not significantly
modulate nicotine’s effects either in vivo or in vitro, arguing
against an involvement of CB1 receptors in themodulation of the
excitatory actions of nicotine on VTA DA neurons. There are
possible explanations for this discrepancy: first, the effects of
URB597 are due to the combination of CB1- (by AEA) and
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PPAR-- (by OEA and PEA)mediated effects. CB1 receptors and
PPAR- may share opposing or reinforcing intracellular path-
ways (including modulation of protein kinases) (for review, see
Alexander and Kendall, 2007). Second, URB597 enhances brain
levels of endogenously released FAEs in a discrete and region-
specific manner, andmay influence the release of other endocan-
nabinoids as well, including 2-arachidonoylglycerol (Di Marzo
andMaccarrone, 2008; Maccarrone et al., 2008). Conversely, ex-
ogenously appliedmAEA induces the activation of CB1 receptors
throughout the brain. The third possible explanation is a differ-
ential involvement of TRPV1 channels, which may be activated
by AEA (following URB597 administration) or by mAEA itself.
However, our results in vitro tend to exclude the possibility that
TRPV1 receptors play a significant role in the modulation of
nicotine effects, since their activation by mAEA, or blockade by
the selective antagonist capsazepine did not change nicotine-
induced excitation of DA neurons.
We investigated also the mechanism by which PPAR- may
modulate the effects of nicotine. Due to the rapid onset of agonist
actions, we hypothesized that this could be a nongenomic effect.
Hence, PPARs exert pleiotropic effects on many different intra-
cellular pathways, including protein kinases (Gardner et al.,
2005). It was recently shown that the functional properties of 7
nAChRs depend on the tyrosine phosphorylation status of the
receptor, being the result of a balance between SFKs and tyrosine
phosphatases (Charpantier et al., 2005), which negatively or pos-
itively modulate nAChR-mediated currents, respectively. Addi-
tionally, phosphorylation/dephosphorylation of tyrosine resi-
dues in nAChRs controls the number of functional surface
receptors (Cho et al., 2005).
Interestingly, we found that the effects of the tyrosine kinase
inhibitor genistein were consistent with the idea that PPAR--
mediated nAChR phosphorylation could account for the block-
ade of neuronal responses to nicotine, although at this stage we
cannot identify the specific tyrosine kinase involved. A proposed
mechanism is displayed in Figure 7. A constitutive interaction
between PPAR- and tyrosine kinases is also possible, and may
tonically control the ratio of phosphorylated/dephosphorylated
nAChRs, as indicated by the enhanced effects of nicotine in the
presence of the PPAR- antagonist MK886. It cannot be ex-
cluded that OEA and PEA may be endogenous modulators of
acetylcholine transmission, since stimulation of muscarinic re-
ceptors was shown to stimulate the biosynthesis of OEA and PEA
(Stella and Piomelli, 2001), suggesting the intriguing possibility
of a reciprocal control between acetylcholine and FAEs.
This novel mechanism of regulation of nAChRs by PPAR-
may represent a new therapeutic avenue for the discovery ofmed-
ications to support patients during nicotine abstinence. Our data
demonstrate that the actions of OEA are not restricted to the
periphery and suggest that modulation of neuronal responses to
nicotine by OEA may represent an interesting extension of its
peripheral anorexic properties. PPAR- agonists, such as fi-
brates, are well established medications clinically used in the
treatment of lipid metabolism disorders. Their central effects are
considered negligible due to their poor ability to cross the blood
brain barrier.However, changes in brain lipidmetabolism and/or
composition, or modifications of the levels of endogenous lipid
signaling molecules may exert unsuspected actions on neuro-
transmitter functions, which might be exploited therapeutically.
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lockade of Nicotine Reward and Reinstatement by
ctivation of Alpha-Type Peroxisome
roliferator-Activated Receptors
aola Mascia, Marco Pistis, Zuzana Justinova, Leigh V. Panlilio, Antonio Luchicchi, Salvatore Lecca,
aria Scherma, Walter Fratta, Paola Fadda, Chanel Barnes, Godfrey H. Redhi, Sevil Yasar,
ernard Le Foll, Gianluigi Tanda, Daniele Piomelli, and Steven R. Goldberg
ackground: Recent findings indicate that inhibitors of fatty acid amide hydrolase (FAAH) counteract the rewarding effects of nicotine in
ats. Inhibitionof FAAH increases levels of several endogenous substances in thebrain, including theendocannabinoid anandamide and the
oncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type perox-
some proliferator-activated nuclear receptors (PPAR-). Here, we evaluated whether directly acting PPAR- agonists can modulate
eward-related effects of nicotine.
ethods: We combined behavioral, neurochemical, and electrophysiological approaches to evaluate effects of the PPAR- agonists
[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid (WY14643) and methyl oleoylethanolamide (methOEA; a long-
asting formofOEA) on1) nicotine self-administration in rats and squirrelmonkeys; 2) reinstatement of nicotine-seekingbehavior in rats and
onkeys; 3) nicotine discrimination in rats; 4) nicotine-induced electrophysiological activity of ventral tegmental area dopamine neurons in
nesthetized rats; and 5) nicotine-induced elevation of dopamine levels in the nucleus accumbens shell of freely moving rats.
esults: The PPAR- agonists dose-dependently decreased nicotine self-administration and nicotine-induced reinstatement in rats and
onkeys but did not alter food- or cocaine-reinforced operant behavior or the interoceptive effects of nicotine. The PPAR- agonists also
ose-dependently decreased nicotine-induced excitation of dopamine neurons in the ventral tegmental area and nicotine-induced
levations of dopamine levels in the nucleus accumbens shell of rats. The ability of WY14643 and methOEA to counteract the behavioral,
lectrophysiological, and neurochemical effects of nicotine was reversed by the PPAR- antagonist 1-[(4-Chlorophenyl)methyl]-3-[(1,1-
imethylethyl)thio]-a,a-dimethyl-5-(1-methylethyl)-1H-Indole-2-propanoic acid (MK886).
onclusions: These findings indicate that PPAR-might provide a valuable new target for antismoking medications.ey Words: FAAH, nicotine, OEA, PEA, PPAR-, reinstatement,
eward
t has recently been recognized that peroxisome proliferator-
activated nuclear receptors, which are known to be involved in
metabolism and other cellular functions in many internal or-
ans, also comprise a cannabinoid-like signaling system in thebrain
1). Like the endogenous cannabinoid anandamide, the fatty acid
mides oleoylethanolamide (OEA) and palmitoylethanolamide
PEA) are endogenous ligands for the alpha subtype of the peroxi-
ome proliferator-activated receptor (PPAR-), are synthesized on
emand, and are primarily degraded by fatty acid amide hydrolase
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oi:10.1016/j.biopsych.2010.07.009 Publish(FAAH). Drugs that selectively inhibit FAAH prevent degradation
and increase brain levels of anandamide, OEA, and PEA (2,3). But,
unlike anandamide, OEA and PEA are devoid of action at cannabi-
noid receptors (4–6).
We recently reported that a FAAH-inhibiting drug can counter-
act addiction-related effects of nicotine in several animal models
(7–9). In rats, FAAH inhibition suppressed the development of nic-
otine-induced conditioned place preference and nicotine self-ad-
ministration, widely used animal models of nicotine’s habit-form-
ing effects (9). Inhibition of FAAH also suppressed reinstatement of
nicotine seeking, ananimalmodel of relapse (7). In addition to these
behavioral effects, we found that FAAH inhibition prevented the
neurochemical and electrophysiological effects of nicotine on re-
ward circuits of the brain that underlie addictive behavior. That is,
FAAH inhibition prevented nicotine-induced elevations of the neu-
rotransmitter dopamine in the nucleus accumbens shell (9), and it
attenuated nicotine-induced excitation of dopamine neurons in
the ventral tegmental area (VTA) (8). Surprisingly, the latter effect
did not appear to bemediated by cannabinoid receptors because it
was not mimicked in vivo by intravenous (IV) or intracerebroven-
tricular administration of the cannabinoid methanandamide (a hy-
drolysis-resistant analog of anandamide) but rather by intracere-
broventricular administration of the noncannabinoid FAAH
substrate, OEA (8). In addition, in vitro activation of VTA dopamine
neurons by nicotine in brain slices was prevented by both OEA and
PEA but not by methanandamide (8). OEA and PEA are potent
agonists of PPAR-, which is expressed in many areas of the rat
brain (including cortex, VTA,midbrain,medulla, hippocampus, sub-
stantia nigra, and olfactory tubercle [10–14]) and might regulate
BIOL PSYCHIATRY 2010;xx:xxx
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ARTICLE IN PRESSholinergic neurotransmissionand learningandmemoryprocesses
15,16). These findings suggest that FAAH inhibition counteracts
he rewarding effects of nicotine by activating PPAR-.
In the present study, we combined behavioral, neurochemical,
nd electrophysiological approaches to determine whether di-
ectly acting PPAR- agonists can counteract several reward- and
ependence-related effects of nicotine: 1) nicotine self-administra-
ion in rats and squirrelmonkeys; 2) reinstatement of nicotine seek-
ng precipitated by re-exposure to nicotine in rats and squirrel
onkeys after a period of abstinence; 3) the interoceptive effects of
icotine in a drug-discrimination procedure in rats; 4) electrophys-
ological effects of nicotine on the activity of VTA dopamine neu-
ons in anesthetized rats; and 5) nicotine-induced elevations in
opamine levels in the nucleus accumbens shell of freely moving
ats.
ethods andMaterials
nimals
Male Sprague-Dawley rats (Charles River Laboratories, Wilming-
on, Massachusetts; Harlan-Nossan, Milan, Italy) weighing 300 g to
50gwere housed in temperature- andhumidity-controlled rooms
n a 12-hour light/dark cycle. Experiments were conducted during
he light phase. For self-administration experiments, food intake
as limited to 20 g/day. For drug discrimination experiments, food
as restricted to maintain weight at85% of the subject’s highest
ecorded weight.
Tenadultmale squirrelmonkeys (Saimiri sciureus)weighing .9 kg
o 1.1 kg were housed in individual cages in a temperature- and
umidity-controlled room with unrestricted access to water. Mon-
eys were fed five high-protein biscuits per day (Laboratory Diet
045, PMI Nutrition International, Richmond, Indiana) and two
ieces of Banana Softies (Bio-Serv, Frenchtown, New Jersey). Fresh
ruits, vegetables, and environmental enrichment were provided
aily. Threemonkeys (441, 431, and577) self-administerednicotine.
hree monkeys (70F7, 5045, and 39B) self-administered cocaine.
our monkeys (34A, 27B, 30 A, 1549) were used for food-reinforce-
ent experiments.
Monkeys and rats at the National Institute on Drug Abuse-Intra-
ural Research Program were maintained in facilities fully accred-
ted by the Association for Assessment and Accreditation of Labo-
atoryAnimal Care International, and all procedureswere approved
y the National Institute on Drug Abuse Institutional Animal Care
nd Use Committee and conducted in accordance with the 2003
uidelines of the National Research Council. Rats in the electro-
hysiology study were maintained at the University of Cagliari,
here all procedures were conducted in accordance with the
uropean Economic Community Council Directive (86/609;
L27/01/92, Number 116).
rugs
Nicotine (Sigma, St. Louis, Missouri) was dissolved in saline (pH
orrected to 7.0) and injected subcutaneously (SC) or IV. Cocaine
ydrochloride (RTI International, Research Triangle Park, North
arolina)was injected IV. The PPAR- agonistmethyl oleoylethano-
amide [methOEA], (N-[(1R)-2-hydroxy-1-methylethyl-9Z-octade-
enamide) (donatedbyDr.Daniele Piomelli, University ofCalifornia,
rvine, California) was dissolved in 2% Tween 80, 2% ethanol, and
terile water. The PPAR- agonist [[4-Chloro-6-[(2,3-dimethylphe-
yl)amino]-2-pyrimidinyl]thio]acetic acid (WY14643) (Tocris, Ellis-
ille, MO, USA) and the PPAR- antagonist 1-[(4-Chlorophenyl)
ethyl]-3-[(1,1-dimethylethyl)thio]-a,a-dimethyl-5-(1-methylethyl)-1H-ndole-2-propanoic acid (MK886) (Tocris) were dissolved in 2% to 4%
ww.sobp.org/journalTween 80, 30% dimethyl sulfoxide, and sterile water. Methyl
oleoylethanolamide,WY14643, andMK886were injected intraperi-
toneally (IP) (1 mL/kg) in rats and intramuscular (IM) (.3 mL/kg) in
monkeys, except for electrophysiology, where methOEA was in-
jected IV. Dose selection was based on previous studies using
WY14643 (8,16,17), methOEA (18), and MK886 (8,16).
Self-Administration (Rats)
General procedure and apparatus were described previously
(9,19). Self-administration sessions (2 hours/day) under a one-re-
sponse fixed-ratio schedule of IV nicotine injection (10 or 30g/kg/
injection) began 7 to 10 days after catheterization. The response
requirement was increased to a five-response fixed-ratio over 15 to
23 sessions. Responses in the left nose-poke hole produced nico-
tine and pulsed the house light (5 Hz) for a 20-second time-out.
Responses in the other, inactive hole hadno scheduled effect. Once
a criterion was reached (9 nicotine injections/session for three
consecutive sessions), rats received apretreatment injection (either
drug or vehicle) before each subsequent session, with drugs tested
only when the criterion had been met during the preceding three
vehicle sessions. Doses of WY14643 (20 or 40 mg/kg IP, 20 minutes
before the session, tested in counterbalanced order) or methOEA
(10 mg/kg IM, 40 minutes before the session) were each tested for
three consecutive sessions. Mean data from the three drug pre-
treatment sessions for each dose were compared with the mean
from the three preceding vehicle pretreatment sessions.
Reinstatement (Rats)
Rats learned to self-administer nicotine (30 g/kg/injection IV)
as described above and then were placed under extinction, during
which responding had no programmed consequence. When there
were 10 active hole responses per session for three consecutive
sessions, reinstatement tests were conducted with a pretreatment
injection (vehicle, 20 or 40 mg/kg WY14643, IP, 20 minutes before
the session) and a priming injection (vehicle or .2 mg/kg nicotine,
SC, 10 minutes before the session). Rats were required to meet the
response-cessation requirement before each test. Nine rats were
tested at both doses of WY14643, and some (two rats at 20 mg/kg
and six rats at 40 mg/kg WY14643) were only tested with one dose
of WY14643. During the reinstatement test session, responding in
the active hole pulsed the house light for 20 seconds; to increase
sensitivity of the reinstatement test, only a single response was
required to produce this cue. This reinstatement procedure com-
bines nicotine- and cue-induced reinstatement, which has been
used in several previous studies (20–23), has several advantages.
First, when the cues are removed during extinction, the response-
cessation criterion is met more rapidly (mean  SEM  5.2  .8
sessions in the present studywithout the stimulus vs. 11.3 1.5 in a
pilot group with the stimulus). Second, reinstatement by the com-
bination of nicotine and cues is more robust than when only nico-
tine or only the cues are presented. This was important because,
consistent with the findings of others (20), we have found that a
substantial number of rats fail to show reinstatement when given
nicotine alone. Finally, the combination of nicotine and cues may
be a more relevant and stringent model of the human relapse
situation than cues alone or nicotine alone.
Self Administration (Monkeys)
General procedure and apparatus were described previously
(24,25). At the start of the session, the house light was extinguished
and a green stimulus light was presented. In the presence of the
green light, 10 responses on the lever (10-response fixed-ratio)
produced a .2-second, .2-mL, 30 g/kg injection of nicotine, extin-
g
f
t
p
w
r
w
p
v
W
s
(
I
(
t
c
fi
R
t
s
d
r
s
i
t
4
P
g
w
s
N
(
d
o
m
l
m
t
v
a
E
t
c
l
M
o
i
d
a
e
p
r
1
w
w
P. Mascia et al. BIOL PSYCHIATRY 2010;xx:xxx 3
ARTICLE IN PRESSuished the green light, and illuminated the amber stimulus light
or 2 seconds. Each reinforcement was followed by a 60-second
ime-out period, during which the chamber was dark and lever
resses had no programmed consequences. One-hour sessions
ere conducted 5 days per week.
After four to five sessions of vehicle pretreatment in which
esponding was stable (15% variability), drug pretreatments
ere given for five consecutive sessions. Data from the five drug
retreatment sessions were compared with the three preceding
ehicle pretreatment sessions. The drug pretreatments were
Y14643 (10, 20, and 40 mg/kg IM, 20 minutes before the ses-
ion), MK886 (1mg/kg IM, 45minutes before the session), MK886
1 mg/kg) plus WY14643 (20 mg/kg), and methOEA (10 mg/kg
M, 40 minutes before the session). The WY14643 pretreatments
20 and 40 mg/kg IM, 20 minutes before the session) were also
ested in two additional groups of monkeys self-administering
ocaine (30 g/kg/injection) or food pellets under the same
xed-ratio schedule.
einstatement (Monkeys)
Monkeys trained to self-administer nicotine (30 g/kg/injec-
ion, IV), as described above, were placed under extinction by
ubstituting vehicle for nicotine but maintaining the response-
ependent presentation of the nicotine-paired stimulus. When
esponding reached a low, stable level (10 injections per ses-
ion, with no obvious increasing or decreasing trend), priming
njections (vehicle or .1 mg/kg IV nicotine, immediately before
he session) were given after pretreatment with WY14643 (20 or
0 mg/kg) or WY14643 (20 or 40 mg/kg) plus MK886 (1 mg/kg).
retreatments were given in the home cage, and primes were
iven while the monkey was in the training chamber. Each test
as performed for a single session followed by extinction ses-
ions with no pretreatment.
icotine Discrimination (Rats)
General procedure and apparatus were described previously
26). Rats were trained under a discrete trial schedule of food pellet
elivery (10-response fixed-ratio, 45-second time-out) to respond
n one lever after a subcutaneous injection of a training dose of .4
g/kg nicotine (10 minutes before the session) and on the other
ever after an injection of saline. Sessions lasted for 20 reinforce-
ents or 30 minutes. WY14643 (40 mg/kg) was substituted for the
raining dose of nicotine and was also administered together with
arious doses of nicotine (.01–.4 mg/kg) to assess possible alter-
tions of the nicotine dose-response curve.
lectrophysiology (Anesthetized Rats)
General procedure was described previously (8). Single-unit ac-
ivity of VTA neurons was recorded extracellularly with glass mi-
ropipettes filled with 2% pontamine sky blue (Sigma-Aldrich, Mi-
an, Italy) dissolved in .5 mol/L sodium acetate (impedance 2–5
). Single units were isolated and identified according to previ-
usly published criteria (27,28). All neurons were antidromically
dentified as projecting to the nucleus accumbens shell by anti-
romic spikes elicited by stimulation of the shell of the nucleus
ccumbens. An antidromic response was defined as the ability of
voked spikes to follow stimulation frequencies of 250 Hz, dis-
laying constant latency and collision with spontaneously occur-
ing spikes (29). Nicotine (.2 mg/kg) was administered IV after 5 to
0 minutes of baseline recording. MethOEA (0, 5, or 10 mg/kg IV)
as injected 4minutes before nicotine.WY14643 (20or 40mg/kg IP)
as injected  30 minutes before the start of recordings; MK886 (3mg/kg IP)was injected15minutes beforeWY14643.Only one cellwas
recorded per rat.
Microdialysis (Freely Moving Rats)
General procedurewas described previously (30). Rats were sur-
gically implantedwith a concentric dialysis probe aimed at the shell
of the nucleus accumbens (anterior 	2.0 and lateral 1.1 from
bregma, vertical –8.0 fromdura) (31). Experiments were performed
on freely moving rats 20 to 24 hours after the surgical implant.
Ringer’s solution (147.0 mmol/L sodium chloride, 2.2 mmol/L cal-
cium chloride, 4.0 mmol/L potassium chloride) was delivered at a
constant flow rate of 1.0 L per minute. Collection of dialysate
samples (10 L) started after 90 minutes, with samples collected
every 20 minutes and immediately analyzed by an high-perfor-
mance liquid chromatography system coupled to electrochemical
detection to quantify dopamine. Rats were treated only after stable
dopaminevalues (10%variability)wereobtained for at least three
consecutive samples. Probe location in the nucleus accumbens
shellwas determinedhistologically after each experiment, andonly
data from rats with correct probe placement were analyzed. The
WY14643 (0, 20, or 40 mg/kg IP) was injected 20 minutes before
nicotine (.4mg/kgSC)or cocaine (3mg/kg IP), andmethOEA (0, 5, or
10mg/kg IP)was injected 40minutes before nicotine (.4mg/kg SC).
The MK886 (3 mg/kg IP) was injected 20 minutes before WY14643
or methOEA.
Statistical Analysis
All results are presented as group means ( SEM). For experi-
ments comparing only two conditions, Student t test was per-
formed. Self-administration and reinstatement data were analyzed
with PROC MIXED (SAS Institute, Cary, North Carolina) with Tukey-
Kramer comparisons. For self-administration, the dependent vari-
ablewas injections per session and the independent variableswere
pretreatment (dose) and session type (baseline sessions vs. pre-
treatment sessions), allowing each pretreatment condition to be
compared with the most recent baseline. For selected conditions
where consecutive sessions are illustrated (Figures 1B, 2B, and 2C),
Figure 1. The PPAR- agonists WY14643 (20 and 40 mg/kg) and methOEA
(10 mg/kg) reduced nicotine self-administration in rats. The PPAR- ago-
nists were given intraperitoneally 20 minutes (WY14643) or 40 minutes
(methOEA) before three consecutive sessions in which rats self-adminis-
tered nicotine (.01 or .03 mg/kg/injection) under a five-response fixed ratio
schedule. (A) Average rate of injection over three test sessions, compared
with average of three sessions of vehicle treatment. (B) Rates of nicotine
self-administration during individual sessions under baseline conditions
(sessions 1–3), after treatment with 40mg/kgWY14643 (sessions 4–6), and
after return to baseline conditions (sessions 7–9). n  6 for rats at the .01
mg/kg/injection nicotine dose; n  12 for rats at the .03 mg/kg/injection
nicotine dose, except for methOEA, where n  5. *Significant difference
from vehicle treatment. Data are represented as group means  SEM. inj.,
injection; mOEA, methOEA; Nic., nicotine; Veh, vehicle; WY, WY14643.additional analyses were performed using session as a factor. For
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ARTICLE IN PRESSeinstatement in rats, the factors were nose-poke hole (active vs.
nactive), prime (saline vs. nicotine), and pretreatment (dose of
Y14643); for monkeys, separate one-way analyses of variance
ere conducted for the three doses ofWY14643. Electrophysiology
nd microdialysis data were analyzed using analysis of variance
ith Dunnett or Student-Newman-Keuls comparison procedures,
espectively. Experiment-wise significance levels of .05 were main-
ained in all analyses.
esults
PAR- Activation Suppressed Nicotine Self-Administration
n Rats andMonkeys
The PPAR- agonists WY14643 and methOEA significantly de-
reased ongoing nicotine self-administration in both rats [Figure
A: main effect of WY14643, F (1,11)  5.4, p  .05; main effect of
ession F (1,11) 41.8, p .0001; for .01 mg/kg nicotine baseline, t
est, t (5)  5.019, p  .05; methOEA: t (4)  5.4, p  .006] and
onkeys [WY14643 in Figure 2A: interaction of WY14643 and ses-
ion F (2,4) 8.25, p .05; methOEA in Figure 2A: t (2) 25.8, p
01]. At the most effective doses, self-administration behavior was
ecreased significantly throughout the course of PPAR- agonist
reatment [Figure 1B: F (3,27) 7.99, p .001; Figure 2B: F (5,10)
1.04, p  .001; Figure 2D: F (5,10)  6.23, p  .007] and rapidly
eturned to higher levels when treatmentwas discontinued. In rats,
esponse rates in the inactive hole occurred at a fairly constant
ercentage of response rates in the active hole regardless of pre-
reatment (mean percentage SEM 26 5 under vehicle treat-
ent, 213under 20mg/kgWY14643, and279under 40mg/kg
igure 2. The PPAR- agonistsWY14643 (10, 20 and 40mg/kg intramuscula
g/kg IM, 40 minutes before session) significantly reduced the rate of nico
atio schedule at a nicotine dose of 30g/kg/injection. The effects ofWY146
1mg/kg IM, 45minutes before session), which hadno significant effectwhe
verage of five sessions of vehicle treatment. (B,D) Rates of nicotine self-ad
fter treatmentwith 40mg/kgWY14643 (sessions 4–8) or 10mg/kgmethO
g/kg IM, 20minutes before session) did not alter the number of 30g/kg c
n identical 10-response fixed ratio schedule in squirrelmonkeys.n 3 form
ifference from vehicle treatment. Data are represented as group meansY14643). The specificity of WY14643’s effects was verified by giv-
ww.sobp.org/journaling the PPAR- antagonist MK886 as a pretreatment in monkeys.
MK886 reversed the decreases in nicotine self-administration pro-
duced by WY14643 but had no effect on nicotine self-administra-
tion when given alone. On the final day of treatment with themost
effective dose of WY14643 (40 mg/kg), nicotine intake was de-
creased by 35% in rats and 76% in monkeys.
PPAR- Activation Suppressed ReinstatementWhen
Abstinent Rats andMonkeysWere Re-exposed to Nicotine
When relapse was modeled using a reinstatement procedure,
thenicotine-seeking response (nosepoking in rats, leverpressing in
monkeys) was reinstated by a noncontingent priming injection of
nicotine before the session (Figure 3). WY14643 significantly re-
duced this reinstatement in rats [Figure 3A: main effect of active vs.
inactive nose-poking hole, F (1,14) 20.4, p .0005; interaction of
WY14643 dose and nicotine, F (2,13)  7.7, p  .01] and monkeys
[Figure 3B: 20 mg/kg WY14643: F (3,6)  15.4, p  .005; 40 mg/kg
WY14643: F (3,6) 93.5, p .001]. WY14643 alone did not reinstate
drug seeking. In rats, nicotine also increased responding in the
inactive hole, and WY14643 prevented this increase. However, it
should be noted that responding in the active hole remained
higher than responding in inactive hole under all testing condi-
tions, indicating that the nicotine-induced increases in active-hole
respondingweredue to reward rather thannonspecific increases in
locomotor activity. Pretreatment of monkeys with the PPAR- an-
tagonist MK886 prevented the effects of WY14643 in this model of
relapse, demonstrating the receptor specificity of these effects (Fig-
], 20minutes before session for five consecutive sessions) andmethOEA (10
njections self-administered by squirrel monkeys under a 10-response fixed
mg/kg)were reversedbypretreatmentwith the PPAR- antagonistMK886
n alone. (A)Average rate of injection over five test sessions, comparedwith
tration during individual sessions under baseline conditions (sessions 1–3),
d after return to baseline conditions (sessions 9–11). (C)WY14643 (20 or 40
e injections self-administered or the number of foodpellets obtained under
ys under all conditions except food reinforcement,wheren 4. *Significant
inj., injection; MK, MK886; mOEA, methOEA; WY, WY14643.rly [IM
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ARTICLE IN PRESSPAR- Activation Did Not Alter Nicotine’s Interoceptive
ffects or Produce a General Depression of Operant Behavior
The ability of WY14643 to reduce nicotine self-administration
nd reinstatement was not due to a nonspecific disruption of
perant behavior. WY14643 had no effect on cocaine- or food-
einforced responding in squirrel monkeys under testing condi-
ions identical to those used with nicotine (Figure 2D), and it did
ot alter food-reinforced responding by rats as measured in the
rug discrimination procedure (evenwhen combinedwith intra-
eritoneal nicotine injection; Figure 4B) or rats’ ability to detect
hat they had received nicotine (Figure 4A) in a drug-discrimina-
igure 3. The PPAR- agonist WY14643 blocked reinstatement of nicotine
elf-administration after a period of abstinence in rats and monkeys. (A) In
ats,WY14643 (20mg/kg intraperitoneally [IP], n 11; and 40mg/kg IP, n
5) dose-dependently reduced the reinstatement of extinguished nicotine-
eeking responses produced by a priming injection of nicotine. (B) In squir-
el monkeys, WY14643 (20 or 40 mg/kg intramuscularly [IM], 20 minutes
efore the session) dose-dependently reduced the reinstatement of extin-
uished nicotine-seeking responses produced by a priming injection of
icotine (.1 mg/kg intravenously) before the session (n  3). This effect of
Y14643 was prevented by pretreatment with the PPAR- antagonist
K886 (1 mg/kg IM, 45 minutes before session). Data are presented as
roup means  SEM. *Significant difference from vehicle pretreatment
uring a saline prime session. # Significant difference from vehicle pretreat-
ent during a nicotine prime session. Diamond represents a significant
ifference from inactive hole responding during a saline prime session. MK,
K886; Nic, nicotine; WY, WY14643.ion procedure.PPAR- Activation Prevented Nicotine-Induced Changes in
Dopamine Cell Firing in the Ventral Tegmental Area of Rats
In single-unit in vivo recording experiments in anesthetized rats,
IV injection of .2 mg/kg nicotine enhanced firing rate [Figure 5A:
F (6,7) 6.99, p .0001] and burst firing [Figure 5B: F (6,7) 2.837;
p .05] of VTA dopamine neurons that were antidromically identi-
fied as projecting to the nucleus accumbens. At doses of WY14643
that significantly reduced nicotine self-administration and nico-
tine-induced reinstatement in the behavioral experiments,
WY14643 and methOEA did not alter spontaneous firing rate (Fig-
ure 5A,C; basal mean Hz SEM; control rats: 3.24 .2; WY14643 20
mg/kg: 3.2  .6; WY14643 40 mg/kg: 3.3  .6; methOEA 5 mg/kg:
3.18  .5; MK886 	 WY14643 40 mg/kg: 3.6  .8; methOEA 10
mg/kg: 3.11  .4] or burst firing (Figure 5B,D; basal mean % of
spikes/bursts SEM; control rats: 12.9 3.72; WY14643 20mg/kg:
13.6 9.88; WY14643 40mg/kg: 15.8 6.1; MK886	WY14643 40
mg/kg: 8.0  6.4; methOEA 5 mg/kg: 8.7  3.57; methOEA 10
mg/kg: 8.9  1.61] of VTA dopamine neurons when given alone.
However, when given before nicotine, 20 mg/kg of WY14643 par-
tially blocked and 40 mg/kg of WY14643 completely blocked nico-
tine-induced excitation of dopamineneurons [Figure 5A,B: effect of
WY14643 on firing rate, F (1,48) 20.36, p .001; and burst firing,
F (1,48) 5.98, p .05]. Intravenous administration of methOEA (5
and 10 mg/kg) also completely prevented excitation of dopamine
Figure 4. The PPAR- agonist WY14643 (40 mg/kg intraperitoneal, 20 min-
utes before session) did not alter the interoceptive effects of nicotine or the
rate of food-maintained lever pressing under a nicotine drug discrimination
procedure in rats (n  12). When given alone or in combination with any
dose of nicotine (.01–.4 mg/kg subcutaneous), WY14643 did not signifi-
cantly affect the percentage of responses on the nicotine-appropriate lever
(A)or the rate of lever responding (B). Data arepresentedasgroupmeans
SEM. Nic., nicotine; Resp., responding; WY, WY14643.
www.sobp.org/journal
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ARTICLE IN PRESSeurons by nicotine [Figure 5C,D: effects of two doses of methOEA
n firing rate: F (1,48)  5.02, p  .05, and F (1,48)  5.24, p  .05;
nd burst firing: F (1,52) 6.34, p .05, and F (1,52) 4.73, p .05].
retreatment with the PPAR- antagonist MK886 completely re-
ersed WY14643’s blockade of nicotine-induced increases in firing
ate (Figure 5A) and burst firing [Figure 5B: MK886	WY14643 vs.
Y14643, F (1,60)16.57,p .01; F (1,60)18.24,p .05, for firing
ate and burst firing, respectively].
PAR- Activation Prevented Nicotine-Induced Increases in
opamine Levels in the Nucleus Accumbens Shell of Rats
In vivo microdialysis experiments in freely moving rats showed
hat systemic injection of .4 mg/kg nicotine increased extracellular
opamine levels in the nucleus accumbens shell by100% [Figure
A: F (12,48)  16.23, p  .0001; Figure 6B: F (13,65)  58.61; p 
0001]. WY14643 alone did not alter dopamine levels, but it signifi-
igure 5. The PPAR- agonists inhibited nicotine-induced activation of vent
timulatory effects of nicotine (.2mg/kg intravenous,n7) ondischarge act
at and the actions of the PPAR- agonists (A,C). Line graphs show the time
eally injected 30 minutes before the start of recordings, n 7) significa
PAR- antagonist MK886 (3 mg/kg injected 45 minutes before the start
A,B).Methyl oleoylethanolamide (methOEA) (5 and10mg/kg intravenously
ignificantly blocking nicotine-induced increases in firing rate (C) and burs
xpressed as percentages of or differences from baseline values, respective
B) are repeated in (D). Arrows indicate time of drug injections. The followin
unnett’s post hoc comparisons): WY14643 40mg/kg,methOEA 5mg/kg, a
0mg/kgandbymethOEA5and10mg/kg. Bothfiring rate andburst firingd
ic, nicotine; MK, MK886; mOEA, methOEA; WY, WY14643.antly reduced nicotine-induced elevations in dopamine levels in a
ww.sobp.org/journaldose-related manner [Figure 6A: time–treatment interaction,
F (18,108)3.01,p .001; basal level, expressedasmean fmoles/10
L sampleSEM for control rats: 312.7;WY1464340mg/kg: 31.8
 5.2]. Administration of methOEA also did not alter dopamine
levels by itself (Figure 6D) but markedly reduced nicotine-induced
elevations in dopamine levels [Figure 6B: time–treatment interac-
tion, F (26,169)  5.95, p  .0001]. The PPAR- antagonist MK886
had no effect when given alone but completely reversed
WY14643’s (40 mg/kg) blockade of nicotine-induced elevations in
dopamine levels [Figure 6C: time–treatment interaction, F (26,169)
 4.06, p .05]. Similarly,MK866prevented the effects of 10mg/kg
of methOEA [Figure 6D: time–treatment interaction, F (28,182) 
3.06, p  .01]. In contrast, WY14643 did not alter the effects of
cocaine on dopamine levels in the nucleus accumbens shell. Basal
levels of dopamine in dialysates, expressed as mean fmoles/10 L
sample  SEM, did not differ between groups before injections
gmental area dopamine neurons in anesthetized rats. Histograms show the
f an individual ventral tegmental areadopamineneuron in a representative
se of nicotine’s effects. The PPAR- agonist WY1463 (40 mg/kg intraperito-
locked nicotine-induced increases in firing rate (A) and burst firing (B). The
cordings, n  5) significantly abolished the effects produced by WY14643
ted4minutesbeforenicotine,n7both)mimicked theeffectsofWY14643,
g (D). Results are presented as mean SEM of firing rates and burst firing,
te that data for vehicle in (A) are repeated in (C) and that data for vehicle in
tments significantly reduced the effects of nicotine on firing rate (ps .05,
thOEA 10mg/kg. Burst firingwas significantly reduced byWY14643 20 and
dwhenWY1464340mg/kgwasgivenwith versuswithoutMK886 (ps .05).ral te
ivity o
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ARTICLE IN PRESSaline: 31.85.2;WY1464320mg/kg	nicotine: 30.84.5;WY14643
0mg/kg	nicotine: 36.05.9;MK886	vehicle	 saline: 41.06.0;
K886 	 WY14643 40 mg/kg 	 nicotine: 32.0  4.8; Figure 5B,D;
ehicle 	 nicotine: 30.8  2.9; methOEA 5 mg/kg 	 nicotine:
1.5  1.3; methOEA 10 mg/kg 	 nicotine: 33.8  4.2; MK886 	
ehicle	 saline: 32.5 3.2; MK886	methOEA 10 mg/kg	 nico-
ine: 30.4 3.3; Figure 5E; vehicle	 cocaine: 34.9 5.8; cocaine	
Y14643: 36.6 5.4).
iscussion
These findings indicate that activation of PPAR- can counteract
ddiction-relatedeffectsofnicotineon thebrainandbehavior. Inboth
atsandmonkeys, thePPAR-agonistsWY14643andmethOEAsignif-
cantly decreased nicotine self-administration and suppressed rein-
igure 6. The PPAR- agonists inhibited nicotine-induced elevations in dop
ithWY14643 (20 and40mg/kg intraperitoneally [IP],n5both) ormethOE
espectively, before nicotine (.4 mg/kg subcutaneous, n 6), significantly re
he PPAR- antagonist MK886 (3 mg/kg IP) injected 20 minutes before 40
eductionof nicotine-inducedelevations indopamine levels producedbyW
ignificantly reduced the effects of nicotine (Tukey post hoc comparisons): W
p .001). TheMK886 (3mg/kg IP, n 4) had no significant effect when giv
ad no significant effect when given with the vehicles of MK886 and saline
ost hoc comparisons): WY14643 20 mg/kg, (p  .05); WY14643 40 mg/kg
njected 20 minutes before cocaine (3 mg/kg IP; n  5) did not significant
Y14643	nicotine in (A) are repeated in (C) and that data for vehicle	nic
f drug or vehicle injection. Results are presented as groupmeans SEM, ex
ic, nicotine; Veh, vehicle; WY, WY14643.tatement of nicotine seeking, whichmodels relapse, themain obsta-cle tosmokingcessation.At thedoses thatproducedtheseeffectswith
nicotine self-administration, there was no indication that PPAR- li-
gands had any effect on food- or cocaine-maintained behavior. The
reductionofnicotineself-administrationandreinstatementbyPPAR-
agonistswasmost likelyduetothesedrugs’ability topreventnicotine-
induced excitation of dopaminergic transmission in reward-related
areas of the brain. Specifically, PPAR- agonists prevented nicotine-
induced increases infiringrateandburstfiring indopamineneurons in
the VTA, and they prevented nicotine-induced (but not cocaine-in-
duced)elevationsofdopaminelevels intheshellof thenucleusaccum-
bens. These potentially therapeutic behavioral, electrophysiological,
and neurochemical effects of PPAR- agonists were reversed by the
PPAR- antagonist MK886, verifying that they were indeed due to
PPAR- activation.
e levels in the nucleus accumbens shell of freely moving rats. Pretreatment
mg/kg IP,n5) but not their vehicle (n5both), given 20 and40minutes,
d the increase in extracellular dopamine levels produced by nicotine (A,B).
g WY14643 (n 6) or 10 mg/kg methOEA (n 6) completely reversed the
3 (40mg/kg IP) andmethOEA (10mg/kg IP) (C,D). The following treatments
43 20mg/kg, (p .05); WY14643 40mg/kg, (p .001); methOEA 10mg/kg
h the vehicle ofWY14643 and saline (C), andmethOEA (10mg/kg IP, n 4)
he following treatments significantly reduced the effects of nicotine (Tukey
.001); methOEA 10 mg/kg (p  .001). The WY14643 (40 mg/kg IP, n  5)
er the effects of cocaine (E). Note that data for vehicle 	 nicotine and for
and formethOEA	nicotine in (B) are repeated in (D). Arrows indicate time
ed as percent of basal values. DA, dopamine; MK,MK886;mOEA,methOEA;amin
A (10
duce
mg/k
Y1464
Y146
enwit
(D). T
, (p 
ly alt
otine
pressThe fact that the PPAR- agonist WY14643 did not alter the
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ARTICLE IN PRESSnteroceptive effects of nicotine in the drug-discrimination proce-
ure is consistent with previous findings that nicotine’s reward-
elated dopaminergic effects are not well captured by this proce-
ure (32). For example, even though the cannabinoid type 1
eceptor antagonist rimonabant can block nicotine reward (i.e.,
elf-administration, conditioned place preference) and nicotine-
nduced increases of dopamine levels in the nucleus accumbens,
imonabant does not alter nicotine discrimination (26,33). Similarly,
ntagonism of the dopamine D3 receptor blocks nicotine-induced
onditioned place preference but does not alter nicotine discrimi-
ation (34). The finding thatWY14643 blocked nicotine’s effects on
opamine but did not alter its discriminative effects is consistent
ith previous data suggesting that neurobiological substrates be-
ween reward-related and interoceptive effects of nicotine are not
ntirely overlapping (35).
The nicotine-related behavioral, electrophysiological, and
eurochemical effects of PPAR- agonists in the present study
re very close to the effects obtained earlier with the FAAH
nhibitor URB597 ([3-(3-carbamoylphenyl)phenyl] N-cyclohexyl-
arbamate) (7,9). The results obtained here with the PPAR-
gonist WY14643 are also consistent with the finding that
RB597 does not alter nicotine discrimination (36). All of these
ndings converge to suggest that the elevation of endogenous
PAR- ligands OEA and PEA induced by URB597 modulates the
ewarding effects of nicotine; further studies are needed to de-
ineate the role of anandamide.
Themechanism by which PPAR- agonists and FAAH inhibition
xert these unanticipated antiaddictive actions is not completely
nderstood. However, the following points are well established.
esolimbic dopamine plays a pivotal role in nicotine dependence,
nd the VTA andnucleus accumbens shell are critical brain areas for
icotine’s rewarding effects (37–39). Nicotinic receptors in the VTA
re located both on cell bodies of dopaminergic neurons and on
resynaptic nerve endings of glutamatergic neurons that descend
rom themedial prefrontal cortex and impinge on these cell bodies
40). Nicotine facilitates dopaminergic neurotransmission and do-
amine release in the nucleus accumbens shell by directly stimulat-
ng nicotinic receptors on cell bodies of dopaminergic neurons and
y indirectly stimulating glutamate release, which in turn stimu-
ates VTA dopaminergic neuron firing and dopamine release in the
ucleus accumbens shell. Our data show that activation of PPAR-,
ither indirectly through FAAH inhibition or directly by administra-
ion of a PPAR- agonist, prevents nicotine-induced increases in
ring rate and burst firing in dopamine neurons in the VTA and as a
onsequence prevents nicotine-induced elevations of dopamine
evels in the shell of thenucleus accumbens. Themechanismunder-
ying these effects was elucidated by our recent in vitro findings
howing that activation of PPAR- produces a nongenomic (rapid)
odulation of nicotinic receptors on cell bodies of dopaminergic
eurons in the VTAbypromoting their phosphorylationby tyrosine
inases (8). Phosphorylated nicotinic receptors show diminished
onic conductance (41) andare rapidly internalized (42), reducingor
bolishing the responses of dopamine neurons to nicotine, andwe
ave demonstrated that the general tyrosine kinase inhibitor
enistein reverses OEA’s ability to block nicotine-induced excita-
ion of VTAdopamine neurons (8). Additionally, we have found that
he 
2 subunit of nicotinic receptors is critical for PPAR- effects,
ecause deletion of this subunit abolished the effects of PPAR-
ompounds, whereas its selective re-expression in VTA dopamine
eurons restores both the behavioral effects of nicotine (motor
ctivity) and PPAR- actions (43). Taken together, all of these find-
ngs suggest a mechanism by which PPAR- may modulate the
ww.sobp.org/journalreward-related dopaminergic effects of nicotine that provide a ba-
sis for nicotine self-administration.
In conclusion, our findings demonstrate that nicotine’s ability to
have rewarding effects and reinstate drug-seeking behavior after a
period of abstinence are suppressed by PPAR- activation, accom-
plisheddirectlybyPPAR-agonists or indirectlybyFAAH inhibition.
These behavioral effects appear to be due to modulation of
nicotine’s excitatory effects on reward-related mesolimbic dopa-
mine transmission. Notably, PPAR- agonists and FAAH inhibitors
appear to suppress nicotine reward and reinstatement much like
the cannabinoid inverse agonist/antagonist rimonabant but donot
share the adverse psychoactive effects produced by medications
that target cannabinoid type 1 receptors (3,9,19). Thus, PPAR- is a
promising newmolecular target for the treatment of the devastat-
ing problem of tobacco dependence.
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ABSTRACT adb_222 1..12
The endocannabinoid system regulates neurotransmission in brain regions relevant to neurobiological and behavioral
actions of addicting drugs.We recently demonstrated that inhibition by URB597 of fatty acid amide hydrolase (FAAH),
the main enzyme that degrades the endogenous cannabinoid N-acylethanolamine (NAE) anandamide and the endog-
enous non-cannabinoid NAEs oleoylethanolamide and palmitoylethanolamide, blocks nicotine-induced excitation of
ventral tegmental area (VTA) dopamine (DA) neurons and DA release in the shell of the nucleus accumbens (ShNAc),
as well as nicotine-induced drug self-administration, conditioned place preference and relapse in rats. Here, we studied
whether effects of FAAH inhibition on nicotine-induced changes in activity of VTA DA neurons were specific for
nicotine or extended to two drugs of abuse acting through different mechanisms, cocaine and morphine. We also
evaluatedwhether FAAH inhibition affects nicotine-, cocaine- ormorphine-induced actions in the ShNAc. Experiments
involved single-unit electrophysiological recordings from DA neurons in the VTA and medium spiny neurons in the
ShNAc in anesthetized rats. We found that URB597 blocked effects of nicotine and cocaine in the ShNAc through
activation of both surface cannabinoid CB1-receptors and alpha-type peroxisome proliferator-activated nuclear recep-
tor. URB597 did not alter the effects of either cocaine or morphine on VTA DA neurons. These results show that the
blockade of nicotine-induced excitation of VTADAneurons, whichwe previously described, is selective for nicotine and
indicate novel mechanisms recruited to regulate the effects of addicting drugs within the ShNAc of the brain reward
system.
Keywords Cocaine, dopamine neurons, electrophysiology, nicotine, nucleus accumbens, peroxisome proliferator-
activated receptor-a.
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INTRODUCTION
The endocannabinoids are a family of lipid signalingmol-
ecules, which play a pivotal role in the modulation of
several physiological and pathophysiological conditions
within the central nervous system (CNS) and in the
periphery. Although there are a number of endogenous
compounds with endocannabinoid-like activity, the
best characterized are n-arachidonoylethanolamide
(anandamide) (Devane et al. 1992) and 2-arachidonoyl
glycerol (2-AG) (Sugiura et al. 1995). Within the CNS,
anandamide and 2-AG are synthesized on demand in
postsynaptic cell membranes and show affinity for type-1
cannabinoid receptors (CB1), which are mainly located
on presynaptic neurons (Kano et al. 2009). Once pro-
duced, endocannabinoids inhibit neurotransmitter
release and then are moved intracellularly by a putative
carrier protein (Hillard & Jarrahian 2000), where they
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are then deactivated by two main enzymes, fatty acid
amide hydrolase (FAAH), which catabolizes anandamide
(Cravatt et al. 1996), and monoacylglycerol lipase,
which catabolizes 2-AG (Dinh et al. 2002). Two
non-cannabinoid N-acylethanolamines (NAEs), the
anorexiant oleoylethanolamide (OEA) and the anti-
inflammatory palmitoylethanolamide (PEA), which are
structurally similar to anandamide but are endogenous
ligands for alpha-type nuclear peroxisome proliferator-
activated receptors (PPAR-a), are also endogenous sub-
strates for FAAH (Rodriguez de Fonseca et al. 2001;
Cravatt & Lichtman 2002). Their centrally mediated
effects have been poorly characterized, although OEA
and PEA might be involved in modulation of synaptic
signaling as endogenous ligands for an independent
endocannabinoid-like system. Evidence is accumulating,
which suggests a significant contribution of OEA and
PEA, and PPAR-a nuclear receptors in effects observed
following pharmacological inhibition of FAAH (Mazzola
et al. 2009).
The endocannabinoid system regulates neurotrans-
mission in brain regions relevant to neurobiological
and behavioral actions of addicting drugs or natural
rewarding stimuli (Maldonado, Valverde & Berrendero
2006; Solinas, Yasar & Goldberg 2007; Solinas, Gold-
berg & Piomelli 2008). Several lines of evidence indicate
that endocannabinoids are released by midbrain dopam-
ine (DA) neurons (Melis et al. 2004; Riegel & Lupica
2004) to regulate their own afferents. As a conse-
quence, pharmacological manipulation of endocannab-
inoid signaling fine-tunes the effects of different
addicting drugs. For example, recent studies have inves-
tigated how pharmacological inhibition of FAAH, and
the consequent increase in anandamide levels, modu-
lates the effects of nicotine (Merritt et al. 2008; Scherma
et al. 2008; Forget, Coen & Le Foll 2009). In rats, the
FAAH inhibitor cyclohexyl carbamic acid 3′-carbamoyl-
3-yl ester (URB597) blocked nicotine-induced condi-
tioned place preference, acquisition of nicotine
self-administration behavior, nicotine-induced relapse to
drug-seeking behavior and nicotine-induced DA
increases in the shell of the nucleus accumbens
(ShNAc) (Scherma et al. 2008). We also found that
URB597 completely prevents nicotine-induced increases
in firing rate and burst firing of ventral tegmental area
(VTA) DA neurons of anesthetized rats (Melis et al.
2008), thus inhibiting one of the primary neuronal
responses to nicotine administration in the brain reward
system (Maskos et al. 2005).
In this study, we asked whether inhibition of FAAH
might prevent not only the effects of nicotine but also the
effects of other addicting drugs, such as cocaine andmor-
phine, on VTA DA neurons. In addition, because DA
neurons in the VTA directly project to the ShNAc, we also
compared the effects of FAAH inhibition on responses to
nicotine, cocaine and morphine of GABAergic medium
spiny neurons (MSNs) in the ShNAc. Together with the
VTA, the ShNAc plays a crucial role in the primary rein-
forcing properties of addicting drugs and orients reward-
seeking behavior (Carlezon & Thomas 2009). We found
that FAAH inhibition by URB597 specifically modulates
neuronal responses to different substances in these two
distinct areas through actions on both cannabinoid CB1-
receptors and PPAR-a nuclear receptors. This suggests
that both endogenous cannabinoid (anandamide) and
non-cannabinoid (OEA and PEA) fatty acid ethanola-
mides, which are all substrates for FAAH, participate in
the fine-tuning of neurophysiological and behavioral
effects of addicting drugs.
MATERIALS AND METHODS
Male Sprague Dawley rats (250–350 g) (Harlan, San
Pietro al Natisone, Italy) were used in both the NAc and
the VTA experiments. We housed animals in groups of
three to six in standard conditions of temperature and
humidity under a 12-hour light/dark cycle (with lights
on at 7:00 a.m.) with food and water available ad libitum.
We anesthetized animals with urethane (1300 mg/kg,
intraperitoneal [i.p.]), cannulated their femoral vein for
intravenous administration of pharmacological agents
and placed in the stereotaxic apparatus (Kopf, Tujunga,
CA)with their body temperaturemaintained at 37  1°C
by a heating pad.
We performed the experiments in strict accordance
with the Guidelines for the Care and Use of Mammals in
Neuroscience and Behavioral Research (Committee on
Guidelines for the Use of Animals in Neuroscience and
Behavioral Research 2003) and EEC Council Directive of
24 November 1986 (86/609). We made all efforts to
minimize pain and suffering, and to reduce the number of
animals used.
Experiments in the VTA
The scalp was retracted and one burr hole was drilled
above the VTA (6.0 mm posterior from bregma, 0.3–
0.6 mm lateral from midline) for the placement of a
recording electrode. We localized structures according to
the stereotaxic atlas of Paxinos &Watson (1997). Single-
unit activity of neurons located in the VTA (V 7.0–
8.0 mm from the cortical surface) was recorded
extracellularly with glass micropipettes filled with 2%
pontamine sky blue dissolved in 0.5 M of sodium acetate
(impedance 2–5 MW). Single-unit activity was filtered
(band pass 500–5000 Hz), and individual spikes were
isolated by means of a window discriminator (Neurolog
Instruments, Digitimer, Herts, UK), displayed on a digital
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storage oscilloscope (TDS 3012, Tektronics, Marlow, UK)
and digitally recorded. We sampled experiments on-line
and off-line with Spike2 software (Cambridge Electronic
Design, Cambridge, UK) by a computer connected to CED
1401 interface (Cambridge Electronic Design). Single
units were isolated and identified according to already
published criteria (Grace & Bunney 1983, 1984; Ungless,
Magill & Bolam 2004). Because we recorded only one cell
per rat, we selected VTA DA neurons when all criteria for
identification were fulfilled: firing rate 10 Hz, duration
of action potential 2.5 ms and inhibitory responses to
hindpaw pinching. We defined bursts as the occurrence
of two spikes at an interspike interval  80 ms. Bursts
terminated when the interspike interval exceeded
160 ms (Grace & Bunney 1983). At the end of each
recording section, direct current (10 mA for 15 minutes)
was passed through the recording electrode to eject pon-
tamine sky blue, which allowed the identification of the
recorded cells. Brains were removed and fixed in 8% for-
malin solution. We identified the position of the elec-
trodes microscopically on serial sections (60 mm) stained
with cresyl violet.
Experiments in the ShNAc
We recorded extracellularly single-unit activity of
neurons located in the medial part of the NAc (shell)
(1.5 mm anterior from bregma, 0.8–1.3 mm lateral from
the midline, 6.5–7.0 mm ventral from cortical surface)
using the same instruments previously described for the
VTA experiments. In addition, because MSNs of the
ShNAc do not fire spontaneously in anesthetized animals,
we delivered electrical stimuli in the basolateral amygdala
(BLA) to evoke spike firing in the NAc cell. For this reason,
we inserted a formvar-coated stimulating stainless steel
bipolar electrode with an inclination of 15° anteroposte-
rior on the coronal plane (250-mm tip diameter) in the
ipsilateral BLA (3.2 mm posterior from bregma, 5.0 mm
lateral from themidline, 7.0 mmventral from the cortical
surface), which is a major excitatory projecting area to
the NAc.
After the glass electrode had been positioned to the
dorsal limit of the NAc, we searched cells that responded
to the stimulation of the BLA. Stimuli (~0.5 mA) were
delivered to the BLA at 1-second intervals, while the
microelectrode was lowered incrementally through the
NAc. Once we detected a cell, we adjusted the position of
the microelectrode in order to maximize the spike ampli-
tude relative to background noise. We identified neurons
that responded to BLA stimulation by their robust excita-
tory response (latency range 10–25 ms). We did not
include in this study cells whose latencies were longer
than 26 ms following BLA stimulation because they
could exhibit a polysynaptic response component
(Mulder, Hodenpijl & Lopes da Silva 1998).
The experimental protocol was essentially that pub-
lished by Floresco et al. (2001) with some modifications
(Pistis et al. 2002). Once we isolated a cell, we adjusted
stimulation currents to approximately half-maximal
intensity, such as ~50% of electrical stimuli (1 Hz) in the
BLA elicited an action potential in the recorded cell. We
calculated evoked spike probability by dividing the
number of action potentials observed by the number of
stimuli administered in 100-second periods.
Once stable levels of evoked spike probability were
achieved (< 10% changes over 10-15 minutes), we
administered drugs intravenously and assessed spike
probability every 100 seconds. Changes in spike probabil-
ity were an index of changes induced by the studied com-
pounds over the excitation of NAc cells evoked by BLA
stimulation. As well as for the VTA experiments, we
recorded only one cell per rat.
Statistical analysis
For VTA experiments, we calculated drug-induced
changes in firing rate and pattern by averaging the effects
after drug administration (2minutes) and normalizing to
the predrug baseline.
For ShNAc experiments, we determined predrug spike
probability baseline as the mean of at least three con-
secutive assessments (100 seconds) over 10 minutes
before drug administration. We generated peristimulus
time histograms (1-ms bins, 100 cumulative sweeps) by
CED Spike2 software (Cambridge Electronic Design). Fol-
lowing drug administration, we calculated spike prob-
ability every 100 seconds and normalized it to the
predrug baseline.
All the numerical data are given as mean  standard
error of the mean. Data were compared and analyzed by
using two-way analysis of variance (ANOVA) for repeated
measures (treatment ¥ time), or one-way ANOVA or Stu-
dent’s t-test for repeated measures, when appropriate.
Post hocmultiple comparisons were made using the Dun-
nett’s or Bonferroni’s tests. We performed statistical
analysis by means of the NCSS program (Kaysville, UT,
USA). The significance level was established at P < 0.05.
Drugs
Nicotine [(–)-nicotine hydrogen tartrate] was purchased
from Sigma (St. Louis, MO). Morphine chloridrate and
cocaine chloridrate were purchased from S.a.l.a.r.s
(Como, Italy) and Akzo Pharmadivision Diosynth (Oss,
the Netherlands). SCH 23390 was purchased from
Sigma/RBI, and L-sulpiride was purchased from Ravizza
(Latina, Italy). Rimonabant (SR141716A) was a gener-
ous gift of Sanofi-Aventis Recherche (Montpellier,
France). URB597 was purchased from Alexis (Lausen,
Switzerland). MK886was purchased fromTocris (Bristol,
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UK). We diluted nicotine, SCH 23390, L-sulpiride,
cocaine and morphine in saline. We adjusted nicotine
solution to pH = 7withNaOH.We emulsified rimonabant
in 1%Tween80 (Sigma, St Louis, MO, USA), and then, we
diluted in saline and sonicated. We dissolved URB597 in
dimethylsulfoxide (DMSO) (100 mg/ml) and diluted to the
final concentration in saline. The final concentration of
DMSO was 0.1%. We emulsified MK886 in 10% of
Tween80, dissolved in 20% of DMSO and then diluted to
the final concentration in distilled water.
RESULTS
FAAH inhibition does not affect morphine and cocaine
effect on VTA DA neurons
We first assessed whether FAAH inhibition modulates
responses of VTA DA neurons to cocaine and morphine.
We recorded from VTA DA neurons (n = 22) only when
they fulfilled all criteria reported in the literature (see
methods). A typical waveform of a DA neuron action
potential is graphically depicted in Fig. 1a. When we iso-
lated a neuron, we recorded its basal activity for at least 5
minutes before administration of vehicle, and, after an
additional 4 minutes, we injected morphine or cocaine.
The vehicle used for these experiments had no effect on
VTA DA neurons.
In line with previous studies (Einhorn, Johansen &
White 1988), cocaine (1.0 mg/kg, i.v.) inhibited firing
rate (61.62  9.35% of baseline; F(5;30) = 5.996; n = 6;
P < 0.001; one-way ANOVA for repeated measures
and Dunnett’s test) (Fig 1b,d) and burst firing
(-16.42  6.14 of baseline level; F(5;25) = 4.659; n = 6;
P < 0.01; one-way ANOVA for repeated measures and
Dunnett’s test) (Fig. 1e) of VTA DA neurons. As reported
in literature (Matthews & German 1984), morphine
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Figure 1 Effects of URB597 on the responses of ventral tegmental area (VTA) dopamine (DA) neurons to cocaine. (a) Average trace,
acquired from a digital storage oscilloscope, showing the typical broad, notched waveform of an isolated VTA DA neuron recorded from an
anesthetized rat. (b) Representative firing rate histogram showing the decrease in firing rate of an individual VTA DA neuron produced by
intravenous cocaine (COC, 1 mg/kg injected at arrowheads) in control conditions.The injection of vehicle (VEH) is ineffective. (c) This rate
histogram displays that URB597 pre-treatment (0.1 mg/kg, i.v.) does not alter cocaine’s depression of firing rate of a VTA DA neuron. (d,e)
Graphs illustrating the time course of cocaine’s effects on firing rate and burst firing of VTA DA neurons with and without URB597
pre-treatment. Pre-treatment with URB597 (0.1 mg/kg, i.v.) does not affect the inhibition of VTA DA neurons induced by cocaine (COC,
1 mg/kg, i.v.; arrow) either in firing rate (d) or burst firing (e). (f) These histograms show that the pre-treatment with URB597 did not affect
baseline firing activity (top) or burst firing (bottom) of recorded VTA DA neurons (P > 0.05, Student’s t-test). Results are means, with vertical
bars representing the standard error of the mean of firing rate and burst firing, expressed as a percentage of, or difference from, the baseline
(BAS). *P < 0.01 versus baseline, one-way analysis of variance and Dunnett’s test
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(4.0 mg/kg, i.v.) stimulated firing rate (Fig. 2a,c) and
burst firing (Fig. 2d) (139.46  8.17% of baseline level;
F(4;20) = 3.299; n = 5; P < 0.05; one-way ANOVA for
repeated measures and Dunnett’s test) of VTA DA
neurons. In a separate group of rats, we administered the
FAAH inhibitor URB597 (0.1 mg/kg, i.v., 1–2 hours
before recordings), which persistently (> 6 hours)
increases brain levels of anandamide (Kathuria et al.
2003). URB597 pre-treatment did not change cocaine
effects on firing rate (URB + cocaine: 66.5  9.98% of
baseline level; F(1;60) = 0.0003; n = 6, P > 0.05 versus
vehicle + cocaine) (Fig. 1c,d) and burst firing (URB +
cocaine: -18.13  6.68 of baseline level; F(1;60) = 0.15;
n = 6, P > 0.05 versus vehicle + cocaine) (Fig. 1e).
URB597 pre-treatment slightly enhanced the excitatory
action of morphine on firing rate, but this effect did
not reach statistical significance (URB + morphine:
159.63  9.06 of baseline level; F(1;40) = 2.76; n = 5,
P = 0.13 versus vehicle + morphine; two-way ANOVA
and Bonferroni’s test) (Fig. 2b,c). The effect of morphine
on burst firing was similar between controls and
URB597-treated animals (URB + morphine: +15.34 
5.13 of baseline level; F(1;40) = 0.12; n = 5, P > 0.05
versus vehicle + morphine; two-way ANOVA and Bonfer-
roni’s test) (Fig. 2d).
URB597 had no significant effect on either the
frequency or burst firing of DA neurons; the mean
baseline frequency of VTA DA neurons recorded was
3.9  1.7 Hz in control animals and 3.8  1.53 Hz in
URB597-pre-treated animals (n = 11, P > 0.05 versus
controls; Student’s t-test) (Fig. 1f). There was also no
significant change in the percent of spikes in bursts
after URB597 (21.5  3.32% for control rats and
33.9  10.22% for URB597-pre-treated animals,
n = 11, P > 0.05; Student’s t-test) (Fig. 1f). Thus, there
was no effect of URB597 on cocaine or morphine-
induced actions on DA neurons in the VTA, in contrast
to our previous findings with nicotine (Melis et al.
2008), demonstrating a selective blockade by FAAH inhi-
bition of nicotine-induced alterations in VTA DA neuron
excitability.
FAAH inhibition blocks the effects of nicotine on MSNs
of the ShNAc
The ShNAc plays a pivotal role in the mechanisms under-
lying the primary reinforcing effects produced by natural
stimuli and by drugs of abuse, as well as in reinstatement
of drug-seeking behavior in abstinent animals. We next
assessed whether FAAH inhibition modulates responses
of MSNs in the ShNAc to nicotine.
All recordedMSNs (n = 59) were quiescent, responded
to BLA stimulation and were located in the medial part
of the ShNAc. BLA stimulation evoked firing in MSNs of
the ShNAc with a mean latency of 18.4  0.7 ms
(Fig. 3a,b). The average baseline spike probability
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Figure 2 Lack of effect of URB597 on
morphine-induced increases in firing rate
and burst firing of ventral tegmental area
(VTA) dopamine (DA) neurons. (a) Repre-
sentative firing rate histogram showing
that intravenous injection of morphine
(MORPH, 4 mg/kg) enhances firing rate of
VTA DA neurons in control conditions. (b)
This exemplificative rate histogram displays
that the administration of URB597 (0.1 mg/
kg, i.v., 2 hours before the recordings) did
not affect morphine-induced enhancement
of firing rate in a VTA DA neuron. (c,d)
Graphical depiction of the time course of
firing rate (c) or burst firing (d) of VTA
DA neurons following intravenous admin-
istration of morphine (MORPH, 4 mg/kg).
Pre-treatment with URB597 (0.1 mg/kg,
i.v.) did not alter the effects of morphine
either on firing rate or burst activity ofVTA
DA neurons. Results are means, with verti-
cal bars representing the standard error of
the mean of firing rate and burst firing,
expressed as a percentage of, or difference
from, the baseline (BAS). *P < 0.05 versus
baseline, one-way analysis of variance and
Dunnett’s test
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following BLA stimulation was 46.3  1.5%. We
recorded evoked activity of MSNs of the ShNAc for 300
seconds before the administration of nicotine, morphine
or cocaine. As previously reported (Hakan, Hart & Eyl
1993), nicotine (0.2 mg/kg, i.v.) depressed the excitability
of MSNs in the ShNAc, as measured by their response to
BLA stimulation (64  12% of baseline level; F(5;40) =
3.44, n = 6, P < 0.01; one-way ANOVA for repeated mea-
sures and Dunnett’s test) (Fig. 3b,c). This effect required
the joint activation of DA receptors by nicotine-induced
release of DA, because combinedadministrationof theDA
D1 receptor antagonist SCH23390 (1.0 mg/kg, i.v.) and
theDAD2receptor antagonist L-sulpiride (10 mg/kg, i.v.),
4 minutes before nicotine, fully prevented the depression
of MSN excitability by nicotine (122.5  10.6% of base-
line level; F(1;80) = 14.09; n = 6; P < 0.001 versus control;
two-way ANOVA and Bonferroni’s test) (Fig. 3d). Neither
L-sulpiride nor SCH23390, when administered sepa-
rately, were able to prevent nicotine-induced depression
of MSN excitability (SCH23390: F(1;70) = 0.05, n = 6,
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Figure 3 Nicotine depresses the excitability of medium spiny neurons (MSNs) in the shell of the nucleus accumbens (ShNAc). (a)
Superimposed traces acquired from a digital storage oscilloscope showing a relatively constant latency of the orthodromic responses of a
representative MSN after basolateral amygdala (BLA) stimulation. The arrowhead indicates the artifacts produced by BLA stimulation; the
arrow shows evoked action potentials of a MSN. Once a cell was isolated, the current applied to the BLA was adjusted to obtain ~50% of
probability to elicit an action potential after a single pulse stimulation. (b) Representative peristimulus time histograms displaying the typical
inhibitory response of a MSN in the ShNAc after BLA stimulation and injection of nicotine (0.2 mg/kg, i.v.). (c) Graph showing the time course
of nicotine-induced inhibition of spike firing of MSNs. (d) Graphical depiction illustrating that nicotine-induced inhibition was prevented by the
combined administration (at arrow), but not by the separate injection, of the dopamine D1 receptor antagonist SCH23390 (SCH, 1 mg/kg,
i.v.) and the D2 receptor antagonist L-sulpiride (L-Sulp, 10 mg/kg, i.v.). Results are means, with vertical bars representing the standard error of
the mean of evoked spike firing, expressed as a percentage of the baseline (BAS). *P < 0.05 versus baseline, one-way analysis of variance
(ANOVA) and Dunnett’s test; #P < 0.05 versus vehicle + nicotine, two-way ANOVA and Bonferroni’s test
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P > 0.05; L-sulpiride: F(1;70) = 0.02, n = 6, P > 0.05; two-
way ANOVA for repeated measures and Dunnett’s test)
(Fig. 3d).
Pre-treatment with URB597 (0.1 mg/kg, i.v., 1–2
hours before recordings) blocked nicotine’s depression of
MSNs in the ShNAc (Fig. 4a,b) (126.6  15.6% of base-
line level, n = 6, F(1;70) = 9.03, P < 0.01 versus control;
two-way ANOVA and Bonferroni’s test). Consistent with
the data obtained in the VTA, URB597 had no significant
effect by itself; the mean current administered for spike
firing evoked by BLA stimulation in MSNs in the ShNAc
was not different between controls and URB597-pre-
treated animals (1.52  0.16 mA versus 1.9  0.4 mA,
respectively; n = 6; P > 0.05; Student’s t-test) (Fig. 4b,
inset). Interestingly, after URB597 treatment, nicotine
increased, rather than depressed, firing evoked by BLA
stimulation in MSNs (F(8;40) = 3.32, n = 6, P < 0.01; one-
way ANOVA for repeated measures and Dunnett’s test)
(Fig. 4a,b). These results indicate that FAAH inhibition
prevents the inhibitory effects of nicotine on MSNs in the
ShNAc.
URB597 blocks nicotine’s effects in the ShNAc via
CB1-receptor- and PPAR-a-dependent mechanisms
Next, we explored the mechanism by which URB597
blocks nicotine-induced inhibition of MSNs in the ShNAc.
In fact, it is well established that URB597 elevates brain
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Figure 4 URB597 suppresses nicotine’s action on medium spiny neurons (MSNs) in the shell of the nucleus accumbens (ShNAc). (a)
Exemplificative peristimulus time histograms showing that nicotine-induced decrease of MSN excitability is reversed by URB597, whereas the
CB1-receptor antagonist rimonabant (SR, 0.5 mg/kg) and the peroxisome proliferator-activated nuclear receptor-a antagonist MK886
(3 mg/kg), administered 15 minutes before URB597, prevented the effects of the fatty acid amide hydrolase inhibitor and restored
nicotine-induced inhibition of MSNs’ responses to basolateral amygdala (BLA) stimulation in the ShNAc. (b,c) Graphical depiction illustrating
that URB597 pre-treatment prevented nicotine-induced inhibition of MSNs and that this inhibition by nicotine was reversed by rimonabant
(SR, 0.5 mg/kg, i.v.) (b) or MK886 (3 mg/kg, i.p.) (c).The histogram in the inset displays that the mean current administered in the BLA to evoke
spike firing in MSNs was not different between controls (CTRL) and URB597-pre-treated animals. Results are means, with vertical bars
representing the standard error of the mean of evoked spike firing, expressed as difference percentage of the baseline (BAS). #P < 0.05 versus
vehicle + nicotine, §§P < 0.001 versus URB + nicotine, two-way analysis of variance and Bonferroni’s test
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levels of both anandamide, an endogenous CB1-receptor
ligand, and also of non-cannabinoid NAEs, such as OEA
and PEA, which show no affinity for CB1-receptors but
are agonists at PPAR-a (Fu et al. 2003; Fegley et al. 2005).
To explore the possible contributions of these two receptor
systems to URB597’s blockade of nicotine’s effects on
MSNs in the ShNAc, we treated one group of rats with
both URB597 (0.1 mg/kg, i.v.) and the CB1-receptor
antagonist rimonabant (SR141716A; 0.5 mg/kg, i.v.)
1–2 hours before recording and treated another group
with URB597 together with the selective PPAR-a antago-
nist MK886 (Kehrer et al. 2001) (3 mg/kg, i.p., 15
minutes before URB597). Interestingly, both rimonabant
and MK886 fully reversed URB597’s blockade of nico-
tine’s effects in MSNs of the ShNAc (rimonabant +
URB597versusURB597: 63.5  21.8%of baseline level;
F(1;63) = 10.3, n = 5, P < 0.05, MK886 + URB597 versus
URB597: 56.8  16% of baseline level; F(1;70) = 5.462,
n = 6, P < 0.05, two-way ANOVA and Bonferroni’s test)
(Fig. 4a–c).
FAAH inhibition prevents cocaine’s action on MSNs in
the ShNAc
We then studied the effects of cocaine and morphine on
MSN excitability in the ShNAc, and the consequences of
FAAH inhibition by URB597. Cocaine (1.0 mg/kg, i.v.), in
agreement with previous studies (White et al. 1993),
depressed the excitability of MSNs of the ShNAc
(37.06  10.6% of baseline level; F(6;48) = 7.28, n = 7,
P < 0.001, one-way ANOVA for repeated measures and
Dunnett’s test) (Fig. 5a,b), as measured by their response
to BLA stimulation. When we studied the effect of mor-
phine (4.0 mg/kg, i.v.), the effects were highly variable
(data not shown) and, overall, did not reach statistical
significance, in line with other studies (Hakan & Henrik-
sen 1987). For this reason, we did not further character-
ize the effect of URB597 on morphine-induced effects on
MSNs. Pre-treatment of rats with URB597 (0.1 mg/kg,
i.v., 1–2 hours before recordings) prevented cocaine-
induced depression of MSNs in the ShNAc (95.3 
15.1% of baseline level; F(1;77) = 11.97, n = 6, P < 0.01
versus control, two-way ANOVA and Bonferroni’s test)
(Fig. 5a,b).
URB597 blocks cocaine’s effects in the ShNAc via a
PPAR-a-dependent mechanism
Finally, we explored the mechanism by which URB597
blocks cocaine-induced inhibition of excitability of MSNs
in the ShNAc.When we coadministered URB597 and the
CB1-receptor antagonist rimonabant (SR141716A;
0.5 mg/kg, i.v.), we found that URB597’s actions were
not reversed by CB1-receptor blockade (98.34  18.45%
of baseline; F(1;70) = 0.04, n = 6, P > 0.05 versus
URB597-pre-treated animals, two-way ANOVA and Bon-
ferroni’s test) (Fig. 5c), suggesting that CB1-receptors
were not involved. However, when we pre-treated rats
withMK886 (3.0 mg/kg, i.p., 15minutes before URB597
administration), URB597’s blockade of cocaine’s inhibi-
tion of MSNs was completely prevented, and cocaine
exerted an inhibitory effect similar to that observed under
control conditions (58.02  15.59% of baseline level;
F(1;70) = 7.028, n = 6, P < 0.05 versus URB597–pre-
treated animals, two-way ANOVA and Bonferroni’s test)
(Fig. 5d). These data suggest that endogenous PPAR-a
ligands modulate the effects of cocaine in the ShNAc.
DISCUSSION
In this study, FAAH inhibition by URB597 blocked the
acute inhibitory effects of both nicotine and cocaine on
firing of MSNs in the ShNAc that was evoked by BLA
stimulation in anesthetized rats. Pharmacological block-
ade of the target receptors for endogenous lipids that are
the primary substrates for FAAH (CB1-receptors and
PPAR-a) showed that URB597’s blockade of nicotine’s
inhibition of MSN excitability was because of the com-
bined activation of both surface CB1-receptor and
nuclear PPAR-a, while URB597’s blockade of cocaine’s
inhibition of MSN excitability was due only to activation
of PPAR-a and did not involve CB1-receptors.
In the VTA, URB597 did not prevent the decreases in
firing rate and burst firing produced by cocaine, or the
increases in firing rate and burst firing produced by mor-
phine, in DA neurons of anesthetized rats. These results
extend our previous findings, where FAAH inhibition
by URB597 completely abolished nicotine-induced
increases in firing rate and burst firing of VTA DA
neurons in anesthetized rats (Melis et al. 2008) and
nicotine-induced neurochemical and behavioral effects in
rats (Scherma et al. 2008). In that study, URB597
blocked nicotine-induced increases in DA levels in the
ShNAc and blocked the development of nicotine self-
administration and nicotine-induced conditioned place
preferences (Scherma et al. 2008).
The present finding that nicotine-induced depression
of MSN excitability requires the combined activation of
D1 and D2 DA receptors suggests that DA release in the
ShNAc plays a crucial role in this effect. Moreover,
because URB597’s blockade of nicotine’s inhibition
of MSN excitability in the ShNAc was reversed by either
the selective CB1-receptor antagonist/inverse agonist
rimonabant or by the PPAR-a antagonist MK886, the
blockade of nicotine’s effects by URB597 appears to
involve both surface CB1-receptors and nuclear PPAR-a.
Following URB597 administration, we found that nico-
tine became excitatory on MSNs in the ShNAc. The
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reason for this reversal of nicotine’s effect is not clear. One
possibility is that it might be the result of a combination
of factors: (1) the depression of nicotine-induced DA
release (Scherma et al. 2008) and (2) activation of CB1-
receptors in the NAc by anandamide and depression of
nicotine-induced GABA release. These effects may ulti-
mately unmask the enhancement of glutamate release
induced by nicotine (Reid et al. 2000) and the consequent
excitation of MSNs.
Although URB597 did not affect the inhibitory
actions of cocaine on VTA DA neurons, it completely
prevented cocaine-induced inhibition of MSN in the
ShNAc. These findings add some complexity to the con-
troversial issue of interactions between the endocan-
nabinoid system and the effects of cocaine or, more
generally, of psychostimulants (Wiskerke et al. 2008).
For example, it has been demonstrated that CB1-
receptor knockout mice will self-administrate cocaine
(Cossu et al. 2001) and that rimonabant does not
modify the development of cocaine-induced conditioned
place preference (Martin et al. 2000). Moreover,
URB597 does not alter cocaine self-administration by
squirrel monkeys under a fixed ratio schedule (Justinova
et al. 2008). In contrast, other studies have shown that
rimonabant prevents cocaine-induced increases in DA
levels in the NAc (Cheer et al. 2007) and increases the
breakpoint for cocaine self-administration under a fixed
ratio schedule in rats with extended access to the drug
(Orio et al. 2009). Thus, the present finding that
URB597 blocks the inhibitory effects of cocaine on MSN
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Figure 5 URB597 suppresses cocaine’s action on medium spiny neurons (MSNs) of the shell of the nucleus accumbens (ShNAc). (a)
Representative peristimulus time histograms showing the response of recorded ShNAc MSNs after basolateral amygdala (BLA) stimulation.
The probability of evoking MSN responses after BLA stimulation decreased after cocaine administration. Pre-treatment with URB597 reversed
cocaine-induced inhibition of MSNs.The peroxisome proliferator-activated nuclear receptor-a antagonist MK886 blocked URB597’s effect and
restored cocaine-induced inhibition of MSNs. (b–d) Graphical depictions of the time course of cocaine’s effects on MSN excitability in the
ShNAc. Cocaine depresses the excitability of MSNs in a long-lasting manner (b).This effect was blocked by URB597, which fully prevented
cocaine-induced inhibition (b). Pre-treatment with the CB1-receptor antagonist rimonabant (SR; 0.5 mg/kg, i.v.) did not alter URB597’s
blockade of cocaine’s actions (c), whereas MK886 (3 mg/kg, i.p.) (d) completely prevented URB597’s blockade of cocaine’s actions and
restored cocaine-induced inhibition of MSNs. Results are means, with vertical bars representing the standard error of the mean of evoked spike
firing, expressed as a percentage of the baseline (BAS). *P < 0.05 versus baseline, one-way analysis of variance (ANOVA) and Dunnett’s test;
#P < 0.05 versus vehicle + cocaine, §P < 0.05 versus URB597 + cocaine, two-way ANOVA and Bonferroni’s test
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excitability in the ShNAc, although not the inhibitory
effects of cocaine on DA neurons in the VTA, was unex-
pected, particularly because we previously found that
URB597 had no effect on cocaine self-administration by
squirrel monkeys (Justinova et al. 2008). However,
besides the difference in experimental subjects (squirrel
monkeys versus rats), there was a difference in the pro-
tocols of cocaine administration in these two studies.
Unlike the self-administration studies in monkeys, where
intravenous injections of cocaine were repeatedly self-
administered during 1-hour sessions and the effects of
URB597 were examined over three consecutive daily
sessions, in the present experiments, the electrical activ-
ity of neurons was examined in a single brain area fol-
lowing a single acute intravenous injection of cocaine. It
is possible that URB597’s effect could impair the drug-
induced acute responses of a specific neuronal popula-
tion without significantly affecting behavior induced by
chronic administration of the same drug. Thus, this
piece of evidence might reveal that, at least for cocaine,
FAAH inhibition might prevent the initial acute effects of
cocaine administration. In support of this hypothesis, a
recent study suggests that FAAH inhibitors do not affect
cocaine self-administration but significantly reduced
cocaine-induced reinstatement in abstinent animals
(Adamczyk et al. 2009).
In the present experiments, URB597 blocked the
inhibitory effect of cocaine on MSN excitability in the
ShNAc through a non-CB1-receptor-dependent mecha-
nism, because MK886, but not rimonabant, completely
reversed URB597’s blockade of cocaine’s inhibition of
MSNs in the ShNAc. This result further supports the con-
clusion that the effects of FAAH inhibition on the actions
of addicting drugs are often because of a combination of
different mechanisms, involving both surface CB1-
receptors for the endocannabinoid anandamide and
PPAR-a nuclear receptors for the non-cannabinoid OEA
and PEA. In line with other studies, however, the lack of
effect of rimonabant in the present experiments with
cocaine indicates that CB1-receptors are probably not
primarily involved in the acute reinforcing effects of psy-
chostimulants (Maldonado et al. 2006; Wiskerke et al.
2008).
How PPAR-a modulated acute neuronal responses to
cocaine in the present experiments is not known. Among
possible explanations, a conservative hypothesis may
involve a negative modulation exerted by PPAR-a ago-
nists, such as OEA and PEA, on cholinergic transmission
within the ShNAc. In fact, cholinergic interneurons of
the NAc were shown to modulate the response of MSNs
(de Rover et al. 2002). In that study, the authors hypoth-
esized that this effect occurred through an increase of
GABAergic interneuron activity within the ventral stria-
tum. These neurons receive inputs from the cholinergic
neurons mediated by nAChRs, and their synapses
impinge directly to MSNs. Moreover, other studies have
demonstrated an increase in acetylcholine release in the
NAc after psychostimulant exposure (Guix, Hurd &
Ungerstedt 1992; Imperato et al. 1992; Bickerdike &
Abercrombie 1997). In our previous in vitro studies in
brain slices, we identified amechanism bywhich PPAR-a,
activated by endogenous agonists OEA and PEA, specifi-
cally modulates nAChRs by inducing their inactivation
through phosphorylation (Melis et al. 2008). By analogy,
it is likely that PPAR-a activation within the NAc might
modulate cocaine’s response through inactivation of
nAChRs in GABAergic interneurons. This should result
in an impairment of GABA transmission to theMSNs that
could explain the lack of inhibitory effect of cocaine on
MSNs after URB597 pre-treatment. Interestingly, interac-
tions between OEA and PEA, and acetylcholine transmis-
sion might be bidirectional, given that their biosynthesis
is increased after stimulation of muscarinic receptors
(Stella & Piomelli 2001), which are present in the termi-
nal regions of GABAergic interneurons (de Rover et al.
2002).
It must be pointed out that, since all drugs were
administered systemically, we were unable to determine
whether the observed effects of PPAR-a agonists were
because of activation of nuclear receptors within the
NAc or other brain regions. However, relatively high
levels of PPAR-a binding was detected in the rodent stria-
tum (Moreno, Farioli-Vecchioli & Ceru 2004), coex-
pressed with tyrosine hydroxylase (Plaza-Zabala et al.
2009), thus a direct action of PPAR-a agonists in this
brain region is likely.
Endocannabinoids have been involved in the modula-
tion of forms of synaptic plasticity that occur in the NAc
or in the VTA early after the administration of addictive
substances belonging to different classes (Hoffman et al.
2003; Mato et al. 2004; Pan, Hillard & Liu 2008).
It is likely that, besides ‘classical’ endocannabinoids,
endocannabinoid-like lipid messengers might also
modulate acute effects of addicting substances. Indeed,
irrespective of mechanisms involved, pharmacological
inhibition of FAAH might represent an opportunity to
reveal how homeostatic signals, such as the endocannab-
inoid anandamide and the non-cannabinoid acetyletha-
nolamides OEA and PEA, and their respective target
receptors, might be recruited to regulate the effects of
addicting drugs within brain reward pathways, and
might represent a potential new approach to the treat-
ment of drug addiction.
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